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Abstract 
Advances in technology have led to the miniaturisation of hysteroscopes without 
compromising optical performance. This development has facilitated the routine 
use of diagnostic hysteroscopy in an outpatient setting without the need for general 
anaesthesia.  Further developments have expanded hysteroscopy from a simply 
diagnostic intervention to an operative one with a plethora of hysteroscopic 
surgical procedures.  The work in this thesis has adopted a mixed methodological 
approach to rigorously evaluate patient selection, feasibility and efficacy of office 
hysteroscopy.  Based on the results of this thesis we recommend:   
1) Women with recurrent PMB should be investigated with either hysteroscopy 
or saline infusion sonography.  
2) Vaginoscopy should probably be used in preference to other techniques to 
introduce the hysteroscope into the uterine cavity. 
3) Women who have a uterine cavity >9cm or dysmenorrhoea should be 
warned they are more likely to require further intervention after endometrial 
ablation.  
4) There appears to be no difference between the effectiveness of bipolar 
radiofrequency ablation and thermal balloon ablation at five years of follow 
up.   
5) Women who present with abnormal uterine bleeding and an endometrial 
polyp should have it removed.   
6) The hysteroscopic morcellator should be used in preference to bipolar 
resection for endometrial polyp removal. 
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Background  
Hysteroscopy describes a technique where a small endoscope called a 
‘hysteroscope’ is placed into the vagina, advanced to pass through the cervix and 
into the uterine cavity allowing direct visualisation of normal anatomy and 
pathological conditions.  Hysteroscopy is the commonest surgical intervention in 
gynaecology being used to diagnose and treat problems with abnormal uterine 
bleeding and reproduction; in the financial year between 2012 and 2013, 37,543 
diagnostic hysteroscopies and 27,127 therapeutic hysteroscopic procedures were 
performed in the NHS1.   
 
Advances in technology have led to the miniaturisation of hysteroscopes without 
compromising optical performance. This development has facilitated the routine 
performance of diagnostic hysteroscopy in an office setting in dedicated 
hysteroscopy facilities, within hospital endoscopy departments or in community 
based settings2–4.  There has thus been a paradigm shift with this most common of 
gynaecological procedures moving from an inpatient, general anaesthetic setting, 
within a formal operating theatre, to a convenient and flexible office environment.  
Further developments have expanded hysteroscopy from a simply diagnostic 
intervention to an operative one with a plethora of hysteroscopic surgical 
procedures to treat abnormal bleeding and reproductive problems5–8. This 
changing paradigm has been incentivised through economic changes in favour of 
office based procedures reflected in improved Department of Health procedure 
tariffs9. Moreover, in a recent trial comparing inpatient and office endometrial 
polypectomy, in those patients that expressed a preference, 80% choose to have 
!Page 19 
an office procedure (OPT, personal communication Clark).  Thus there is both 
economic and patient demand for increasing office hysteroscopic services.  This is 
reflected in the British Society for Gynaecological Endoscopy (BSGE) and Royal 
College of Obstetrics and Gynaecology (RCOG) Greentop guideline 59, which 
recommends that all NHS trusts should offer office hysteroscopic services4.  Office 
hysteroscopy has been shown to be a safe, feasible and accurate diagnostic test3.  
Moreover, common gynaecological procedures traditionally the preserve of 
inpatient hospital based treatment are now achievable in a convenient office 
setting.  Such office hysteroscopic therapeutic interventions include removal of 
uterine polyps, fibroids, adhesions and sterilisation procedures using specially 
designed miniaturised health technologies7,8.  Evidence is mounting for the 
feasibility, effectiveness and cost-effectiveness of office hysteroscopic 
interventions3,4,10. 
 
Identifying the right patients and offering the best treatments are of key importance 
to optimise clinical outcomes.  Moreover, with the continuous rapid development of 
technology extending the repertoire of office hysteroscopic procedures, it is 
essential that we critically evaluate current practice and new health technologies 
before they become embedded in clinical practice.  The work presented in this 
thesis has adopted a mixed methodological approach to rigorously evaluate patient 
selection, feasibility and efficacy of office hysteroscopic interventions for common 
gynaecological conditions in order to help identify best practice and enhance 
clinical outcomes  (Table 1). 
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#
Objectives 
 
 
1.  To improve patient selection for procedures in office hysteroscopy in order to 
optimise clinical outcomes. 
 
 
2.  To identify the most effective health technologies for the treatment of common 
gynaecological conditions. 
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Table 1.  Summary of research studies within the PhD thesis. 
Chapter Title Population Intervention  Comparator Study Type Objectives 
Chapter 2 
The role of 
hysteroscopy in 
recurrent post-
menopausal 
bleeding  
Women with 
postmenopausal 
bleeding 
Investigation 
pathway for 
postmenopausal 
bleeding 
N/A 
Observational 
Study 
To estimate the prevalence of 
genital tract pathologies in women 
presenting with initial and recurrent 
postmenopausal bleeding (PMB) to 
help inform diagnostic pathways 
Chapter 3 
Vaginoscopy 
versus 
traditional 
hysteroscopy: a 
pilot study  
Women having 
a diagnostic 
hysteroscopy in 
the office setting 
Vaginoscopy 
Standard 
Hysteroscopy 
Randomised 
Controlled Trial 
To evaluate whether vaginoscoopy 
or standard hysteroscopy is more 
favourable in an office setting in 
terms of feasibility, complications, 
pain, and acceptability.  
Chapter 4 
Prognostic 
factors that 
predict success 
in office 
endometrial 
ablation  
Women 
receiving 
endometrial 
ablation in the 
office setting 
Failed treatment 
defined as further 
surgical 
intervention 
Successful 
treatment 
defined as no 
further surgical 
intervention 
Observational 
Study  
To identify factors within the patient 
history, demographics and 
examination findings that may 
predict the chance of a satisfactory 
result from endometrial ablation 
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Chapter 5 
A randomised 
controlled trial to 
compare the 
effectiveness of 
office 
endometrial 
ablation: a five 
year follow-up  
Women 
receiving 
endometrial 
ablation in the 
office setting 
Bipolar 
Radiofrequency 
Ablation 
Thermal Balloon 
Ablation 
Randomised 
Controlled Trial 
To estimate the longer-term 
effectiveness of office based 
bipolar radiofrequency ablation 
compared with thermal balloon 
ablation of the endometrium for the 
treatment of heavy menstrual 
bleeding at five years follow-up. 
Chapter 6 
Uterine 
polypectomy for 
the treatment of 
abnormal uterine 
bleeding  
Women with 
endometrial 
polyps 
associated 
abnormal 
uterine bleeding 
All available 
therapeutic 
interventions 
No intervention 
Systematic 
Review 
To assess the effictiveness of 
uterine polypectomy in the 
treatment of abnormal uterine 
bleeding. 
Chapter 7 
Hysteroscopic 
morcellation of 
intrauterine 
polyps: a 
randomised 
controlled trial  
Women with 
benign 
endometrial 
polyps for 
removal in the 
office setting 
Hysteroscopic 
Morcellation 
Electrical 
Resection 
Randomised 
Controlled Trial 
To evaluate whether hysteroscopic 
morcellation or bipolar 
electrosurgical resection is more 
favourable for removing 
endometrial polyps in an office 
setting in terms of feasibility, 
speed, pain, and acceptability.  
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CHAPTER 2: THE ROLE OF HYSTEROSCOPY IN RECURRENT 1 
POST-MENOPAUSAL BLEEDING 2 
 3 
Publication 4 
The work has been published with the Journal of Minimally Invasive Gynecology; 5 
Smith P, O’Connor S, Gupta J, Clark TJ.  Recurrent postmenopausal bleeding: a 6 
prospective cohort study. J Minim Invasive Gynecol, September 2014 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
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Abstract 19 
Objective 20 
The aim of this study was to estimate the prevalence of genital tract pathologies in 21 
women presenting with initial and recurrent postmenopausal bleeding (PMB) to help 22 
inform diagnostic pathways. 23 
 24 
 25 
Methods   26 
A prospective cohort study was conducted in a large, urban teaching hospital in 27 
Birmingham, UK.  A total of 1938 consecutive women presented with 28 
postmenopausal bleeding, of which, 106 (5%) women were investigated for a 29 
recurrent episode after previously having normal investigations.  All women 30 
underwent a pelvic examination and ultrasound scan.  An endometrial biopsy was 31 
performed when endometrial thickness was >4mm in women presenting for the first 32 
time with PMB, with recourse to office hysteroscopy following correlation between 33 
clinical and pathological findings.  All women had an endometrial biopsy and office 34 
hysteroscopy with a recurrent PMB presentation. 35 
 36 
Results 37 
The chance of having endometrial cancer or hyperplasia with atypia was 38 
significantly lower in women who presented with recurrent PMB as compared to 39 
those presenting with PMB for the first time (0% and 8% respectively, P = 0.002).   40 
However, those with recurrent PMB were significantly more likely to have benign 41 
!Page 25 
endometrial polyps compared to women presenting with PMB for the first time (28% 42 
and 19% respectively, RR 1.47 [95% CI 1.07, 2.02], P = 0.02).    43 
 44 
Conclusion 45 
Investigations of women with recurrent PMB are less likely to show pre-malignant or 46 
malignant endometrial disease, but one in four women have endometrial polyps as 47 
a cause of PMB.  First line investigation for women with recurrent PMB should be 48 
with tests that have a high accuracy for diagnosing focal pathologies such as office 49 
hysteroscopy or saline infusion sonography.  50 
 51 
 52 
 53 
 54 
 55 
 56 
 57 
 58 
 59 
 60 
 61 
 62 
 63 
 64 
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Introduction 65 
Background 66 
Postmenopausal bleeding (PMB) is a common condition affecting between 7-15% 67 
of the postmenopausal population11.  Women with PMB are most likely to present in 68 
the sixth decade of life, with consultation rates in primary care of 14.3/1000 69 
population12.  Prompt investigation is needed because there is a 3-10% risk of 70 
endometrial cancer13.  Guidelines14,15 recommend first line investigation with 71 
transvaginal sonography (TVS) to measure endometrial thickness.  The prevalence 72 
of malignancy is reduced to <1% when the endometrial echo complex (EEC) is 73 
≤4mm and it is regular with no fluid in the uterine cavity.  Under these 74 
circumstances further testing is usually not required16–18.  Above this cut-off 75 
endometrial sampling is recommended14,15 because the risk of malignancy is 76 
higher19.  In contrast to the standardised approach to investigating initial 77 
presentations of PMB, the management of women that re-present with PMB is more 78 
ambiguous.   This is despite recurrence being common with estimated rates ranging 79 
between 19.4 and 33%20–22.  80 
 81 
Need for cohort study looking at recurrent PMB 82 
All investigations for PMB carry a false negative rate so it is important to re- 83 
investigate women who remain symptomatic or who have recurrent symptoms23.  84 
However, evidence on when and how these women should be investigated is 85 
lacking.  Research and published guidance14,15 has concentrated on the diagnosis 86 
of endometrial malignancy following first presentation with PMB, which may not be 87 
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applicable to those presenting with recurrent PMB.  It is likely that the prevalence of 88 
malignant and benign uterine pathologies, such as polyps, fibroids, endometrial 89 
hyperplasia and endometritis, differs between those women with PMB presenting 90 
for the first time and those with recurrent PMB.  Therefore, the emphasis on rapid 91 
referral and investigation to evaluate for endometrial cancer may result in these 92 
benign conditions being overlooked resulting in a failure to adequately treat these 93 
undetected benign pathologies.  Thus, the aim of this study was to estimate and 94 
compare the prevalence of all underlying genital tract pathologies in women with 95 
first presentation and women with recurrent PMB to help inform diagnostic 96 
pathways and the need for ongoing surveillance.  97 
 98 
 99 
 100 
 101 
 102 
 103 
 104 
 105 
 106 
 107 
 108 
 109 
 110 
 111 
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Objectives 112 
 113 
1. To estimate the prevalence of genital tract pathologies in women who 114 
present for the first time after PMB. 115 
2. To estimate the prevalence of genital tract pathologies in women with 116 
recurrent PMB who did not have malignant or premalignant pathology 117 
identified on previous investigation. 118 
3. Construct management pathway for women presenting with recurrent PMB. 119 
 120 
 121 
 122 
 123 
 124 
 125 
 126 
 127 
 128 
 129 
 130 
 131 
 132 
 133 
 134 
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Methods 135 
Study design 136 
A prospective cohort study of the incidence of genital tract pathology associated 137 
with PMB, comparing those who present initially to those with recurrent symptoms 138 
and previous normal investigations. 139 
 140 
Study setting 141 
1938 women were seen consecutively in the postmenopausal bleeding clinic at the 142 
Birmingham Women’s Hospital between 27th February 2007 and 27th July 2011.  143 
 144 
Participants 145 
PMB was defined as an episode of vaginal bleeding 12 months or more after the 146 
last menstrual period.  Recurrent PMB was defined as any repeat presentation of 147 
bleeding after previously being investigated for PMB.  Women taking HRT with 148 
unscheduled bleeding were also considered to have PMB.  Some clinicians may 149 
consider re-presentation over 12 months to represent a ‘new’ episode of PMB rather 150 
than a ‘recurrence’ of the initial problem, so we further subdivided recurrent PMB 151 
into those women that presented ≤12 months and those that presented >12 months.   152 
Women were excluded from the recurrent cohort if they were diagnosed with 153 
cancer, hyperplasia or an untreated polyp during the first episode of bleeding. 154 
 155 
 156 
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Investigation  157 
All women with PMB underwent TVS as a first-line screening test.  Final diagnosis 158 
for PMB was made using the following reference standards: 159 
1. Transvaginal sonography (TVS): if the endometrium was regular, ≤4mm on 160 
TVS with no evidence of fluid, the patient was considered to have an atrophic 161 
endometrium and sampling was not performed.  The patient was reassured 162 
after performing a lower genital tract examination and consequently 163 
discharged. A trained sonographer who was not blinded to the clinical 164 
symptoms performed all TVS. Colour Doppler was used when endometrial 165 
irregularities were seen.  166 
2. Endometrial biopsy (EB): women who screened positive i.e. TVS with EEC 167 
>4 mm or irregular endometrium (even if the EEC was ≤4mm), or incomplete 168 
visualisation of the endometrium, underwent aspiration endometrial biopsy 169 
(EB). A senior pathologist reviewed all histology and was not blinded to the 170 
clinical symptoms. 171 
3. Office hysteroscopy (under conscious sedation): where an outpatient 172 
endometrial biopsy (EB) failed (defined as failure to instrument the uterus or 173 
a non-diagnostic sample) an office hysteroscopy was arranged and a further 174 
biopsy taken unless the cavity seemed atrophic on hysteroscopic 175 
visualisation.  Atrophy on hysteroscopic visualisation was defined as a pale, 176 
avascular uterine surface with visible underlying stroma with no endometrial 177 
tissue avulsed following contact with the tip of the hysteroscope.  Office 178 
hysteroscopy was performed on all patients with a recurrent presentation of 179 
PMB.  An office hysteroscopy was also performed where focal pathology 180 
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(polyps, submucous fibroids) were suspected on TVS or EB reports.  If 181 
confirmed on office hysteroscopy, they were removed and sent for 182 
histological confirmation.  All office hysteroscopy was performed by a senior 183 
gynaecologist or a specialist nurse who was not blinded to the clinical 184 
symptoms.   185 
 186 
Diagnosis 187 
For the purposes of this study we restricted final diagnosis to a single pathology.  188 
When more than one endometrial histological diagnosis was made the patient was 189 
categorised using the following hierarchy:  Endometrial cancer / hyperplasia with 190 
atypia > hyperplasia without atypia > polyps > infection > functional > atrophic.  191 
Cancer and hyperplasia with atypia were included together because of the high rate 192 
of under-call and progression to cancer where complex hyperplasia is found with 193 
cytological atypia24–26.  194 
 195 
Statistical methods 196 
We prospectively collected standardised data on a specially designed password 197 
protected MicrosoftTM Access Database.  The relative proportion of different 198 
pathologies in women with first and recurrent PMB was compared using Chi-square 199 
test or Fisher’s exact test when the expected frequency was less than five.  For the 200 
purpose of working out relative risk, values of zero were replaced with 0.5.  201 
Statistical analysis was performed using SPSSTM version 15. 202 
 203 
 204 
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Results 205 
Participants 206 
Over the 53 month study period, 1832 women with a median duration of follow up of 207 
35 months (range 1–56 months), presented with PMB for the first time to the 208 
Birmingham Women’s Hospital. Of this cohort, 106 (5%) women had recurrent 209 
PMB. The median follow up in this subgroup of women with recurrent PMB was 12 210 
months (range 1–45 months).  All had previously been investigated for PMB and 211 
had endometrial cancer or hyperplasia excluded. When comparing baseline 212 
characteristics for women with first presentation versus those with recurrent PMB 213 
results were similar: mean age (62.9 vs 61.1); body mass index (BMI) (30.7 vs 31.8 214 
kg/m2), EEC (8.3 vs 7.7 mm) and percentage taking HRT (11.7% vs 12.3%) was 215 
similar in women with first or recurrent PMB.   216 
 217 
Outcome data 218 
Endometrial cancer or hyperplasia with atypia was diagnosed in 152/1832 (7.8%) 219 
women with first presentation PMB but no cases were found in the 106 women with 220 
recurrent PMB.  In contrast, benign endometrial polyps were found to be 221 
significantly more prevalent in the recurrent PMB group compared with first 222 
presentation PMB (30/106, 28.3% vs 349/1832, 19.6%, P = 0.02 respectively). The 223 
prevalence of all other endometrial pathologies was equivalent between initial and 224 
recurrent PMB groups (Table 2).  Because of a possible association between HRT 225 
and the development of polyps27, we re-analysed the data after removing the 226 
women taking HRT.  Endometrial polyps remained more prevalent in women with 227 
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recurrent PMB, but the difference was no longer significant (25/94, 27% in recurrent 228 
PMB presentation vs 313/1616 19%, in initial PMB presentation, P = 0.09). 229 
Removing the women taking HRT had no effect on the significant decrease in 230 
cancer and atypia in recurrent PMB presentation.  No significant differences in the 231 
prevalence of endometrial pathologies were noted in women with recurrent PMB 232 
when stratified into re-presentation within and beyond 12 months of initial 233 
presentation (Table 3).  234 
 235 
 236 
 237 
 238 
 239 
 240 
 241 
 242 
 243 
 244 
 245 
 246 
 247 
 248 
 249 
 250 
 251 
 252 
 253 
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 254 
Table 2.  Comparison of endometrial pathology rates between women with PMB 255 
presenting for the first time or recurrently after previously normal investigations. 256 
 257 
 
Initial PMB 
presentation 
Recurrent PMB 
presentation RR (95% CI) P value1 
Infection 20 (1%) 0 (0%) 0.42 (0.03 to 6.86)2 0.3 
Polyps 349 (19%) 30 (28%) 1.47 (1.07 to 2.02) 0.02 
Hyperplasia 97 (5%) 7 (7%) 1.24 (0.59 to 2.59) 0.6 
Cancer and 
Atypia 152 (8%) 0 (0%) 0.06 (0.00 to 0.90)
2 0.002 
Functional3 348 (19%) 18 (17%) 0.93 (0.62 to 1.42) 0.7 
Atrophy 866 (47%) 51 (48%) 1.01 (0.82 to 1.24) 0.9 
Total 1832 106   
 258 
 259 
PMB = postmenopausal bleeding; RR = relative risk 260 
1) Chi square test, presented to one significant figure 261 
2) For the purpose of working out relative risk values of 0 were replaced with 0.5. 262 
3) Functional = included histology described as weakly proliferative and weakly secretary 263 
 264 
 265 
 266 
 267 
 268 
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Table 3.  Comparison of endometrial pathology rates stratified by time to re- 269 
presentation in women with recurrent PMB.   270 
 271 
 272 
 273 
 Recurrent PMB 
≤12 months 
Recurrent PMB 
>12 months 
P value1 
Average follow-up time 
in months (range) 
7.5 (2-12) 21.8 (13-45)  
Infection 0 (0%) 0 (0%) No value 
Polyps 13 (25%) 17 (32%) 0.5 
Hyperplasia 4 (8%) 3 (6%) 0.7 
Cancer and Atypia 0 (0%) 0 (0%) No value 
Functional2 12 (23%) 6 (11%) 0.2 
Atrophy 24 (45%) 27 (51%) 0.2 
Total  53 53  
    
 274 
PMB = postmenopausal bleeding 275 
1) Chi square test, presented to one significant figure 276 
2) Functional = included histology described as weakly proliferative and weakly secretary 277 
 278 
 279 
 280 
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Discussion 281 
Key results 282 
In our study, 106 (6%) women had recurrent PMB over a 4.5 year period, but no 283 
cases of endometrial cancer or hyperplasia with atypia were detected.  However, 284 
women with recurrent PMB had a significantly increased risk of having benign 285 
endometrial polyps irrespective of the time to recurrence.   286 
 287 
Interpretation 288 
The apparent increased prevalence of endometrial polyps with recurrent PMB may 289 
reflect the higher accuracy of office hysteroscopy for detecting focal pathologies.28,29 290 
This was undertaken routinely in the recurrent PMB group, but only selectively in 291 
women presenting with PMB for the first time. Alternatively, women with recurrent 292 
PMB may have more frequently developed polyps de novo accounting for further 293 
bleeding symptoms. In either case, the finding that benign endometrial polyps are 294 
more prevalent has potential implications for how to best manage women with 295 
recurrent PMB.  With it’s focus on diagnosing endometrial cancer, the current 296 
consensus for working up women with PMB using first-line TVS EEC 297 
measurement14,15,30, may be inappropriate in women with recurrent PMB.  Although 298 
the vast majority of endometrial polyps are benign31,32, and the consequences are 299 
less serious to health than endometrial cancer, they are associated with abnormal 300 
uterine bleeding and removal by polypectomy frequently resolves symptoms31,33. 301 
Thus, diagnostic pathways in recurrent PMB should be developed with the aim of 302 
diagnosing benign as well as malignant endometrial disease. 303 
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Proposed pathway for investigation of recurrent PMB 304 
Figure 1. illustrates a potential testing pathway for women presenting with recurrent 305 
PMB based upon the findings from our study. We propose that office hysteroscopy 306 
should be incorporated because it is more accurate in diagnosing discrete 307 
pathologies such as endometrial polyps29,34. Moreover, structured interviews 308 
exploring women’ preferences in the evaluation of PMB have shown that women 309 
are prepared to undergo more invasive hysteroscopy to evaluate for any additional 310 
pathology, rather than adopt the currently recommended expectant management 311 
after ultrasound35.  It is possible that this preference for additional testing may be 312 
even more likely with recurrent PMB because of increased anxiety associated with 313 
repeated symptoms, even though paradoxically the risk of endometrial cancer 314 
appears to be low. 315 
 316 
The low risk of serious endometrial disease in recurrent PMB after previous normal 317 
investigation is reassuring and so reinvestigation of women who have already had 318 
endometrial polyps excluded by office hysteroscopy may be unnecessary. However, 319 
if the nature of bleeding has changed (i.e. increased quantity or persistence) or 320 
other relevant symptoms such as pain have developed then it would seem prudent 321 
to undertake timely re-investigation to exclude endometrial cancer (Figure 1). We 322 
found no difference in the likelihood of endometrial cancer or hyperplasia in women 323 
with recurrent PMB according to whether re-presentation was within or beyond 12 324 
months of initial negative testing. However, the median duration of follow up in our 325 
series was only 12 months. Therefore a cautious approach should be adopted, 326 
especially in women with recurrent symptoms and longer time intervals from 327 
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previously negative testing. For this reason the proposed diagnostic algorithm 328 
recommends re-investigation for all women with recurrent PMB after 12 months, 329 
regardless of previous testing history (Figure 1).  330 
 331 
 332 
Comparison with other studies 333 
Several other studies have estimated recurrence rates for PMB and evaluated the 334 
prevalence of malignant although not benign uterine pathology20,22,36–38. One study 335 
evaluated 126 women presenting with recurrent PMB and reported an 8% recurrent 336 
PMB38 rate in keeping with our observed estimate of 6%. In contrast to our findings, 337 
no significant difference in the incidence of cancer or atypical hyperplasia were 338 
observed compared to women presenting for the first time. However, initial 339 
diagnostic work up was not in line with current recommendations14,15 such that two 340 
of the five women with endometrial cancer in the recurrent group re-presented 341 
within a year, but neither had undergone initial endometrial sampling despite having 342 
an EEC >9mm.  The likelihood of recurrent bleeding has been reported to be as 343 
high as 33%22 and the rates of cancer and atypical hyperplasia up to 22.7% 344 
(15/66)20.  These differences may be explained by differences in patient selection 345 
and referral criteria, variations in initial diagnostic work-up and the sample size and 346 
duration of follow-up.  Closer analysis of these studies revealed that significant 347 
pathology usually occurred 12 months after initial investigation20,21,38.  When cancer 348 
or atypical hyperplasia did present within 12 months, endometrial sampling was 349 
either not normal, inadequate or not performed at first presentation20,38. It is for this 350 
reason that in our suggested pathway (Figure 1) all patients with recurrent PMB are 351 
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investigated with office hysteroscopy with an attempt at biopsy irrespective of the 352 
EEC and that a full review of previous investigations is undertaken.  Larger studies 353 
are needed to externally validate our findings before we can make robust clinical 354 
recommendations. 355 
 356 
Strengths and limitations 357 
A strength of our study is that the data were collected prospectively, consecutively 358 
and in a standardised fashion minimising bias from incomplete data.  However, 359 
whilst the generalisability of our findings are limited because they are derived from a 360 
single centre, we believe that they are likely to mirror other centres because we 361 
adopted testing for PMB in line with current guidelines14,15 from a large, unselected, 362 
general postmenopausal population.  363 
 364 
Although we did not follow up apparently asymptomatic women, it is unlikely that 365 
that our low prevalence of serious endometrial disease in women with recurrent 366 
PMB reflects high rates of loss to follow up. This is because PMB is an alarming 367 
symptom so women are unlikely to ignore it and general practitioners are well 368 
educated in the need to rapidly refer. Furthermore, postmenopausal women are not 369 
a particularly itinerant population and our hospital is the largest provider of 370 
gynaecological care in Birmingham.  A potential criticism of our study is the lack of a 371 
common reference standard for diagnosing endometrial disease. Our study was 372 
pragmatic, with data collected within a clinical setting such that the indication for 373 
further testing with office hysteroscopy, after the standard use of TVS and EB if 374 
EEC≥4mm14,15, was based upon clinico-pathological correlation in the absence of 375 
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uniform guidance. We also restricted diagnosis to a single pathology so that we may 376 
have underestimated the prevalence of some pathologies. However, in the 377 
presence of multiple endometrial pathologies, we based our final diagnosis 378 
according to the most significant pathology and so the clinical implications of our 379 
simplification are likely to be negligible.   380 
 381 
 382 
 383 
 384 
 385 
 386 
 387 
 388 
 389 
 390 
 391 
 392 
 393 
 394 
 395 
 396 
 397 
 398 
 399 
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Figure 1. Proposed diagnostic pathway for recurrent PMB 400 
 401 
 402 
 403 
 404 
 405 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
EB = Endometrial Biopsy; PMB = Postmenopausal Bleeding; * increased quantity or 418 
persistence of bleeding, pain, weight loss, bowel or urinary symptoms. 419 
 420 
 421 
 422 
 423 
Did the woman’s last workup for PMB 
include hysteroscopy? 
Recurrent PMB 
Perform 
hysteroscopy +/- EB 
Were the woman’s last 
investigations >12 
months ago? 
No further investigation 
required unless a change 
in symptoms*. 
Perform 
hysteroscopy +/- EB 
Yes 
Yes 
No 
No 
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Conclusions 424 
At least one in twenty women with PMB will have recurrent symptoms. Compared to 425 
women presenting for the first time with PMB, the risk of endometrial cancer in 426 
recurrent PMB in women who have had previously normal investigations in line with 427 
current diagnostic guidelines14,15 appears to be much lower, but the risk of having 428 
benign endometrial polyps is significantly higher. All women with recurrent PMB, 429 
irrespective of when they re-present after their initial negative investigations, should 430 
undergo a test with a high sensitivity for focal pathology such as office 431 
hysteroscopy.  432 
 433 
 434 
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 436 
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CHAPTER 3: A RANDOMISED CONTROLLED TRIAL OF 446 
VAGINOSCOPY AGAINST STANDARD TREATMENT  447 
 448 
 449 
 450 
 451 
 452 
 453 
 454 
 455 
 456 
 457 
 458 
 459 
 460 
 461 
 462 
 463 
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Abstract 465 
Objective  466 
To evaluate whether vaginoscopy or standard hysteroscopy was more successful in 467 
the office setting by comparing rates of failure, complications, infection, patient 468 
acceptability, and pain scores. 469 
 470 
 471 
Methods  472 
A single centre randomised controlled trial of vaginoscopy compared with standard 473 
hysteroscopy was conducted.   A total of 200 women were randomly allocated to 474 
one of the two methods in an office setting.  The primary outcome was “success”; 475 
this was a composite outcome defined as: a complete procedure, no complications, 476 
a level of pain acceptable to the patient and no sign of infection two weeks after the 477 
procedure.  Secondary outcomes consisted of the individual elements of a 478 
successful procedure, duration and pain, measured using a 100mm electronic 479 
visual analogue scale.  480 
 481 
Results  482 
Vaginoscopy was significantly more successful than standard hysteroscopy (OR 483 
4.28 [95% CI; 1.52 to 12.09]).  One (1%) women receiving vaginoscopy reported the 484 
procedure unacceptable, compared to two (2%) women in the standard 485 
hysteroscopy group (OR 0.20 [95% CI; 0.01 to 4.14]).  Vasovagal reactions 486 
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occurred in two women receiving vaginoscopy and five women receiving standard 487 
hysteroscopy (OR 2.58 [95% CI; 0.48 to 13.62]).  There were two (2%) women 488 
undergoing vaginoscopy and five (6%) after standard hysteroscopy who met the 489 
criteria for having a post-procedural infection.  Significantly more procedures failed 490 
with standard hysteroscopy compared to vaginoscopy (eight [8%] versus one [1%] 491 
respectively; OR 8.61 [95% CI; 1.05 to 70.20]).  The median time taken to complete 492 
vaginoscopy was two minutes compared to three minutes for standard hysteroscopy 493 
(P < 0.001). The median pain measured on a 100mm electronic visual analogue 494 
scale was 33 for vaginoscopy compared to 38 standard hysteroscopy (P = 0.3). 495 
 496 
Conclusions  497 
There is evidence to suggest that vaginoscopy is quicker to perform and more 498 
successful than standard hysteroscopy and therefore should be considered the 499 
technique of choice for office hysteroscopy.  500 
 501 
Clinical Trial Registration:  ClinicalTrials.gov, www.clinicaltrials.gov, 502 
NCT01972945 503 
 504 
 505 
 506 
 507 
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Introduction 508 
Background 509 
Office hysteroscopy can be associated with significant anxiety, pain and patient 510 
dissatisfaction4. One technical modification identified to potentially reduce pain at 511 
hysteroscopy is ‘vaginoscopy’, otherwise known as the ‘no touch’ technique3,39,40.  512 
This describes a technique where the hysteroscope is guided into the uterus without 513 
the need for potentially painful vaginal instrumentation.  Pain is often experienced 514 
by the patient at a number of stages during the standard hysteroscopy practice, 515 
these include passage of a vaginal speculum to separate the vaginal walls in order 516 
to visualise the cervix, cleansing of the cervix and sometimes application of 517 
traumatic forceps to the ectocervix in order to stabilise it.  Vaginoscopy could be 518 
less traumatic because the approach minimises potentially painful manoeuvres in 519 
the lower genital tract.   520 
 521 
Recent technological advances have led to the miniaturisation of hysteroscopes, 522 
which facilitates vaginoscopy by reducing resistance to advancement of the 523 
hysteroscope through the relatively narrow and often tortuous cervical canal. 524 
However, despite these modifications in instrumentation, few clinicians use 525 
vaginoscopy routinely preferring more invasive traditional approaches.  This may 526 
reflect a lack of familiarity with the technique as well as concerns over the ability to 527 
identify and traverse the cervical canal in order to access the uterine cavity. 528 
 529 
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We therefore designed a randomised controlled trial (RCT) to compare standard 530 
approach to hysteroscopy against vaginoscopy evaluating important clinical 531 
outcomes such as pain, feasibility, acceptability, vasovagal responses and infection.  532 
To inform the study design we conducted pilot work including a survey of 533 
gynaecological endoscopists, and a systematic review of the current evidence. 534 
 535 
 536 
 537 
 538 
 539 
 540 
 541 
 542 
 543 
 544 
 545 
 546 
 547 
 548 
 549 
 550 
 551 
 552 
 553 
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Survey of members of the British Society of Endoscopy 554 
We surveyed the members of the British Society of Endoscopy (BSGE) to identify 555 
the most popular techniques and the most important questions for a trial in 556 
vaginoscopy. 557 
 558 
Methods 559 
A series of questions were distributed via email to all the members of BSGE using 560 
surveymonkey.  Participants were identified through the BSGE electronic database 561 
of members (as of January 2013).  In order to enhance response rates we restricted 562 
the survey to six questions with closed responses.  The questions were formulated 563 
to help identify current practice, to assess the likely impact of a comparative trial 564 
comparing vaginoscopy and standard technique and to inform selection of primary 565 
and secondary outcomes. 566 
 567 
Results 568 
 569 
A total of 128/658 (20%) of participant responded to the email questionnaire.  Table 570 
4 shows the responses to the questions. 571 
 572 
 573 
 574 
 575 
 576 
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Table 4.  Answers to survey of BSGE members 577 
Question Answer options Response 
Q1. Do you perform outpatient 
or office hysteroscopy (ie. 
hysteroscopy without general 
anaesthesia)? 
Yes 115/128 (90%) 
No 13/128 (10%) 
      
Q2. Which technique do you 
use most often? 
Hysteroscopy using a speculum with or 
without cervical instrumentation to steady 
the cervix 36/88 (41%) 
Hysteroscopy with local anaesthetic 10/88 (11%) 
Vaginoscopy (hysteroscopy without a 
speculum or cervical instrumentation to 
steady the cervix) 32/88 (36%) 
Flexible hysteroscopy 10/88 (11%) 
   
Q3. Do you employ more than 
one technique and if so which 
ones? 
Traditional Hysteroscopy 59/85 (69%) 
Traditional Hysteroscopy with local 
anaesthetic 49/85 (58%) 
Vaginoscopy 51/85 (60%) 
Flexible hysteroscopy 20/85 (24%) 
      
Q4. What is the approximate 
diameter of the hysteroscopes 
that you are currently using in 
mm? Size in mm Mean 4.06 
   
Q5. If one technique was 
shown to be superior based on 
patient orientated outcomes, 
would it change your practice? 
Yes 76/84 (90%) 
No 8/84 (10%) 
      
Q6. When comparing different 
techniques which outcomes 
are most important? (You can 
choose more than one). 
Pain scores 83/87 (95%) 
Failure rates 81/87 (93%) 
Infection rates 23/87 (26%) 
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Complication rates 33/87 (38%) 
 578 
 579 
Discussion 580 
Office hysteroscopy is established practice within BSGE members, with 90% of 581 
respondents performing the procedure. The most common first line technique for 582 
performing office hysteroscopy, using a speculum and no anaesthesia.  583 
 584 
The survey showed that only 60% of BSGE members are familiar with vaginoscopy. 585 
These estimates, based upon enthusiasts for endoscopy are likely to be much lower 586 
within the general gynaecological community and so the potential benefit to patients 587 
would be even greater if widely adopted, subject to vaginoscopy being shown to be 588 
beneficial.  Our survey reported that over 90% of respondents were willing to 589 
change their practice, if vaginoscopy was shown to be superior to traditional 590 
approaches based on patient orientated outcomes.  Therefore, a well conducted 591 
and designed RCT has the potential to change practice in one of the commonest 592 
surgical instruments in gynaecological practice.  The respondents considered pain 593 
to be the most important clinical outcome and whilst infection was considered 594 
important, 26% of respondents identified it as an important endpoint to evaluate. 595 
 596 
There are several limitations to our questionnaire.  Firstly, to make the 597 
questionnaire quick we only asked six questions with closed responses.  More 598 
questions with open responses may have generated more information on current 599 
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practice and the impact of a trial.  Also, the survey was distributed amongst 600 
enthusiasts of endoscopy, which affects the generalisability of the results to the 601 
wider gynaecological community.   Furthermore, given the response rate of 20% it is 602 
difficult to determine if those that did not respond would have answered the 603 
questions differently. 604 
 605 
The findings from our cross-sectional survey suggests that an RCT comparing 606 
vaginoscopy and standard approaches is feasible and likely to influence current 607 
practice for a common procedure.  Based on current practice it appears that 608 
hysteroscopy using a speculum without local anaesthesia should be the comparator 609 
against which vaginoscopy is compared and that the outcomes of pain, feasibility 610 
and complications including rates of infection should be evaluated.  611 
 612 
Systematic review and meta-analysis 613 
We have previously completed and reported a systematic review and meta-analysis 614 
of vaginoscopy compared to standard hysteroscopy39.   The databases searched 615 
included MEDLINE, EMBASE, and CINAHL using a combination of the keyword 616 
‘hysteroscopy’, ‘vaginoscopy’, vaginoscop*’, ‘no-touch’, and their associated word 617 
variants and medical subject headings.  The Cochrane Library was searched using 618 
the keywords ‘hysteroscopy’, ‘vaginoscopy’, ‘vaginoscopic’ and ‘no-touch’. 619 
 620 
Of the 1167 citations retrieved, six studies met the criteria for inclusion and in four 621 
there was suitable data for meta-analysis.  Vaginoscopy was found to be less 622 
painful than traditional approaches, with a standard mean difference in visual 623 
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analogue scales (VAS) pain scores of -0.44 (95% CI -0.65 to -0.22)39.  However 624 
there was statistically significant heterogeneity and this was also seen in the wide 625 
variation in procedure feasibility (failure rates varying from 2% to 17%)39.  This 626 
inconsistency reflected the lack of standardisation of approach both in relation to 627 
vaginoscopy and traditional speculum based approaches where there was variation 628 
between studies in the administration of local cervical anaesthesia, application of 629 
cervical tenaculum forceps, and the size and angle of the rigid hysteroscope 630 
employed.  None of these small RCTs 41–46 had optimal randomisation processes in 631 
terms of using computer generated random number sequences and third party 632 
concealment. The review and subsequent BSGE and RCOG guideline 4,39 633 
recommended further higher quality adequately powered RCTs to examine more 634 
comprehensively the role of vaginoscopy in terms of pain, feasibility, acceptability 635 
and complications.   636 
 637 
 638 
The need for a RCT comparing vaginoscopy to standard 639 
hysteroscopy 640 
 641 
The current restricted use of vaginoscopy is likely to be the result of a lack of 642 
experience with the technique and uncertainty as to whether the technique is 643 
associated with a worthwhile reduction in procedural pain and improvement in 644 
patient acceptability.  Furthermore, there is concern that vaginoscopy is technically 645 
more challenging leading to prolonged procedures which may fail to be completed, 646 
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lead to more vaso-vagal fainting episodes and a higher likelihood of post-operative 647 
infection of the uterus.   648 
 649 
 650 
In view of the uncertainty over the effectiveness of vaginoscopy we designed an 651 
RCT.  The aim was to evaluate whether vaginoscopy or standard hysteroscopy was 652 
potentially more successful in the office setting by comparing failure rates, 653 
complications, infection rates, patient acceptability, and pain scores.  In the first 654 
instance we designed a feasibility pilot trial (VAginoscopy versus Standard 655 
Teloscope for office hysteroscopy trial; VAST) to inform the design, conduct and 656 
feasibility of a larger scale RCT. 657 
 658 
 659 
 660 
 661 
 662 
 663 
 664 
 665 
 666 
 667 
 668 
 669 
 670 
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Objectives 671 
1. To estimate whether the vaginoscopic technique is potentially more 672 
successful compared to traditional approaches where success is defined as 673 
a completed diagnostic hysteroscopy with an acceptable level of patient 674 
reported pain without a vasovagal episode or post-operative uterine infection.   675 
 676 
2. To test the hypothesis that in women undergoing an office hysteroscopy, a 677 
vaginoscopic technique is associated with on average at least 10% less pain 678 
(as measured by visual analogues scores) compared to traditional 679 
approaches.  680 
 681 
3. To test the hypothesis that in women undergoing an office hysterosocpy, a 682 
vaginoscopic technique is associated with fewer vaso-vagal episodes 683 
compared to traditional approaches. 684 
 685 
4. To test the hypothesis that in women undergoing an office hysteroscopy, 686 
there is no difference in the rates of failure to complete the procedure 687 
between vaginoscopy and traditional approaches. 688 
 689 
 690 
5. To test the hypothesis that in women undergoing an office hysteroscopy, 691 
there is no difference in the incidence of post-operative infection between 692 
vaginoscopy and traditional approaches. 693 
 694 
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6. To test the hypothesis that in women undergoing an office hysteroscopy, a 695 
vaginoscopic technique is associated with better patient acceptability. 696 
 697 
 698 
 699 
 700 
 701 
 702 
 703 
 704 
 705 
 706 
 707 
 708 
 709 
 710 
 711 
 712 
 713 
 714 
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Methods 715 
Study design 716 
A parallel-group unblinded RCT comparing vaginoscopy versus standard 717 
hysteroscopy was conducted.  718 
 719 
Study setting 720 
Women were recruited from office hysteroscopy clinics within Birmingham Women’s 721 
Hospital Foundation Trust.   722 
 723 
Patient eligibility 724 
Inclusion criteria 725 
All women over 16 attending for an office hysteroscopy were approached to 726 
participate in the trial. All participating women gave written informed consent. 727 
 728 
Exclusion criteria 729 
Women were excluded from participation if they preferred the procedure under 730 
general anaesthesia, or if it was known that cervical dilation would be needed based 731 
upon previous reports of severe cervical stenosis or that they would not tolerate a 732 
speculum prior to the procedure beginning e.g. history of vaginismus, virgins and 733 
severe lichen sclerosis.  734 
 735 
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Trial registration 736 
This trial was registered on clinicaltrials.gov (identifier: NCT01972945).  The 737 
National Research Ethics Service, UK, granted ethical approval (identifier: 738 
13/WM/0471).  Research and Development approval was sought and granted at 739 
Birmingham Women’s Hospital. The trial was conducted according to the principles 740 
of Good Clinical Practice (GCP)47.   Appendix 1 shows the consent form that women 741 
had to complete before entering the trial.  Prior to hysteroscopy all women were 742 
provided with evidence based patient information leaflets (Appendix 2). 743 
 744 
 745 
Randomisation 746 
Women were allocated in a 1:1 ratio to either of the interventions through a 747 
telephone-based system managed by the Birmingham Clinical Trials Unit.  The 748 
randomisation blocks were kept centrally in the Birmingham Clinical Trials Unit and 749 
the sizes varied so that the allocation could not be deduced pre-randomisation. 750 
Blocks were stratified by menopausal status (premenopausal versus post- 751 
menopausal) to ensure we achieved balance between groups for this variable. 752 
Menopausal status was chosen because of the influence of oestrogen has on the 753 
elasticity of the female genital tract.  754 
 755 
Interventions  756 
All procedures were performed in the office setting without general anaesthesia or 757 
conscious sedation. Three practitioners experienced in both vaginoscopy and 758 
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standard hysteroscopy performed all surgical procedures (TJC, SOC, PS).  759 
Vaginoscopy consisted of guiding the hysteroscope into the uterus without the need 760 
for any vaginal instrumentation or vaginal antiseptic preparation.  Standard 761 
hysteroscopy consisted of passage of a vaginal speculum to separate the vaginal 762 
walls, cleansing of the ectocervix and when necessary the application of traumatic 763 
forceps to the ectocervix in order to stabilise it.  All procedures were done using 764 
either the 3.1mm 00 Single-flow hysteroscopy system (Storz Endoscopy, Tuttlingen, 765 
Germany) or a 3.5mm 00 Alphascope hysteroscopy system (Gynecare; Ethicon Inc., 766 
New Jersey, USA). No cervical preparation was used prior to the procedure. Normal 767 
Saline (0.9% w/v NaCl) was instilled from a 50ml syringe, controlled by a nursing 768 
assistant, to provide distension and irrigation of the uterine cavity.  In line with 769 
departmental protocols, fluid deficit was not calculated for office hysteroscopy 770 
because procedures were short and performed through small diameter operating 771 
hysteroscopes 3. The use of local anaesthesia (direct cervical block using 6.6ml of 772 
3% Mepivacaine) placed in four quadrants3 was restricted to procedures where 773 
dilatation of the cervix was required to pass the hysteroscope through the 774 
endocervical canal.  Where the allocated technique failed the operator could revert 775 
to the alternative technique if they considered it appropriate.   776 
 777 
For a procedure to be considered satisfactorily completed the operator must have 778 
done the following: 779 
• Obtained a panoramic view of the uterine cavity from the position of the 780 
internal cervical os. 781 
• Identified both tubal ostia or cornual recesses under magnification. 782 
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• Inspected the endometrium over the fundus and all four uterine walls 783 
(anterior, posterior, right lateral and left lateral) under magnification. 784 
• Identified the origin of focal lesions (polyps/submucous fibroids) 785 
• Inspected the endocervical canal and ectocervix. 786 
 787 
 788 
Outcomes 789 
Procedure failure  790 
This was defined as an inability to enter the uterine cavity and obtain a satisfactory 791 
view for a duration of time sufficient to allow complete systematic examination of the 792 
uterine cavity and cervical canal.  The reason for failure was documented: patient 793 
(pain, anxiety), adverse anatomy (cervical stenosis, inability to identify cervix, acute 794 
uterine deviation, adhesions), or suboptimal visualisation. 795 
 796 
Complications   797 
Serious complications in the office setting such as uterine perforation are rare, but 798 
vaso-vagal reactions (defined physiologically as a sudden drop in heart rate and 799 
blood pressure leading to syncope) can complicate between 2.3 – 9.0% of 800 
procedures8,39,48.  For the purpose of this trial vaso-vagal reactions were defined 801 
clinically as a woman being unable to leave the operating couch within five minutes 802 
of cessation of the procedure due to feeling faint, dizzy or nauseous.  803 
 804 
 805 
 806 
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Procedural pain & patient acceptability  807 
These data were collected on a ipad miniTM (AppleTM, California, USA) device.  We 808 
designed a novel system, programming the ipad device to allow easy patient input; 809 
all patients were familiarised with the system before they got changed for their 810 
procedure.  Additionally, all women were informed that their responses were 811 
confidential and once completed the screen would become ‘blank’ at which point the 812 
device should be returned to the clinical team. In this was we hoped that the validity 813 
of the patient response would be optimised by facilitating an immediate response 814 
(minimal recall bias) and blinding their response from the clinical trial (reducing 815 
observer bias).  This was administered to the participating women immediately after 816 
the diagnostic procedure but before any further intervention (e.g. endometrial 817 
biopsy, polypectomy or levonorgestrel intrauterine device (LNG-IUS, Bayer, 818 
Leverkusen, Germany) insertion.  To assess acceptability women were asked ‘Did 819 
you find the procedure acceptable?’ ‘Yes’; ‘No’.  Pain was assessed using a slider 820 
on a 100mm visual analogue scale (0 for no pain and 100 for worst imaginable pain) 821 
(Appendix 3).  822 
 823 
Infection rates  824 
The patients were contacted via email or telephone two weeks after the procedure.  825 
An infection was defined as any of the following i) if the woman had received 826 
antibiotics for a urinary tract infection or vaginal discharge; ii) if the women had two 827 
out of the following three symptoms: offensive vaginal discharge, pelvic pain and 828 
pyrexia. 829 
 830 
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Surgical technique  831 
Surgeons completed a standard form following the procedure to record technical 832 
aspects of the procedure including time taken and peri- or post-operative 833 
complications.  Data collected by the operator at the time of hysteroscopy included: 834 
the use of local anaesthesia; the need for dilatation of the cervix; the use of a 835 
vaginal speculum; the use of a tenaculum; completeness of procedure; any further 836 
procedures after the diagnostic hysteroscopy; the time taken to complete the 837 
procedure (defined as the time from insertion of vaginal instrumentation post- 838 
randomisation until the end of the diagnostic procedure); details of any adverse 839 
events (Appendix 4). 840 
 841 
Primary clinical outcome 842 
The primary clinical outcome was success, which was defined as a composite 843 
outcome of a completed hysteroscopy with an acceptable level of pain for the 844 
patient without a vasovagal episode or post-operative uterine infection.  A 845 
composite outcome was chosen as it was felt that all of these factors were 846 
important to classify a hysteroscopy as ‘successful’ based upon the evidence from 847 
the literature39 and data from our cross-sectional survey of the BSGE (see 848 
preceding section on the survey of British Society of Endoscopy members).  Each of 849 
the individual constituents of the primary clinical outcome was also examined 850 
individually as a secondary outcome.  851 
 852 
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Serious and unexpected adverse events 853 
Office hysteroscopy is performed widely across the NHS and regarded as a safe 854 
procedure.  However, all serious adverse events (SAE) were to be reported as soon 855 
as possible (Appendix 5). For the purposes of this study, “serious” adverse events 856 
were those that were fatal, life-threatening, disabling or caused prolonged 857 
hospitalisation and resulted from the hysteroscopy, or associated procedures. 858 
 859 
Data management 860 
All data were inputted into the electronic VAST database by PS.  At the end of the 861 
trial, a random 10% sample of all of the trial data were re-entered by the Chief 862 
Investigator JC to verify correct data input.  Any discrepancies between originally 863 
entered data and re-entered data were reviewed and checked against the original 864 
paper copy.  An initial data entry error rate of >5% would have triggered a 865 
requirement to re-enter the entire data set from that questionnaire.  This was not 866 
found to be necessary.   867 
 868 
Sample size 869 
A recent review of the vaginoscopy approach compared with traditional methods39 870 
found the proportion of failed procedures to be similar for both approaches: 7% for 871 
former compared with 5% for the later.  The same review found pain levels (on a 872 
visual analogue scale) to be lower with vaginoscopy (-0.44, 95%CI: -0.65 to -0.22; P 873 
< 0.001), but did not include details on the other components of our primary 874 
composite outcome measure (rates of unacceptable pain levels, vasovagal 875 
episodes and genital tract infections).  Trial data is available from other sources for 876 
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the traditional outpatient approach for these components (but not for vaginoscopy); 877 
a randomised controlled trial found that 16% of women found the procedure to be 878 
unacceptable (30% required some sort of pain relief on the day)49.  Vasovagal 879 
response rates were also reviewed in a recent systematic review found to be 880 
around 9%39.  Genital tract infections rates are thought to be around 1%50,51.   881 
 882 
Given pain levels have been shown to be lower with vaginoscopy (notwithstanding 883 
the poor quality of the current evidence) our hypothesis is that we expect this to 884 
translate to lower rates of unacceptable pain and vasovagal responses.  Rates of 885 
genital tract infection could be slightly higher than the traditional approach.  886 
Obviously there is some potential for overlap in the four components of the primary 887 
outcome.  If a conservative figure of 24% is assumed for the 'failure' rate in the 888 
traditional hysterosocpy arm (16% unacceptable plus a further 8% either failure of 889 
procedure, vasovagal response or infection).  To be able to detect a 25% relative 890 
reduction from this rate (i.e. reduced to 18%) with 80% power (P = 0.05) we would 891 
require 1500 women.   To allow for loss to follow-up and incomplete data we would 892 
aim to recruit at least 10% more than the target above.  However, given the 893 
uncertainties in our composite outcome we felt a pilot trial needed not just to 894 
ascertain feasibility and trial procedures, but also to estimate the likely magnitude of 895 
effect and confirm or refute whether our estimate for N = 1500 are correct. 896 
 897 
Statistical analysis 898 
Analysis for all parameters was intention to treat. The primary outcome was a 899 
combined measure of acceptable pain, procedure completion, no vasovagal 900 
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episodes and no infection.  This was a dichotomous outcome and was compared 901 
using chi-squared tests.  The individual components were compared as secondary 902 
outcomes using t-test and chi squared test as appropriate.  Mean 903 
differences/relative risks and 95% confidence intervals were presented alongside 904 
results of significance testing for all parameters. All analyses were carried out using 905 
SPSS software version 21 (IBM, Armonk, NY, USA). 906 
 907 
 908 
 909 
 910 
 911 
 912 
 913 
 914 
 915 
 916 
 917 
 918 
 919 
 920 
 921 
 922 
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Results 923 
 924 
Participants 925 
In total, 200 women requiring hysteroscopy were randomised over 8 months 926 
between April 2014 and August 2014.  There were 182/200 (91%) that responded to 927 
follow-up 2 weeks after the procedure to check for infection.  Figure 2. summarises 928 
the flow of participants through the trial in line with the recommendations of the 929 
consolidation standards of reporting trials (CONSORT) statement 52.   930 
 931 
 932 
 933 
 934 
 935 
 936 
 937 
 938 
 939 
 940 
 941 
 942 
 943 
 944 
 945 
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 946 
Figure 2. CONSORT flow diagram of women in trial. 947 
 948 
 949 
 950 
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Baseline characteristics 951 
The baseline variables were balanced between the groups post-randomisation 952 
(Table 5).  953 
 954 
 955 
Table 5.  Baseline characteristics of trial participants. 956 
    
Vaginoscopy 
(N=100) 
Standard 
Hysteroscopy 
(N=100) 
Age (years) Mean (SD) 44.3 (12.3) 44.2 (13.4) 
BMI (kg/m2) Mean (SD) 28.4 (7.6) 28.0 (6.8) 
Parity Mean (SD) 1.6 (1.7) 1.5 (1.5) 
Previous caesarean 
Yes 13 17 
No 87 83 
Menopausal status 
Premenopausal 70 70 
Postmenopausal 30 30 
Indication 
Bleeding 61 61 
Dysmenorrhoea 2 1 
Fertility 20 15 
Lost intrauterine device 5 6 
Pregnancy loss 0 2 
Abnormal imaging 11 15 
Amenorrhoea 1 0 
Practitioner 
J Clark 31 30 
P Smith 48 49 
S O'Connor 20 22 
  957 
BMI = body mass index; SD = standard deviation  958 
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Outcome data 959 
 960 
Overall, 99% of women found office hysteroscopy to be acceptable; with no women 961 
receiving vaginoscopy reporting the procedure as unacceptable, compared to 2 962 
(2%) women in the standard hysteroscopy group (OR 0.20 [95% CI 0.01 to 4.14]) 963 
(Table 6).  The only complications to occur during the trial were vasovagal 964 
reactions, which occurred in two women receiving vaginoscopy and five women 965 
receiving standard hysteroscopy (OR 2.58 [95% CI; 0.48 to 13.62]) (Table 6). There 966 
were two (2%) women for vaginoscopy and five (6%) for standard hysteroscopy 967 
who were classified as having an infection (Table 6).  Of the seven (4%) women 968 
who had an infection 1 (14%) was treated with antibiotics, while (86%) had at least 969 
two of the following: offensive discharge, pyrexia and pelvic pain in the two weeks 970 
after the procedure.  Significantly more procedures failed with standard 971 
hysteroscopy eight (8%) compared to vaginoscopy one (1%); (OR 8.61 [95% CI; 972 
1.05 to 70.20]) (Table 6).  The primary outcome was a successful procedure that 973 
was defined as a composite score of an acceptable level of pain, with no 974 
complications, no infection and no failures.  Vaginoscopy was significantly more 975 
successful than standard hysteroscopy (OR 4.28 [95%; 1.52 to 12.09]) (Table 6).  976 
There was no strong evidence for a difference in the median pain measured on a 977 
100mm visual analogue scale between the two techniques (33 for vaginoscopy 978 
versus 38 for standard hysteroscopy; P = 0.3). However, the median time taken to 979 
complete vaginoscopy was 2 minutes compared to 3 minutes for standard 980 
hysteroscopy (P < 0.001). 981 
 982 
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 983 
Table 6.  Outcome data for vaginoscopy compared to standard hysteroscopy. 984 
Outcome 
Vaginoscopy 
n/N (%) 
Standard 
Hysteroscopy 
n/N (%)  
OR (95% CI) 
    
Acceptable 100/100 (100) 98/100 (98) 0.20 (0.01 to 4.14) 
        
Complications    
Vasovagal reactions 2/100 (2) 5/100 (5) 2.58 (0.48 to 13.62) 
Others 0/100 (0) 0/100 (0)  
Infection       
Women meeting criteria 
for infection1 2/92 (2) 5/90 (6) 2.65 (0.50 to 14.01) 
Antibiotics for UTI 0/92 (0) 0/90 (0)  
Antibiotics for discharge 1/92 (1) 0/90 (0)  
Offensive discharge 3/92 (3) 5/90 (6)  
Pelvic pain 20/92 (22) 16/90 (18)  
Pyrexia 3/92 (3) 5/90 (6)  
        
Procedure Failed 1/100 (1) 8/100 (8) 8.61 (1.05 to 70.20) 
    
Composite score2 5/92 (5) 18/90 (20) 4.28 (1.52 to 12.09) 
        
 985 
n/N = number with positive outcome/total number reported with outcome; OR = odds ratio; CI = 986 
confidence interval; UTI = urinary tract infection 987 
1) Criteria for infection = either antibiotics for UTI or vaginal discharge or 2 of the following: offensive 988 
discharge, pelvic pain, pyrexia. 989 
2) Composite score of failure, were success was defined as an acceptable procedure, with no 990 
complications, no infections and complete procedure. 991 
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 992 
Subgroup analysis 993 
A subgroup analysis was only done for the stratification variable of menopausal 994 
status for the primary outcome of successful procedure.  In premenopausal women 995 
significantly more procedures failed with standard hysteroscopy (9/63; 14%) 996 
compared to vaginoscopy  (2/65; 3%) (OR 5.25 [95% CI; 1.09 to 25.35]).  For 997 
postmenopausal women there were more failures with standard hysteroscopy (9/29; 998 
31%) compared to vaginoscopy (3/28; 11%), but this did not reach statistical 999 
significance (OR 3.75 [95% CI; 0.90 to 15.72]). 1000 
 1001 
 1002 
 1003 
 1004 
 1005 
 1006 
 1007 
 1008 
 1009 
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Discussion 1010 
Key findings 1011 
This RCT provides evidence to suggest that vaginoscopy is quicker to perform and 1012 
more successful than standard hysteroscopy.  That is more procedures were fully 1013 
completed with an acceptable level of pain and without complications.  1014 
Vaginoscopic hysteroscopy was associated with a lower procedure failure rate but 1015 
procedural pain scores were comparable and both approaches were equally safe 1016 
and acceptable.  The improved performance of vaginoscopy may be attributed to 1017 
the avoidance of instrumentation of the lower genital tract.   1018 
 1019 
Interpretation 1020 
One of the advantages of office hysteroscopy is that it allows the investigation of 1021 
women without the risks of a general anaesthetic.  However, it is the women for 1022 
whom avoiding a general anaesthetic is most advantageous, i.e. the elderly or 1023 
obese, that can provide the biggest challenges when performing office 1024 
hysteroscopy. For instance, increasing age is associated with decreased elasticity 1025 
of the vaginal tract, and so passing a speculum maybe associated with increased 1026 
pain and anxiety for elderly women.  Access can be compromised within the lower 1027 
genital tract in women with increased BMI’s and increased soft tissue that can make 1028 
identifying the cervix difficult and painful with a speculum.  Thus, avoiding 1029 
instrumentation of the genital tract by utilising a vaginoscopic approach could be 1030 
particularly beneficial in these groups of patients, in addition to the general female 1031 
population.  However, the decreased elasticity that is associated with increasing 1032 
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age can also be associated with stenosis of the cervix.  In this situation a speculum 1033 
is necessary to allow local anaesthetic infiltration and cervical dilatation, so 1034 
vaginoscopy may not always the appropriate technique.  A subgroup analysis in 1035 
postmenopausal participants did not show a significantly more failed procedures for 1036 
standard hysteroscopy compared to the vaginoscopy (OR 3.75 [95% CI; 0.90 to 1037 
15.72]).  Although this could of been explained by the smaller number of 1038 
participants who were postmenopausal (60/200; 30%). 1039 
 1040 
Only 9/200 (4.5%) of office procedures failed.  However, it is of interest that in all 1041 
procedures where the procedure failed with the allocated treatment, the procedure 1042 
was ultimately successful with the other technique. This shows the importance of 1043 
becoming proficient in both vaginoscopy and standard hysteroscopy if one is to 1044 
perform procedures in the office setting. However, vaginoscopy failed in only 1/100 1045 
(1%) case, when a stenosed cervix was identified and a speculum was needed to 1046 
perform cervical anaesthesia to allow dilatation, compared to 8/100 (8%) cases with 1047 
standard hysteroscopy.  It appears to be the preferential technique to adopt.  1048 
Standard hysteroscopy most commonly failed because of pain associated with 1049 
insertion of the speculum.  Also, it may be that removing the speculum, and other 1050 
vaginal instrumentation, enables the manoeuvrability of the camera to be improved 1051 
allowing more successful and quicker procedures (median time 2 minutes for 1052 
vaginoscopy compared to 3 minutes for standard hysteroscopy).  Also, less torque 1053 
on the cervix may minimise pain and vasovagal responses, although our relatively 1054 
small study did not show these effects.  The size of the hysteroscope used may 1055 
influence the pain and feasibility of the procedure. In clinical settings were different 1056 
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sized hysteroscopes are employed the results may be different.  However, a larger 1057 
randomised study would be needed to have sufficient power to provide subgroup 1058 
analysis of different hysteroscope sizes.  Whilst further work is needed to improve 1059 
patient selection, the evidence suggests that vaginoscopy should be the default 1060 
technique unless it is known that cervical dilatation is needed.   1061 
 1062 
One potential advantage of having access to the cervix using the standard 1063 
technique is that the cervix can be cleaned, hypothetically reducing the incidence of 1064 
ascending infection.  However, infection rates in relation to office hysteroscopy are 1065 
very few50,51 and this had not been investigated in a rigorous RCT.  We used broad 1066 
criteria aimed to detect all infections associated with hysteroscopy including: uterine 1067 
endometritis, tubal infection, pelvic infection and tuboovarian abscess.  1068 
Reassuringly, we have demonstrated no significant difference in the rate of infection 1069 
using thorough follow-up, although given the small incidence a very large sample 1070 
would be needed. 1071 
 1072 
Comparison with other studies 1073 
Previous work comparing vaginoscopy to standard hysteroscopy has focused on 1074 
pain scores 41–46.  A meta-analysis of this work concluded that vaginoscopy 1075 
significantly reduced pain compared to standard hysteroscopy. This study showed a 1076 
trend for decreased pain with vaginoscopy, which did not reach significance.  In this 1077 
study the average pain scores for the standard technique were lower than in 1078 
previous trials 39.  This could be explained because all the studies included within 1079 
the meta-analysis used a tenaculum for standard hysteroscopy in addition to vaginal 1080 
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speculum and avoiding cervical instrumentation may confer a significant pain 1081 
reduction.  Another difference in our study compared to the studies in the meta- 1082 
analysis was the lower procedural failure rate in the vaginoscopy group compared 1083 
to the standard group.  This could have been because the hysteroscopes used in 1084 
the current study were of a smaller diameter, thus negating the need for cervical 1085 
dilatation in some cases.   We also developed and used a normal patient reported 1086 
outcome measure for estimating the degree of procedural pain; the electronic VAS 1087 
allowed immediate, blinded responses limiting recall and observer bias. 1088 
 1089 
Strengths and limitations 1090 
The main strength of our trial was the strict randomisation and the completeness of 1091 
follow-up, with 91% of women having complete data.  The hysteroscopic evaluation 1092 
of the uterine cavity was standardised and we evaluated a range of outcome 1093 
measures identified as important to women and gynaecologists, which included an 1094 
assessment of post-operative infection, an outcome not previously reported.  1095 
 1096 
One of the main limitations was the lack of blinding.  Operating in conscious 1097 
patients makes it difficult to blind participants to their allocated intervention unless 1098 
they are indistinguishable.  In the VAST trial, we did not inform the women of the 1099 
allocated procedural technique, but it is likely that most women were aware of the 1100 
particular intervention they underwent in view of the pre-randomisation verbal and 1101 
written information provided describing the techniques.  Moreover, a vaginal 1102 
speculum examination is familiar to most women over 25 years who are eligible for 1103 
cervical screening.   1104 
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 1105 
The small sample size also restricts the inferences we can draw.  However, this 1106 
RCT is more rigorously conducted and nearly as large as the biggest RCT to date42 1107 
(sample size 400).  However, this RCT is a pilot to help design and inform a larger, 1108 
more generalisable multicentre study.  Such a study would also allow investigation 1109 
of subgroups of women e.g. post-menopausal, nullliparous, high BMI who may 1110 
benefit more from one or other approaches to hysteroscopy. The generalisability of 1111 
the results would also be improved if there had been a multicentre design.  1112 
However, our general unselected population of women is likely to be representative 1113 
of the demography of women undergoing office hysteroscopy in many units.  1114 
 1115 
Our adoption of a composite outcome, in addition to evaluating outcomes 1116 
individually helped aid interpretation and inform clinical decisions regarding choice 1117 
of technique for this very common gynaecological intervention.  This is because the 1118 
procedure is established as safe and feasible and is generally acceptable with 1119 
moderate to low pain scores39,40.  Thus, we anticipated that distinguishing between 1120 
the different approaches would be difficult if looking at individual components of an 1121 
office hysteroscopy in isolation whereas evaluating the procedure in totality, using 1122 
outcome measures deemed by gynaecologists a-priori to influence their practice, 1123 
we believe aids interpretation. 1124 
 1125 
 1126 
 1127 
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 1128 
 1129 
 1130 
Conclusion 1131 
 1132 
Advances in medical technologies have facilitated increasingly convenient but 1133 
invasive office procedures.  Instrumenting the uterine cavity requires intimate genital 1134 
tract examination and can be associated with substantial pain.  Thus, in view of the 1135 
ubiquity and importance of office hysteroscopy in day-to-day gynaecological 1136 
practice, it is important to minimise pain, complications and failure associated with 1137 
the procedure to benefit patients, stream-line management and ethically utilise 1138 
healthcare resources.  In centres already providing office services, vaginoscopy 1139 
could offer a potential benefit to patients undergoing hysteroscopy with minimal 1140 
training and could save resources by reducing the need for subsequent inpatient 1141 
procedures under general anaesthesia because of failed office procedures.  A 1142 
larger, multicentre RCT is now needed to confirm these preliminary findings and to 1143 
allow subgroup analysis to estimate types of women that may particularly benefit 1144 
from vaginoscopy.  1145 
 1146 
 1147 
 1148 
 1149 
 1150 
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 1151 
CHAPTER 4: PROGNOSTIC FACTORS THAT PREDICT 1152 
SUCCESS OF ENDOMETRIAL ABLATION IN THE OFFICE 1153 
SETTING 1154 
 1155 
Publication 1156 
The work has been submitted to the Journal of Gynecolgoical Surgery to be 1157 
considered for publication. 1158 
 1159 
 1160 
 1161 
 1162 
 1163 
 1164 
 1165 
 1166 
 1167 
 1168 
 1169 
 1170 
 1171 
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Abstract 1172 
Objective 1173 
To identify clinical factors that influence the rate of further surgical intervention in 1174 
women who have endometrial ablation.   1175 
 1176 
Methods 1177 
Prospectively held electronic databases and patient records were scrutinised to 1178 
obtain historical, examination, investigative and procedural data considered to be 1179 
potentially predictive of the need for further surgical intervention after endometrial 1180 
ablation in the office setting.  1181 
 1182 
Results 1183 
A total of 391 consecutive women were identified who received endometrial ablation 1184 
in the office setting between July 2005 and December 2012, with an average follow- 1185 
up of 4.3 years. Univariable and multivariable logistic regression were used to 1186 
estimate the influence of these variables on prognosis. Factors predictive of further 1187 
surgical treatment were dysmenorrhoea (aOR 4.82; 95% CI 1.81 to 12.82) and a 1188 
uterine cavity length >9cm OR (aOR 3.13; 95% CI 1.52 to 6.43).   1189 
 1190 
Conclusion 1191 
Dysmenorrhoea before treatment or a uterine cavity length >9cm are associated 1192 
with the need for further surgical interventions after office endometrial ablation. 1193 
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These findings should help inform clinician and patient decision making when 1194 
considering treatment options for heavy menstrual bleeding. 1195 
. 1196 
 1197 
 1198 
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Introduction 1216 
Background 1217 
Heavy menstrual bleeding is a common gynaecological condition that has a 1218 
significant impact on the morbidity of premenopausal women53,54.  In the majority of 1219 
cases no organic cause is found and this is termed dysfunctional uterine bleeding.  1220 
The first line therapy for dysfunctional uterine bleeding is pharmacological 1221 
treatment55.  If this fails it is appropriate to perform an endometrial ablation55.  The 1222 
uterine sparing ablative procedure has the advantage that it can be performed in the 1223 
office setting and does not have the costs, morbidity and mortality associated with 1224 
major surgery56.  1225 
 1226 
Endometrial ablation 1227 
Endometrial ablation is targeted destruction of the endometrial lining in the uterine 1228 
cavity.  It should only be considered in women who have completed their family.  1229 
The first generation hysteroscopic techniques included resection of the 1230 
endometrium, endometrial laser ablation and roller ball ablation.  These were 1231 
rigorously evaluated against hysterectomy in number of RCTs57,58.   The first- 1232 
generation techniques still provide a treatment option in women with irregular 1233 
endometrial cavities due to submucous fibroids or congenital abnormalities.  1234 
However, they have been replaced by the second-generation techniques that have 1235 
been developed for smoother cavities.  These have included thermal balloon 1236 
devices, bipolar radiofrequency and microwave ablation.  They are safer and 1237 
technically easier to learn than the hysteroscopy based techniques and can be 1238 
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performed in the office setting.  Women undergoing endometrial ablation should 1239 
have endometrial histology prior to the procedure to ensure that malignant or 1240 
premalignant disease is not responsible for bleeding symptoms.  They should also 1241 
have a hysteroscopy before and after the procedure to make sure there is no 1242 
perforation.   Potential complications include: infection, uterine perforation, visceral 1243 
burns, haematometra and fluid overload due to absorption of distension media57,58. 1244 
 1245 
 1246 
The need to look for prognositic factors that predict failure with 1247 
endometrial ablation 1248 
 1249 
In contrast to hysterectomy, endometrial ablation cannot guarantee amenorrhoea 1250 
and the need for further surgical intervention, usually in the form of a hysterectomy, 1251 
is well recognised59. A randomised controlled trial (RCT) comparing the two most 1252 
commonly used second generation ablative devices in a novel office setting, bipolar 1253 
radiofrequency ablation and thermal balloon ablation, showed satisfaction rates of 1254 
90% and 79% respectively at 1 yr follow-up60.  However, after five years there were 1255 
eight women in the bipolar radiofrequency group (9.8%) and five in the thermal 1256 
balloon ablation group (12.9%) who had undergone a hysterectomy60.  1257 
 1258 
If it were possible to predict the chance of such treatment failure following 1259 
endometrial ablation, then alternative, potentially more effective, treatment 1260 
interventions could be considered. Two earlier studies evaluating treatment 1261 
outcomes after second generation endometrial ablation performed in a traditional 1262 
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inpatient setting under general anaesthesia have provided evidence that prognostic 1263 
variables may be identified from information gleaned from the patient history, 1264 
examination and uterine imaging61,62. Both studies identified dysmenorrhoea and 1265 
enlarged uterine cavity size as predictive of treatment failure, although the results 1266 
for age, parity and tubal sterilisation were conflicting61,62. While a network meta- 1267 
analysis of second generation endometrial ablation found only uterine cavity length 1268 
>8cm had an adverse impact on patient satisfaction63.   1269 
 1270 
In light of these inconsistent findings and the increasing adoption of the office 1271 
setting to conduct endometrial ablation64,65, we studied our cohort of office 1272 
endometrial ablations.  1273 
 1274 
 1275 
 1276 
 1277 
 1278 
 1279 
 1280 
 1281 
 1282 
 1283 
 1284 
 1285 
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Objectives 1286 
 1287 
1. To establish which women having an endometrial ablation at Birmingham 1288 
Women’s Hospital needed further intervention. 1289 
 1290 
2. To identify treatment clinical factors associated with further intervention. 1291 
 1292 
 1293 
 1294 
 1295 
 1296 
 1297 
 1298 
 1299 
 1300 
 1301 
 1302 
 1303 
 1304 
 1305 
 1306 
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Methods 1307 
Study design 1308 
We performed an observational analysis of 391 patients. 1309 
 1310 
Study setting 1311 
All women who underwent endometrial ablation in the office setting at the 1312 
Birmingham Women’s Hospital, between July 2005 and December 2012 were 1313 
included in the analysis.   1314 
 1315 
Participants 1316 
Women who had undergone office endometrial ablation for heavy menstrual 1317 
bleeding were identified through the surgical logbooks.  1318 
 1319 
Interventions 1320 
Endometrial ablations were done using either thermal balloon ablation 1321 
(ThermachoiceTM; GynecareTM; EthiconTM Inc., New Jersey, USA), or bipolar 1322 
radiofrequency ablation (NovaSureTM; HologicTM Bedford, MA, USA).  The office 1323 
endometrial ablative procedure has been previously described6,64. In short, women 1324 
were pre-medicated one hour before the procedure with either 100mg Diclofenac 1325 
rectal suppository (or 100mg oral Tramadol Hydrochloride if contraindicated), two 1326 
oral tablets of Co-dydramol 10mg/500mg and 50mg of oral Cyclizine. A direct 1327 
intracervical block was administered by infiltrating 2.2ml of 3% Mepivicaine into the 1328 
12 and 6 o’clock position before infiltrating 1.1ml into the 3 and 9 o’clock positions, 1329 
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using a 35mm, 27 gauge dental syringe; the majority of the solution was infiltrated 1330 
at the level of the internal os with the rest evenly distributed along the length of the 1331 
cervix on withdrawal of the needle. A preliminary diagnostic hysteroscopy was 1332 
performed to exclude pathology that would distort the intrauterine cavity and to 1333 
ascertain likely compliance to the procedure and the uterine length was sounded. 1334 
This was followed by endometrial ablation with bipolar radiofrequency ablation or 1335 
thermal balloon ablation, performed according to the recommended manufacturers 1336 
instructions for use. 1337 
 1338 
Data collection 1339 
The analysis included the following data parameters for each patient: age, body 1340 
mass index (BMI), caesarean section, ablation type, duration of symptoms, uterine 1341 
size, regularity of cycle, dysmenorrhea, premenstrual syndrome, anti-platelet 1342 
medication, failed medical therapy, cycle phase, uterine axis, fibroids on imaging or 1343 
examination, hysteroscopy findings and further surgical intervention.  Data for 81 1344 
patients were collected prospectively as part of the Comparison of Office Ablation 1345 
Techniques trial6,64, while data for the remaining 310 patients were collected 1346 
retrospectively by scrutinising medical records.   1347 
 1348 
Statistical methods 1349 
Data were analyzed using the SPSS statistical software version 21 (IBM, Armonk, 1350 
NY, USA). Univariable logistic regression analysis was used to determine the 1351 
influence of individual prognostic factors on the odds of requiring further surgical or 1352 
radiological intervention i.e. endometrial ablation, myomectomy, hysterectomy or 1353 
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uterine artery embolisation (UAE), which were considered to be consistent with 1354 
treatment failure. The relative importance of the above covariates was determined 1355 
with multivariate regression analysis using the stepwise backward likelihood ratio 1356 
method.  1357 
 1358 
 1359 
 1360 
 1361 
 1362 
 1363 
 1364 
 1365 
 1366 
 1367 
 1368 
 1369 
 1370 
 1371 
 1372 
 1373 
 1374 
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Results 1375 
Baseline characteristics 1376 
The average follow-up for the 391 women undergoing office endometrial ablation 1377 
during the study period was 4.3 years (range 0.2 to 8.9 years).  Table 1 shows the 1378 
baseline demographics and clinical characteristics of the women.  Of the 360/391 1379 
(92%) who had been unsuccessfully treated with medical therapy, 216/360 (60%) 1380 
had a hormonal therapy (including the levonorgestrel releasing intrauterine system), 1381 
95/360 (26%) had a non-hormonal therapy and in 49/360 it was not stated which 1382 
medical treatment they had received.  Of the 64 women who had abnormalities on 1383 
hysteroscopy before treatment: 18/64 (53%) had fibroid changes (either small 1384 
submucous fibroids or slight distortions by intramural fibroids), 8/64 (23%) had 1385 
endometrial polyps, 8/64 (14%) had congenital abnormalities (mildly arcuate) and 1386 
6/64 (9%) had synechiae.  1387 
 1388 
Further surgery 1389 
Further surgical intervention after the office ablation was subsequently reported in 1390 
49 women: 46 (12%) underwent hysterectomy, two (1%) had a uterine artery 1391 
embolisation and one woman had a myomectomy (<1%).  The majority of 1392 
interventions were performed within 24 months of endometrial ablation; 41% of 1393 
interventions by one year of follow up and 75% performed by two years. Of those 1394 
women that had a hysterectomy, pain alone was the most common indication 1395 
(19/46; 41%), followed by bleeding alone (17/46; 37%), then bleeding and pain 1396 
(7/46; 15%), 2/46 (4%) had bleeding with an ovarian mass, 1/46 (2%) had a 1397 
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persistent watery discharge and 1/46 (2%) was diagnosed with complex 1398 
endometrial hyperplasia.  Two other women had a hysterectomy, but were not 1399 
considered as treatment failures; one woman had a hysterectomy for uterine 1400 
prolapse, while the other woman had a hysterectomy for an ovarian mass 1401 
discovered as incidental finding after investigation for upper abdominal symptoms. 1402 
 1403 
Abnormal findings were found in 32/46 (70%) of the hysterectomy specimens, while 1404 
14/46 (30%) were normal (except for endometrial scarring secondary to the 1405 
endometrial ablation).  The most common abnormality found was adenomyosis 1406 
alone (14/46; 30%).  The remainder comprised of: fibroids and adenomyosis (6/46; 1407 
13%), fibroids alone (5/46; 11%), fallopian tube endometriosis (4/46; 9%), 1408 
endometrial polyps 2/46 (4%) and malignant ovarian mass 1/46 (2%).  The uterus of 1409 
the woman who had a hysterectomy because of complex hyperplasia showed 1410 
complete regression of disease.  1411 
 1412 
Pre-operative predictors of the need for further surgery 1413 
Table 7 shows the results of univariable analysis.  Both increased uterine cavity 1414 
length (OR 2.28, 95% CI 1.20 to 4.33; P = 0.01) and presence of dysmenorrhoea 1415 
before treatment (OR 3.30, 95% CI 1.50 to 7.26; P = 0.003), demonstrated 1416 
evidence for an association with the need for further surgical intervention. These 1417 
findings remained independently predictive of further surgical intervention after 1418 
multivariable analysis; dysmenorrhoea (aOR 4.82, 95% CI 1.81 to 12.82; P = 0.002) 1419 
and uterine size >9cm (aOR 3.13, 95% CI 1.52 to 6.43; P = 0.002).  1420 
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Table 7  Factors assessed for prediction of further uterine surgical intervention after office endometrial ablation. 1421 
        Univariable analysis Multivariable analysis 
Characteristic   
No Intervention 
(n=340) 
Further 
Intervention 
(n=51) Odds Ratio (95% CI) P1 Odds Ratio (95% CI) P1 
Age  >45 110 (33) 17 (35) reference    
 40 to 45 135 (40) 12 (25) 0.59 (0.27 to 1.27) 0.2   
 <40 96 (28) 20 (41) 1.36 (0.67 to 2.75) 0.5   
BMI <18.5 1 (0) 0 (0) not recordable    
 18.5 to 25.0 95 (28) 7 (14) reference    
 25.1 to 30.0 103 (30) 18 (37) 2.37 (0.95 to 5.93) 0.07   
 >30.0 143 (42) 24 (49) 2.28 (0.94 to 4.570) 0.07   
Previous caesarean 82 (24) 14 (29) 1.27 (0.65 to 2.47) 0.5   
Endometrial ablation technique 
(Bipolar Radiofrequency vs Thermal 
Balloon) 
189 (55) 29 (59) 1.17 (0.64 to 2.16) 0.6 
  
Failed medical treatment 364 (92) 44 (90) 0.72 (0.26 to 1.98) 0.8   
Phase of 
cycle Secretory 110 (32) 17 (35) reference    
 Proliferative 120 (35) 12 (25) 0.65 (0.30 to 1.42) 0.3   
 Menses 33 (10) 6 (12) 1.18 (0.43 to 3.23) 0.8   
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 Progesterone effect 79 (23) 14 (29) 1.15 (0.53 to 2.46) 0.7   
Uterine Axis Anteverted vs Other 50 (15) 8 (16) 1.14 (0.51 to 2.57) 0.8   
Abnormal hysteroscopy findings2 57 (17) 7 (14) 0.83 (0.36 to 1.95) 0.7   
Presence of fibroids3 276 (81) 38 (78) 0.83 (0.40 to 1.70) 0.6   
Duration of symptoms (months) 40.0 (43.4)4,5 32.9 (32.0)4,6 1.00 (0.99 to 1.00) 0.3   
Uterine Size >9cm7 65 (20)8 18 (37) 2.28 (1.20 to 4.33) 0.01 3.13 (1.52 to 6.43) 0.002 
Menstrual Cycle Irregular 137 (41)9 17 (37)10 0.84 (0.45 to 1.59) 0.6   
Dysmenorrhea 208 (61) 41 (84) 3.30 (1.50 to 7.26) 0.003 4.82 (1.81 to 12.82) 0.002 
Premenstrual syndrome 90 (26) 15 (31) 1.24 (0.64 to 2.37) 0.5   
Antiplatelet drugs or anticoagulants 8 (2) 2 (4) 1.78 (0.37 to 8.62) 0.5     
Data are n (%) unless otherwise specified      
1)    P = one significant figure       
2) Of the 64 women who had abnormalities on hysteroscopy: 53% had fibroid changes (either small submucous fibroids or slight distortions by intramural fibroids), 
23% had endometrial polyps, 14% had congenital abnormalities (mildly arcuate) and 9% had synechiae.  
3) Fibroids of any location found on imaging, hysteroscopy or clinical examination    
4) Data are mean average (standard deviation)      
5) Data missing for 24 cases       
6) Data missing for 5 cases       
7) Measured on a uterine sound      
8) Data missing in 22 cases       
9) Data missing in 8 cases       
10) Data missing in 3 cases       
 1422 
 1423 
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Discussion 
Key findings 
This study has provided evidence to show that women with pre-existing 
dysmenorrhoea or a uterine cavity size above 9cm are more likely to require further 
intervention after having endometrial ablation in the office setting.  Knowledge of 
these unfavourable features following history taking and examination should help 
inform patient counselling and decision making regarding the appropriateness of 
endometrial ablation in comparison to other medical and surgical treatment options 
for heavy menstrual bleeding. 
 
Comparison with other studies 
The most important risk factor for further intervention identified within this study was 
dysmenorrhoea before treatment. This is consistent with previous studies that have 
shown similar findings61,62.  Higher rates of further intervention among those women 
with pre-existing dysmenorrhoea could be caused by coexisting conditions such as 
adenomyosis.  This contention could be supported by the finding of adenomyosis in 
43% of all failed treatment hysterectomy specimens. However, 41% of all women 
undergoing subsequent hysterectomy did so because of menstrual pain, so it is 
possible that the ablative procedure could have induced or exacerbated this 
symptom because of (i) iatrogenic adenomyosis (as has been reported following 
first generation hysteroscopic ablation procedures66) or (ii) formation of intrauterine 
adhesions obstructing menstrual outflow i.e. haematometra.  The second most 
important risk factor for further surgery after ablation was a uterine cavity depth 
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>9cm.  In a larger cavity there is a more endometrium to destruct and the ablation 
devices may not be optimised for treatment of more capacious uterine cavities. 
 
There were no significant differences in hysterectomy rates based on age.  This is 
consistent with one previous case-controlled study6 but contrasts with other 
research that identified age under 40 as significantly associated with increased 
hysterectomy rate67,68. Having a previous caesarean section, taking anticoagulants 
or anti-thrombotics, irregular menstrual bleeding, uterine axis, duration of symptoms 
and BMI were not associated with an increased hysterectomy rate consistent with 
previous work61,7.  The phase of menstrual cycle has not been previously assessed 
but we did not find an association with subsequent hysterectomy. 
 
Previous work identified submucous fibroids as being associated with treatment 
failure and higher hysterectomy rates62,68,69 following ablation.  This observation is 
thought to reflect suboptimal endometrial coverage by the ablation device because 
of uterine cavity distortion. However, a recent meta-analysis of second generation 
techniques did not find the presence of submucous fibroids and intrauterine polyps 
predictive of patient satisfaction63. Our study found no association between uterine 
fibroids and further intervention, but we did not restrict our analysis to submucous 
fibroid locations.  This was because the prevalence of submucous fibroids was low 
in the current study and where they did exist they were <1cm with negligible cavity 
distortion.  Whilst many second generation ablative devices only consider 
submucous fibroids of >3cm as contraindications, in our unit most women have had 
a pre-treatment transvaginal ultrasound or office hysteroscopy and this thorough 
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diagnostic work up may have selectively removed women with any degree of cavity 
distortion by fibroids thought to impact upon the feasibility of endometrial ablation.   
 
This study showed no difference between the need for surgical intervention 
according to the type of ablative procedure, bipolar radiofrequency ablation or 
thermal balloon ablation, at a mean follow up of 4 years. This finding is consistent 
with two RCTs that have reported similar rates of hysterectomy and satisfaction 
health related quality of life measures at five years of follow up60,64. 
 
Strengths and limitations 
This cohort study original in that it is the first to look specifically at endometrial 
ablations performed in the office setting.  Other strengths of the study include the 
exploration of a wide range of possible prognostic factors for subsequent surgical 
intervention within a large population of women undergoing office endometrial 
ablation. Although the generalisability of the findings may be limited because data 
were derived from a single treatment centre, we believe that the findings are likely 
to be representative because standardised procedures were used in a large, 
diverse population of women with heavy menstrual bleeding.  
 
A limitation of this study is that it does not show if women who did not have further 
intervention were completely satisfied after treatment. There may have been women 
who were not satisfied with treatment but were not willing, or considered not 
suitable, for a further surgical procedure. Furthermore, we considered women 
undergoing a hysterectomy because of premalignant endometrial disease to have 
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failed treatment even if asymptomatic.  These patients were included because 
surveillance of endometrial hyperplasia can be hampered subsequent to 
endometrial ablation due to the formation of uterine adhesions (Asherman’s 
syndrome).  Also, without formal follow-up for all women some may have moved or 
decided to be treated in a different hospital.  However, it was reassuring that the 
hysterectomy rate was the same for the women who had data collected 
prospectively as part of the Comparison of Office Ablation Techniques trial6,64, and 
those who’s data was collected retrospectively by scrutinising medical records.   
 
The majority of the data were collected retrospectively, so results in this paper 
depended on the quality of the data obtained from clinical records.  However, the 
clinical information required was recorded as standard in the medical notes and so 
most of the data were complete; the variable with the most missing data was 
duration of symptoms, and this was only missing in 7% of cases.   
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Conclusions 
 
This study showed that one in eight women had further uterine surgery after office 
endometrial ablation and that dysmenorrhoea before treatment and a uterine cavity 
length >9cm were predictive of this need for subsequent surgery. These findings, 
derived from endometrial ablation performed in an innovative and increasingly 
utilised office, local anaesthetic setting, corroborate earlier studies performed with a 
variety of second generation ablative systems under general anaesthesia in 
hospital61,62,68. Women with pre-existing dysmenorrhoea or enlarged uteri should be 
counselled about their increased chance of requiring additional uterine surgery after 
endometrial ablation. This knowledge should help women and their clinicians 
formulate more informed decisions regarding treatment for heavy menstrual 
bleeding refractory to previous medical therapy.   
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CHAPTER 5: FIVE YEARS FOLLOW-UP OF A RANDOMISED 
CONTROLLED TRIAL TO COMPARE THE EFFECTIVENESS OF 
OUTPATIENT ENDOMETRIAL ABLATION. 
 
 
Publication 
This work has been published in the Green Journal; Smith PP, Malick S, Clark TJ. 
Bipolar radiofrequency compared with thermal balloon ablation in the office: a 
randomized controlled trial.  Obstet Gynecol. 2014 Aug;124(2 Pt 1):219-25.) 
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Abstract 
Objective 
To estimate the effectiveness of office based bipolar radiofrequency ablation 
compared with thermal balloon ablation of the endometrium for the treatment of 
heavy menstrual bleeding at five years follow-up. 
 
Methods 
A single blind randomised controlled trial (RCT) was conducted in an office 
hysteroscopy clinic in a university teaching hospital.  A total of 81 women were 
randomly allocated to either bipolar radiofrequency ablation or thermal balloon 
ablation in an office setting avoiding use of general anaesthesia or conscious 
sedation.  The main outcome measures were amenorrhoea rates, patient 
satisfaction, health related quality of life and incidence of further uterine surgery at 
five year follow up. 
 
Results 
At five years follow-up 59 (73%) of women responded to postal questionnaires.  
Amenorrhoea was reported in 60% of thermal balloon ablation and 62% of bipolar 
radiofrequency ablation (OR 1.09; 95% CI 0.38 to 3.11) and satisfaction with 
treatment outcome in 96% of thermal balloon ablation and 96% of bipolar 
radiofrequency ablation (OR 0.92; 95% CI 0.05 to 25.59). Further surgical 
intervention was needed in 3/29 (7%) women treated with bipolar radiofrequency 
ablation compared to 4/30 (13%) of women treated with thermal balloon ablation (P 
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= 0.7).  There was no significant difference in either condition specific or generic 
health related quality of life measures.  
 
Conclusions 
There was no difference in the effectiveness of bipolar radiofrequency ablation and 
thermal balloon ablation performed in an office setting at five years follow-up.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!!
Page 99 
Introduction 
 
Various methods exist to destroy the endometrium as a way of controlling HMB 
(heavy menstrual bleeding).  The range of chemicals and substances used to create 
an iatrogenic Asherman’s syndrome has even extended to the use of 
radiotherapy70.  However, endometrial ablation only gained real popularity with the 
introduction of the first generation techniques, which included rollerball endometrial 
ablation, transcervical resection of the endometrium and endometrial laser ablation.  
Trials, mainly in comparison to hysterectomy, proved these techniques were 
associated with increased patient satisfaction and decreased HMB57,71–77.  
Unfortunately, the first-generation techniques needed a high level of operator skill 
and took a long time to complete.  Moreover, national audits showed that they were 
associated with uterine perforations and fluid overload syndrome with electrolyte 
imbalances78,79. 
 
The introduction of the global endometrial ablation devices heralded the beginning 
of the second-generation minimally invasive treatments for HMB.  Not only were 
these devices shown to be more favourable to traditional resectoscopic methods in 
amenorrhoea and patients satisfaction, but they also had the advantage of being 
quicker, faster to learn and have decreased complication rates58,80.  These 
advantages led clinicians to consider the feasibility of using these methods in the 
office setting with local anaesthetic or conscious sedation.  
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The safety, feasibility, acceptability and short-term effectiveness of endometrial 
ablation for the treatment of heavy menstrual bleeding in an office setting has been 
demonstrated 6,65.  The results of longer-term follow-up are important so that women 
can be counselled properly about the results of the hysterectomy sparing surgery on 
heavy menstrual bleeding. Whilst five and ten year effectiveness data have recently 
been published for conventional inpatient endometrial ablation under general 
anaesthesia 60,81–83, there is a lack of any longer-term data for office based 
endometrial ablation.   
 
We have previously published the results of an randomised controlled trial (RCT) 
showing that office-based bipolar radiofrequency ablation (NovaSureTM; HologicTM 
Bedford, MA, USA) was significantly quicker and achieved a greater degree of 
endometrial destruction than the thermal balloon ablation (Thermachoice IIITM; 
GynecareTM; EthiconTM Inc., New Jersey, USA), although there was no significant 
difference in amenorrhoea rates at six months6.    
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Objectives 
1. To compare thermal balloon and bipolar radiofrequency ablation in the office 
setting at 3 months, 6 months, 12 months and 5 years follow-up in terms of 
bleeding amount and patient satisfaction. 
2. To assess the effects of thermal balloon and bipolar radiofrequency ablation 
in the office setting at 3 months, 6 months, 12 months and 5 years follow-up 
in terms of quality of life 
3. To compare thermal balloon and bipolar radiofrequency ablation in the office 
setting at 3 months, 6 months, 12 months and 5 years follow-up in terms of 
further uterine surgery, namely repeat endometrial ablation or hysterectomy. 
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Methods 
Study design 
A single-blinded, parallel-group, RCT comparing bipolar radiofrequency ablation to 
thermal balloon ablation for the treatment of heavy menstrual bleeding. 
 
Study setting 
This was a single centre study conducted in the office hysteroscopy clinic of 
Birmingham Women’s Hospital Foundation Trust between May 2006 to October 
2007.   
 
Eligibility  
Inclusion criteria 
To be included in the trial women needed to have heavy menstrual bleeding that 
impacted on their quality of life and opt for ablative treatment in the office setting. It 
should be noted that HMB is defined objectively as menstrual loss in excess of 80ml 
per menstrual cycle84.  In clinical practice, it is not possible to routinely perform an 
objective quantitative assessment of menstrual loss or semi-quantitative 
assessment using pictorial charts. Moreover, HMB is a subjective perception85, 
which will vary from individual to individual, and so inclusion or exclusion of women 
without regard for clinical practice would have impacted on the external validity of 
study findings.  For these reasons, eligibility criteria were a subjective complaint of 
excessive menstrual loss refractory to medical treatment.   
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Exclusion criteria 
Women were excluded if they had pathology that distorted the uterine cavity, 
previous classical caesarean section or myomectomy, were younger than 25 years, 
were perimenopausal (defined as follicle-stimulating hormone level of ≥40 
international unit/L), or there was suspicion of genital tract infection. Endometrial 
sampling was performed prior to the procedure to rule malignant and premalignant 
causes for bleeding.  All participating women gave written informed consent after 
reading a patient information leaflet (Appendix 6 – 8).   
 
Trial registration 
This trial was registered on clinicaltrials.gov (identifier: NCT01124357).  The 
National Research Ethics Service (NRES), UK, granted ethical approval (identifier: 
06/q2709/34).  Research and Development approval was sought and granted at 
Birmingham Women’s Hospital Community Trust. 
 
Randomisation 
Women were allocated in a 1:1 ratio to either of the interventions through a 
telephone-based system managed by the University of Birmingham Clinical Trials 
Unit.  The randomisation blocks were kept centrally in the Birmingham Clinical Trials 
Unit and block sizes varied so that the allocation could not be deduced pre-
randomisation.  Blocks were stratified by age (<40 or ≥40) and uterine cavity length 
(≤8cm or >8cm) to ensure we achieved balance between groups for these variables.   
Uterine cavity length was chosen because it could influence the area ablated and 
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age was chosen because of its association with an ensuing menopause (Appendix 
9).  
 
Interventions 
All women were treated in the office setting without general anaesthesia and were 
informed not to fast to prevent hypoglycaemia and reduce vasovagal episodes.  
Premedication was given one hour prior to the procedure and consisted of: 100mg 
diclofenac rectal suppository (oral if the patient did not want rectal suppository), two 
tablets of co-dydramol and an antiemetic (usually 50mg of cyclizine orally).   If the 
patient could not tolerate non-steroidal analgesics then Tramadol Hydrocholoride 
100mg orally was given instead.  During the procedure there was a designated 
nurse who stayed with the patient to offer support and distraction, providing “vocal-
local”.  The patient was positioned in the dorso-lithotomy position before being 
administered with a cervical block.  This was achieved by infiltrating 2.2ml of 3% 
mepivicaine into the 12 and 6 o’clock position before infiltrating 1.1ml into the 3 and 
9 o’clock positions, using 35mm, 27 gauge dental syringe.   The majority of the 
solution was infiltrated at the level of the internal os with the rest evenly distributed 
along the length of the cervix on withdrawal of the needle. A preliminary diagnostic 
hysteroscopy was performed to exclude pathology that would distort the intrauterine 
cavity and to ascertain likely compliance to the procedure.   Gynaecologists with 
suitable training and experience in both thermal balloon and bipolar radiofrequency 
ablation carried out all procedures.  The allocated ablative technologies were 
performed according to manufacturer’s instructions using a standard departmental 
protocol for office endometrial ablation. 
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Thermal Balloon ablation 
The Thermachoice IIITM consists of a disposable catheter with a silicone balloon at 
its distal end.  The diameter is 4.5mm before the balloon is instilled with up to 30ml 
of sterile fluid, so cervical dilation is not always necessary. The balloon catheter is 
primed ready for use using a syringe to purge air from the system and deflate the 
balloon. It is then inserted into the uterine cavity to the level of the fundus and the 
cavity length noted from the graduated catheter. The balloon is then inflated with 
sterile 5% dextrose until the pressure is stabilised between 160-180mmHg. This 
pressure allows optimal contact between the balloon and tissue ensuring an even 
heat penetration through the tissue thereby destroying the endometrium and 
underlying myometrium to a depth of 3-10mm. Intrauterine pressure fluctuation 
occurs as a result of contraction and relaxation of stimulated myometrial smooth 
muscle. The amount of intrauterine fluid required will depend upon cavity size, but is 
between 10-15ml on average. No more than 30mls of dextrose should be instilled 
and the procedure abandoned if therapeutic pressure not reached. The system is 
then switched on so that fluid within the balloon is heated to a pre-set temperature 
of 87°C, which takes 30-45 seconds on average (depending upon the amount of 
fluid instilled). The system then begins a standard 8-minute treatment cycle. On 
completion of the treatment cycle, the balloon is deflated and removed. 
 
Bipolar radiofrequency ablation 
The NovoSureTM system consists of single-use bipolar radio-frequency ablation 
device, which is inserted into the uterine cavity after cervical dilatation to 8mm.  
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Once inside the cavity the fan-shaped bipolar electrode is deployed with tips in each 
cornua.  A cavity integrity test is then performed, before the power is delivered 
which is imputed by the cavity size determined by uterine length (sound) and width 
(integral measuring device – cornu to cornu distance) measurements.  Active 
treatment is for a maximum of 120 seconds, during which suction maintains 
opposition between the electrode array and endometrium and removes steam, 
blood and endometrium from desiccated tissue. After automatic termination the 
device is closed and removed from the cavity. 
 
Outcomes 
Baseline characteristics 
The baseline characteristics of the patient were collected by the surgeon on a 
specially designed form (Appendix 10). 
 
Assessment of menstrual bleeding 
The objective of any treatment for HMB is to substantially reduce the amount of 
menstrual blood loss. The aim of endometrial ablation is to provide destruction of 
the entire endometrium so that cyclical endometrial regeneration is prevented and 
menstruation suppressed thereby inducing amenorrhoea (complete cessation of 
menstrual blood loss).  Continuing menstrual loss occurs when the entire 
endometrial surface is not removed and islands of endometrium remain functional, 
the amount is dependant upon the surface area of functional endometrium 
remaining.  For this reason amenorrhoea rates are often chosen as the primary 
outcome measure in clinical trial of the effectiveness of endometrial ablation in 
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women with HMB. Also, the complete absence of bleeding (amenorrhoea) is 
relatively objective when compared to the subjective concepts of light blood loss 
(‘hypomenorrhoea’) or restoration of ‘normal’ menstrual blood loss (‘eumenorrhoea’) 
following treatment. Therefore, the primary outcome was the proportion of women 
with amenorrhoea.  This was assessed using the following Likert scale: ‘How would 
you describe your menstrual periods?’: ‘No bleeding’, ‘Spotting or discharge only’, 
‘Light bleeding’, ‘Moderate bleeding’, ‘Heavy bleeding’.   Satisfaction with treatment 
was also measured using a Likert scale using the following response categories: 
‘Compared to before treatment, would you say that your heavy menstrual bleeding 
is: ‘Much better, ‘A little better’, ‘Same’, ‘Worse’.   
 
Dysmenorrhoea and premenstrual pain 
HMB can be associated with a number of other symptoms such as dysmenorrhoea 
and mood disturbances, either as a direct result of the bleeding, or because of 
coexisting diseases.  Moreover, successful endometrial ablation should avoid 
ablating the glandular lining of the endocervical canal because this may lead to 
cervical stenosis and subsequent problems with haematometra and pelvic pain.  For 
these reasons dysmenorrhoea measured using a Likert scale using the following 
response categories: ‘Compared to before treatment, would you say that your period 
pain is: ‘Much better’, ‘A little better’, ‘Same’, ‘Worse’, ‘Never had period pain’.  While 
premenstrual pain was measured using the following Likert scale: ‘If you had pre-
menstrual symptoms before treatment please complete the following: ‘Improved’, 
‘Same’, ‘Worse’. 
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Further intervention 
Women were asked directly in the questionnaire if they had undergone any further 
surgical treatment for gynaecological problems. 
 
Assessment of sexual function 
Sexual function is an important aspect of life quality in patients with heavy 
menstrual bleeding. HMB is an anti-aphrodisiac and it impacts upon sexual function. 
Most of the available sexual functioning questionnaires are designed specifically to 
investigate sexual dysfunction.  These were deemed unnecessarily detailed for the 
purposes of assessing the impact of treatments for HMB. The sexual activity 
questionnaire (SAQ) was developed as a self-report questionnaire for use in 
gynaecological clinical trials, which would be quick to complete and acceptable to 
the majority of women 86,87. The SAQ has been extensively field-tested for this 
purpose. The SAQ has excellent internal consistency and test retest reliability 86. It 
also has excellent concurrent and construct validity and has been shown to be 
acceptable to women in other clinical trials87.  The SAQ measures sexual function 
using a scale from 0 to 18 for pleasure and 0 to 6 for discomfort86,87, with higher 
scores indicating more pleasure and less discomfort.    In the questionnaire it was 
clearly stated that the measure of sexual function covers material that was sensitive 
and personal. Patients were reassured that their responses would be kept 
completely confidential and that if they do not wish to answer any questions, they 
were allowed to leave the questionnaires blank.  
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Generic quality of life measures 
General health related quality of life was measured using the EuroQoL-5D scale 
(best possible score was 1 for utility and 100 for the health thermometer)88,89. It 
provides a single index value for health status that can be used in a wide range of 
health conditions and treatments.  Responses will be given valuations derived from 
published UK population tariffs. 
 
Disease specific quality of life measures 
Disease specific quality of life was measured using the menorrhagia multi-attribute 
utility assessment score (Shaw score)90 and the menorrhagia outcomes 
questionnaire91.  The menorrhagia multi-attribute utility assessment score gives a 
maximum score of 100, which indicates no problems with the monthly cycle. For the 
menorrhagia outcomes questionnaire the lower the score the better; no baseline 
measurement was taken and the results were standardised to a mean of 50 as 
recommended by the author.  
 
Follow-up 
Data were collected using postal questionnaires, which were posted to women at 3, 
6, 12 and 60 months follow-up.   In cases were there was no reply a second 
questionnaire was sent.  If there was still no reply, the women were phoned and a 
third questionnaire sent with their permission. 
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Sample size 
The sample size for this trial was originally chosen to give statistical power to detect 
a significant difference in the primary measure of amenorrhoea at six months follow-
up and has been previously described. It was assumed that there would be a 10% 
rate of amenorrhoea in the control ablation group and a 40% rate in the 
experimental group (clinically important difference equal to 30%).  This meant a 
sample of 62 patients was required (31 patients in each group) based on a α = 0.05, 
β= 0.2 (80% power) and a moderate to large (0.65 SD) effect. To account for a 30% 
loss to follow-up the sample size was inflated to 80 patients (40 in each group).  
 
 
Statistical methods 
Analysis was performed by intention-to-treat. For the purpose of analysis all women 
who had undergone hysterectomy were considered to have amenorrhoea although 
a sensitivity analysis was performed in which they were considered not to have 
amenorrhoea.  Furthermore, hysterectomised women were excluded from the 
comparison of age between ablation groups because the relationship between age 
and menopause was no longer relevant. Logistic regression was employed for the 
dichotomous outcomes amenorrhoea, reduction in bleeding, dysmenorrhoea, 
premenstrual syndrome and further intervention rates. Odds ratios and 95% 
confidence intervals were derived with a chi-squared test used to assess statistical 
significance.  Mean differences and corresponding 95% confidence intervals were 
calculated for the EuroQoL-5D, health thermometer, menorrhagia multi-attribute 
utility assessment, menorrhagia outcomes questionnaire and sexual activity 
!!
Page 111 
questionnaire. A t-test was used to assess statistical significance.  All analyses 
were carried out using SPSS software version 21 (IBM, Armonk, NY, USA).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
!!
Page 112 
Results 
Participants 
Between May 2006 to October 2007, 39 women were randomised to thermal 
balloon ablation and 42 women were randomised to bipolar radiofrequency ablation 
(Figure 3)  At five years follow-up 59 (73%) women responded to postal 
questionnaires.  
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Figure 3. A randomised controlled trial of office ablation techniques 
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Baseline characteristics 
There were 29 (69%) women who responded in the bipolar radiofrequency group 
compared to 30 (77%) who responded in the thermal balloon ablation group.  The 
baseline characteristics were comparable between the two groups, although there 
was a mean 2.2yr gap between those treated with thermal balloon ablation 
compared to bipolar radiofrequency ablation (49.2yrs versus 47.0yrs; Table 8).  
There was no significant difference in baseline characteristics between the women 
that returned the questionnaires compared to those that did not.   
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Table 8. Baseline characteristics of those followed up for five years 
  
Thermal Balloon 
(n=30)  
Bipolar 
Radiofrequency 
(n=29)  
P 
#Age at 5 yrs fu (SD) 49.2 (4.6) 47.0 (4.4) NS 
(min,max) (41,59) (35,55)  
Parity (SD) 2.5 (1.2) 2.7 (1.2) NS 
(min,max) (0,6) (1,5)  
Caesarean Section (%) 5 (17) 6 (21) NS 
BMI (kg/m2) (SD) 29.3 (6.6) 29.7 (5.9) NS 
    
Folicle Stimulating Hormone 
(internation units/L) (SD) 7.2 (6.4) 5.7 (5.0) NS 
(min,max) (2.1, 31.4) (1.5, 26.4)  
    
Uterine cavity length (cm) 
(SD) 8.6 (1.2) 8.1 (0.6) NS 
(min, max) (6, 11) (7, 9.5)  
Uterine axis    
Anteflexed (%) 22 (73) 23 (82) NS 
Retroflexed (%) 8 (27) 5 (18) NS 
Axial (%) 0 (0) 0 (0) NS 
Endometrium    
Proliferative (%) 12 (40) 9 (32) NS 
Secretory (%) 9 (30) 10 (35) NS 
Menstrual (%) 8 (27) 9 (32) NS 
Atrophic (%) 1 (3) 0 (0) NS 
Dysmenorrhoea (%) 25 (83) 21 (75) NS 
Premenstrual Syndrome (%) 21 (70) 22 (79) NS 
 
# = does not include the age of those that had hysterectomy;  NS = not significant (P > 0.05). 
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Outcome data 
Assessment of menstrual bleeding 
Over the five-year follow-up there was an increase in rates of amenorrhoea for both 
treatment groups (Table 9).  At three, six and twelve months follow-up there were 
higher amenorrhoea rates in the bipolar radiofrequency ablation group, but this only 
reached a significant difference at twelve-months follow-up.  However, this 
difference in amenorrhoea rate had disappeared at five years follow-up; bipolar 
radiofrequency ablation 18/29, 62% compared to thermal balloon ablation 18/30, 
60% (OR 1.09 [95% CI 0.38 to 3.11]).  Similarly, no difference in amenorrhoea was 
observed when an adjusted odds ratio was calculated to account for the age 
difference noted in respondents and the possible effects of menopause on the 
results (OR 1.39 [95% CI 0.42 to 4.62]). Of the women who returned questionnaires 
at 12 months, 45 (90%) returned questionnaires at 5 years.  A further sensitivity 
analysis was performed to check for a response bias by presuming that those who 
did not return the questionnaires at five years had the same symptoms as they did 
at 12 months (OR 1.21 [95% CI 0.43 to 3.42]).  For the purpose of these analyses, 
women who had hysterectomy were considered to be amenorrhoeic. A sensitivity 
analysis was performed in which those women with hysterectomy were considered 
not to have amenorrhoea (OR 1.22 [95% CI 0.44 to 3.40]; P = 0.7).  
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Table 9.  The effect of office radiofrequency and thermal balloon ablation of 
the endometrium on rates of amenorrhoea  
!
 
Time point 
Thermal 
Balloon  
Bipolar 
Radiofrequency  
P 
value 
Odds Ratio (95% 
Confidence Interval) 
Amenorrhoea     
3 month 7/36 (19%) 12/36 (33%) 0.2 2.07 (0.71 to 6.09) 
6 months 7/34 (21%) 11/28 (39%) 0.1 2.50 (0.81 to 7.69) 
12 months 6/26 (23%) 14/25 (56%) 0.02  4.24 (1.27 to 14.18)  
5 years 18/30 (60%) 18/29 (62%) 0.9 1.09 (0.38 to 3.11)  
   #0.6 1.39 (0.42 to 4.62) 
Amenorrhoea + spotting    
3 month 15/36 (42%) 19/36 (53%) 0.3 1.56 (0.62 to 3.97) 
6 months 14/34 (41%) 17/28 (61%) 0.1 2.21 (0.80 to 6.13) 
12 months 15/26 (58%) 17/25 (68%) 0.4 1.56 (0.50 to 4.90) 
5 years 22/30 (73%) 23/29 (79%) 0.6 1.39 (0.42 to 4.67) 
          
 
Data are n/N (%) 
# = value at five years adjusted for age 
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Further surgical intervention 
At five years follow-up there were 3/29 (10%) women treated with bipolar 
radiofrequency ablation underwent hysterectomy compared to 4/30 (13.3%) of 
women treated with thermal balloon ablation (P = 0.7).  Two of the four women 
treated with thermal balloon ablation who ultimately had a hysterectomy had also 
undergone a repeat thermal balloon ablation procedure in the interim. Indications for 
hysterectomy in those who had thermal balloon ablation included: one woman who 
had complex hyperplasia on biopsy and three women who had persistent heavy 
menstrual bleeding.  While indications for hysterectomy in those who had bipolar 
radiofrequency ablation included: one woman who had cyclical pelvic pain, one 
woman who had offensive watery vaginal discharge and one woman who had 
persistent heavy menstrual bleeding. 
   
Patient satisfaction, dysmenorrhoea and premenstrual syndrome 
Significant improvement in heavy menstrual bleeding, premenstrual syndrome and 
dysmenorrhoea symptoms were observed following both treatments throughout the 
five-year follow-up period, but there was no evidence of difference between the 
groups (Table 10).  
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Table 10. The effects of office radiofrequency and thermal balloon ablation of the 
endometrium on menstruation, dysmenorrhea and premenstrual syndrome. 
"
Time point 
Thermal 
Balloon 
Bipolar 
Radiofrequency  
P 
value 
Odds Ratio (95% 
Confidence Interval) 
Heavy bleeding now improved:   
3 month 33/36 (92%) 34/36 (94%) 0.6 1.54 (0.24 to 9.85) 
6 months 30/33 (91%) 28/28 (100%) 0.2 #6.54 (0.32 to 132.29) 
12 months 24/26 (92%) 23/23 (100%) 0.3 #4.80 (0.22 to 105.26) 
5 years 26/27 (96%) 24/25 (96%) 0.9 0.92 (0.05 to 25.59) 
     
Period pain now improved:   
3 month 22/29 (76%) 23/30 (77%) 0.9 1.05 (0.32 to 3.47) 
6 months 21/29 (72%) 20/24 (83%) 0.3 1.90 (0.50 to 7.33) 
12 months 12/21 (57%) 16/21 (78%) 0.2 2.40 (0.64 to 9.03) 
5 years 18/21 (86%) 17/21 (81%) 0.7 0.71 (0.14 to 3.64) 
     
Improvement in emotional symptoms of premenstrual syndrome 
3 month 9/21 (43%) 17/26 (65%) 0.1 2.52 (0.77 to 8.22) 
6 months 11/22 (50%) 11/18 (61%) 0.7 1.57 (0.44 to 5.56) 
12 months 10/16 (63%) 10/20 (50%) 0.5 0.60 (0.16 to 2.29) 
5 years 13/21 (62%) 14/22 (64%) 0.9 1.08 (0.31 to 3.71) 
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Improvement in physical symptoms of premenstrual syndrome 
3 month 12/21 (57%) 15/25 (60%) 0.8 1.13 (0.35 to 3.65) 
6 months 14/21 (67%) 12/17 (71%) 0.8 1.20 (0.30 to 4.78) 
12 months 8/16 (50%) 13/20 (65%) 0.4 1.86 (0.48 to 7.12) 
5 years 14/22 (64%) 15/21 (71%) 0.6 1.43 (0.40 to 5.16) 
          
 
Data are n/N (%) 
# = for the purpose of working out the odds ratio a value of 1 was used instead of 0. 
"
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Quality of life assessment 
At five years follow-up there was no significant change from baseline for generic 
health related quality of life or sexual activity scores for either technique.  The 
disease specific health related quality of life (multi-attribute utility score) was 
significantly higher at all time points compared with baseline for both techniques, 
but there was no significant difference between techniques (Table 11).  
"
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Table 11. The effects of office radiofrequency and thermal balloon ablation of 
the endometrium on quality of life measures 
"
Time point Thermal balloon 
Bipolar 
Radiofrequency Difference (95% CI, P)* 
    
        
Euroqol change from baseline   
3 month 0.13±0.3 (36) 0.14±0.3 (35) 0.01 (-0.13 to 0.15, 0.9) 
6 months 0.14±0.3 (32) 0.16±0.4 (27) 0.02 (-0.15 to 0.20, 0.8) 
12 months 0.12±0.3 (24) 0.15±0.4 (25) 0.03 (-0.16 to 0.23, 0.7) 
5 years 0.54±1.9 (28) 1.5±1.9 (22)  -0.94 (-2.0 to 0.15, 0.09) 
    
Health Thermometer change from baseline  
3 month 6.7±18.7 (32) 4.8±18.7 (30)  -1.9 (-11.4 to 7.6, 0.7) 
6 months 7.6±20.8 (29) 7.7±21.2 (26) 0.1 (-11.2 to 11.5, >0.99) 
12 months 3.7±22.2 (21) 8.5±27.4 (22) 4.9 (-10.5 to 20.3, 0.5) 
5 years 10.6±30.9 (26) 7.5±29.0 (25) 2.7 (-14.5 to 20.0, 0.8) 
    
Multi-attribute utility score change from baseline  
3 month 41.1±27.4 (36) 46.2±26.8 (35) 4.8 (-8.0 to 17.6, 0.5) 
6 months 38.8±24.9 (33) 48.8±24.9 (27) 9.9 (-3.0 to 22.8, 0.1) 
12 months 39.5±24.0 (25) 48.3±30.0 (26) 8.9 (-6.5 to 24.2, 0.3) 
5 years 52.7±23.5 (26) 48.7±22.3 (24) 4.0 (-9.4 to 17.1, 0.6) 
    
Menorrhagia Outcome Questionnaire#  
3 month 50.3±5.8 (36) 49.9±5.6 (36)  -0.4 (-3.1 to 2.3, 0.8) 
6 months 51.4±6.8 (33) 48.3±4.2 (28)  -3.1 (-6.1 to -0.1, 0.04) 
12 months 50.2±6.1 (25) 49.6±5.8 (26)  -0.6 (-3.9 to 2.8, 0.7) 
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5 years 50.7±7.5 (28) 49.0±5.8 (21) 1.9 (-2.1 to 5.9, 0.3) 
    
Sexual Activity Questionnaire pleasure change from 
baseline  
3 month 2.1±4.0 (22) 2.2±5.9 (15) 0.1 (-3.2-3.4, 0.9) 
6 months 3.1±3.9 (18) 1.0±4.5 (13)  -2.1 (-5.1 to 1.0, 0.2) 
12 months 2.4±3.3 (14)  -1.9±7.7 (11)  -4.3 (-9.0 to 0.4, 0.07) 
5 years  -1.00±4.6 (20)  -0.46±5.2 (13)  -0.5 (-4.1 to 3.0, 0.8) 
    
Sexual Activity Questionnaire discomfort change from 
baseline  
3 month 0.35±1.34 (23)  -0.38±1.54 (16)  -0.72 (-1.66-0.22, 0.1) 
6 months 0.00±0.84 (18) 0.25±1.3 (12) 0.25 (-0.54 to 1.04, 0.5) 
12 months  -0.20±1.08 (15) 0.40±1.35 (10) 0.60 (-0.41 to 1.61, 0.2) 
5 years  -0.15±1.5 (20)  -0.75±1.5 (12) 0.60 (-0.50 to 1.70, 0.3) 
    
Sexual Activity Questionnaire increase in habit change from baseline‡ 
3 month 11/27 (41) 8/20 (40) 1.0 (0.3 to 3.2, >0.99) 
6 months 3/21 (14) 6/19 (32) 2.8 (0.6 to 13.2, 0.2) 
12 months 7/17 (41) 5/17 (29) 0.6 (0.1 to 2.5, 0.5) 
5 years  10/21 (48)  4/13 (31)  0.5 (0.1 to 2.1, 0.3) 
CI = confidence interval 
Data are mean ± standard deviation (n) unless otherwise stated 
* Those more than 0 favour bipolar radiofrequency ablation, those less than 0 favour thermal balloon 
ablation, apart from menorrhagia outcome questionnaire, for which less than 0 favours bipolar 
radiofrequeny ablation. 
# Menorrhagia outcome questionnaire standardised to a mean of 50.  Post-treatment scores only 
‡ “Much or somewhat more” compared with “the same or less”.  Odds ratio shown 
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Discussion 
Key findings 
This RCT has shown that both bipolar radiofrequency ablation and thermal balloon 
ablation are equally effective at treating heavy menstrual bleeding, dysmenorrhoea, 
premenstrual syndrome and improving health related quality of life at five years 
following treatment.  
 
Comparison with other studies 
The 62% amenorrhoea rate for bipolar radiofrequency ablation at five years 
reported in this trial is similar to longer term follow up rates previously reported for 
bipolar radiofrequency ablation performed under general anaesthesia 60,83. 
However, the 60% rate of amenorrhoea for thermal balloon ablation was almost 
double that of other studies where rates of 29-32% have been reported60,92.  This 
improvement in thermal balloon ablation may be explained in part by our use of 
Thermachoice IIITM, in contrast to earlier studies that have employed the previous, 
now no longer available model (Thermachoice ITM), which did not distribute heat so 
evenly throughout the balloon. The only other RCT comparing bipolar 
radiofrequency ablation and thermal balloon ablation was conducted under general 
anaesthesia and used the older thermal balloon ablation technology. Whilst the 
authors reported that bipolar radiofrequency ablation was superior to thermal 
balloon ablation at five years follow-up, this conclusion was not substantiated by 
their results that showed no significant differences in rates of amenorrhoea (RR 1.6 
[95% CI, 0.9 to 2.6])60. This group have just reported their ten year follow up data 
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and again identified no differences in longer term rates of amenorrhoea (RR 1.1 
[95% CI, 0.83-1.5])81.   
 
It was reassuring to note that other pertinent clinical outcomes supported the 
sustained and comparable effectiveness of bipolar radiofrequency ablation and 
thermal balloon ablation at five years; condition specific health related quality of life 
was substantially improved from baseline in both groups and nine in every ten 
women treated avoided hysterectomy. Our surgical re-intervention rates for heavy 
menstrual bleeding were consistent with rates reported in other trials of second 
generation ablative technologies at five years60,82. Two of the four women in the 
thermal balloon ablation group who had a hysterectomy also had a preceding 
repeat thermal balloon ablation, suggesting that that there may not be any clinical 
benefit to this strategy.   
 
Strengths and limitations 
The strength of this trial includes its strict randomisation and its originality, with no 
other RCTs to our knowledge, comparing ablative technologies in the office setting. 
Although we achieved more complete follow up at five years than at 12 months6, the 
27% loss to follow-up may have affected the validity of our findings to an uncertain 
degree. However, there were no significant differences in baseline characteristics 
between responders and non-responders to postal-questionnaires at five years.  In 
keeping with other RCTs evaluating endometrial ablation, our primary outcome was 
amenorrhoea83,93,94.  However, whilst this outcome is relatively objective, it may not 
be the most relevant clinical outcome when evaluating long-term successful 
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treatment.  This is because a proportion of women will enter menopause during 
follow up, thereby increasing amenorrhoea rates indirectly. The older mean age of 
the thermal balloon ablation group could explain the blunting of treatment effect 
seen at five years compared to that observed earlier at twelve months. However an 
adjusted analysis using increasing age as a surrogate marker for menopause 
provided no evidence to support this contention. It should be noted that the mean 
ages of women in both treatment groups were under 51 years, the average age of 
female menopause95. 
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Conclusions 
 
Office endometrial ablation may be convenient, but it is important that women are 
fully counselled about the longer-term effects of treatment. They should understand 
that clinical outcomes appear equivalent to data from inpatient procedures 
performed under general anaesthesia and that approximately 10% of women will 
require subsequent hysterectomy within five years. Such information will facilitate 
clinical decision making for women and their clinicians.   
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CHAPTER 6: A SYSTEMATIC REVIEW OF UTERINE 
POLYPECTOMY FOR THE TREATMENT OF ABNORMAL 
UTERINE BLEEDING 
 
Publication 
This work will be published as part of the outpatient versus inpatient polypectomy 
trial (OPT, http://www.opt.bham.ac.uk, ISRCTN65868569) Health Technology 
Assessment report.  The OPT trial has been accepted for publication by the British 
Medical Journal; Cooper NAM, Clark TJ, Middleton L, Diwaker L, Smith P, Denny E, 
et al. A randomised trial of outpatient versus inpatient uterine polyp treatment for 
abnormal uterine bleeding. BMJ. 2015;In Print. 
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Abstract 
 
Objective 
The aim of the study was to assess the efficacy of uterine polypectomy in the 
treatment of abnormal uterine bleeding 
 
Methods 
A systematic review of uterine polypectomy for abnormal bleeding was conducted. 
MEDLINE, EMBASE and CINAHL were searched (from inception to 2013) using 
MeSH headings for polyps combined with word variants for endometrium 
(endometri* OR uter*) and surgical polypectomy (surgery OR curettage OR 
hysteroscopy OR polypectomy).  Furthermore, all the bibliographies of relevant 
studies were hand searched to identify articles not captured by the electronic 
searches. Two reviewers independently selected trials. Data were extracted for 
relief of abnormal bleeding symptoms measured in general terms (improvement 
from baseline, normalisation of bleeding patterns) and patient satisfaction. 
Secondary outcomes included technical feasibility and complications.  Due to a lack 
of studies with a comparative group meta-analysis could not be performed and the 
data were tabulated to allow qualitative analysis. 
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Results 
17 studies met our inclusion criteria enrolling a total of 1829 patients between 1989 
and 2009.   There were two randomised controlled studies and 15 observational 
studies, only two of which were controlled.  All the studies reported an improvement 
in abnormal uterine bleeding following uterine polypectomy in the range of 60 -
100%. 
 
 
Conclusions 
The evidence collated in this review supports the notion that removing uterine 
polyps is effective at improving symptoms of abnormal uterine bleeding. However, 
most of the evidence was derived from observational studies that reported high 
success rates, but in general the quality of the research was poor. The highest 
quality studies, the two randomised controlled trials, reported more modest 
improvements in symptoms.   
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Introduction 
Background  
Endometrial polyps are focal outgrowths that can occur anywhere within the uterine 
cavity. Uterine polyps are composed of either functional and/or basal endometrium. 
They are typically a mixture of dense fibrous tissue (stroma), large and thick walled 
vascular channels, and elongated glandular spaces of varying shapes96,97, which 
protrude into the uterine cavity. The underlying cause of uterine polyp formation 
remains unclear, but is believed to be multifactorial 98.   
 
The prevalence of uterine polyps in a general adult female population without 
abnormal uterine bleeding (AUB) is generally estimated to be around 10%3. Case 
series of asymptomatic women are generally small and estimates of prevalence 
imprecise; following transvaginal ultrasound, uterine polyps were detected 
incidentally in 12% of premenopausal women99 and in 6%-11% of infertile women 
without AUB100,101.  In asymptomatic postmenopausal women, prevalence of 
between 13%99 and 16%102 have been reported following investigation with 
ultrasound and hysteroscopy respectively. However, they are found with increasing 
frequency in women undergoing investigation for problems with abnormal uterine 
bleeding.  In addition to AUB, risk factors for uterine polyp development are thought 
to include obesity, late menopause and the use of the partial oestrogen agonist 
Tamoxifen 99,103–105.  The role of hormone replacement therapy (HRT) on polyp 
formation is unclear with some studies supporting an association 99,103 and others 
not 106,107. 
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Once a uterine polyp has been diagnosed, the current clinical consensus is to 
remove it 108. The rationale for this approach is based upon (i) a belief that they are 
unlikely to spontaneously resolve, (ii) a desire to alleviate AUB symptoms or 
optimise fertility and (iii) a need to exclude serious endometrial disease 3. The vast 
majority of uterine polyps are benign and endometrial cancer originating within the 
polyp is a rare occurrence. Case series of varied populations report a cancer 
prevalence of approximately 0.5-3% 109–116.   
 
Since the introduction of diagnostic hysteroscopy and high-resolution pelvic 
ultrasound it has become apparent that uterine polyps are highly prevalent during 
investigation of AUB. The reported prevalence of endometrial polyps in general is 
considered to be between 20-30% 106,117,118, this variation reflects the criteria used 
to define a polyp, the diagnostic test used and the type of population studied. Whilst 
the prevalence of uterine polyps may be increased after the menopause 99, polyps 
are found to commonly affect both pre- and postmenopausal women across all age 
groups 119. In recognition of the frequency in which uterine polyps are discovered in 
women of reproductive age, the International Federation of Gynecology and 
Obstetrics have recently accepted a new classification system for causes of 
abnormal uterine bleeding in the reproductive years, based on the acronym ‘PALM-
COEIN’ with the ‘P’ denoting a ‘polyp’ i.e. describing AUB associated with the 
presence of uterine polyps120. 
 
With more endometrial polyps being diagnosed there has been an increase in 
surgical removal of polyps (‘polypectomy’).   This is the accepted practice for the 
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majority of gynaecologists, not only to treat symptoms, but also to obtain tissue for 
histological analysis to ensure the polyp is benign108.   
 
 
Treatment of uterine polyps  
Traditionally, investigation and treatment of endometrial polyps was done under 
general anaesthetic using blind dilation and curettage (‘D&C’).  This involves dilating 
the cervix to allow the blind insertion of polyp forceps or a curette to explore the 
uterine cavity.  This technique is still employed by many gynaecologists today, 
although a diagnostic hystesteroscopy is usually performed beforehand to identify 
the location of the polyp and guide blind avulsion 35,108.  Due to the discomfort 
associated with D&C, it is necessary to perform the procedure under a general 
anaesthesia, which is associated with significant use of health care resources. In 
the United Kingdom there is an increasing trend for more endometrial 
polypectomies; between 2011-2012 there were 25,000 procedures which was an 
increase of over 4,000 procedures from 1998-1999 (Department of Health, Hospital 
Episode Statistics) 121. 
 
 
Expectant management 
The observation that polyps are an incidental finding in around 5-15% of women 99–
102, that the majority of polyps are benign 122,123, and that some may naturally 
regress 119,124 has led some to question whether removal of uterine polyps is 
necessary 125.  Furthermore, removal of polyps may subject women to unnecessary 
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morbidity and wastage of scarce health service resources. Two RCTs have 
addressed this issue randomising women with AUB and uterine polyps to expectant 
management or surgical removal 122,125.  One trial failed to recruit women with PMB 
because neither doctors nor patients were in equipoise and so were unwilling to 
participate 125.  This finding is consistent with postmenopausal women having a 
preference for hysteroscopic diagnosis and treatment where an abnormality is found 
35. The other RCT randomised 150 women with uterine polyps, of which 60% had 
AUB symptoms.  Overall, no reduction in periodic blood loss was demonstrated at 6 
months follow up, but inter-menstrual bleeding (IMB) symptoms were significantly 
improved 122.  However, it should be noted that the findings from this study are 
limited for a number of reasons: the study was restricted to pre-menopausal 
women, the sample size was small, only 60% of the population included were 
symptomatic, their presenting complaints were heterogeneous and the study length 
of follow up was short. 
 
Medical management 
Medical management is widely adopted for the treatment of menstrual complaints 
and includes the use of hormonal contraceptives. Whilst some of these women may 
have undiagnosed uterine polyps, evidence for the use of medical therapy is lacking 
and not recommended55. Gonadotrophin releasing hormone analogues (GnRH-a) 
have been used prior to hysteroscopic resection of focal pathologies in pre-
menopausal women 126, but the costs and menopausal side effects are difficult to 
justify for the removal of uterine polyps. This is because polyps are successfully 
removed in the majority of cases without the need for adjunctive medical 
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preparation, in contrast to submucous fibroids. One small series evaluated different 
HRT regimens to see whether some have a reduced propensity to polyp 
formation127.  The use of levonorgestrel releasing intrauterine system in women 
taking Tamoxifen has been reported to reduce the incidence of endometrial polyps 
128. 
 
Surgical management (Polypectomy) 
A UK national survey 108 and two subsequent Dutch surveys 129,130 confirmed that 
the vast majority of gynaecologists advocated surgical removal of polyps from the 
uterus after diagnosis with 854/918 (93%)108 455/553 (83%)129 and 411/585 (91%) 
respondents performing polypectomy 130. In the UK, the predominant method for 
removal of uterine polyps was by blind avulsion or curettage, after hysteroscopic 
location of the focal lesion under general anaesthesia 108 whereas in the 
Netherlands removal under direct hysteroscopic vision under general or regional 
anaesthesia 129,130  was the favoured approach.  
 
Blind methods to retrieve focal intrauterine pathology included blind curettage of the 
endometrium or avulsion with polyp forceps. These approaches can be associated 
with potential uterine trauma which can be unrecognised and lead to serious 
complications from intra-abdominal damage 131,132. Failure to remove polyps and 
problems with incomplete removal are well recognised 28,132–136. 
 
Advances in hysteroscopic equipment have enabled polyps to be removed under 
direct vision. Fine mechanical instruments, such a scissors, biopsy cups, forceps 
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and snares can be used down a 5 or 7 Fr working channel of a rigid operative 
hysteroscope and the safety and feasibility of such approaches have been reported 
3,33,137,138.  Potential drawbacks of mechanical instrumentation are the fragility of the 
instruments, limited manipulation, difficulty with cutting or avulsing large and fibrous 
pathology and in some instances bleeding 3,139.  
 
The adoption of electrosurgical technologies may help overcome these difficulties. 
Large diameter hysteroscopic resectoscopes, developed originally to resect the 
endometrium for the treatment of HMB 140, can also be used to resect focal 
pathologies such as submucous fibroids 126,141, or polyps 142,143.  They have the 
advantage of speed and manipulation, but the large diameter of the instruments 
necessitates general anaesthesia, specialised skills are required 144,145 and potential 
serious complications from fluid overload and inadvertent electrosurgical injury can 
occur 78.   
 
In contrast to firm submucous fibroids of myometrial origin, polyps are generally 
softer structures derived from the underlying endometrium. Thus, it has been 
recognised that smaller, less traumatic electrosurgical instruments would suffice. A 
miniature bipolar electrosurgical system has been developed  (Versapoint® 
(Gynecare, Ethicon, Somerville, NJ, USA)) to cut away polyps and the safety, 
acceptability and feasibility of this approach has been reported 146–148.  However, 
retrieval of the tissue specimen from the uterine cavity can be problematic and 
usually requires the additional use of mechanical instruments to effect 3.  Other 
technologies including monopolar electrosurgical snares 138 and more recently 
!!
Page 137 
morcellation technologies  (TRUCLEAR™, Smith & Nephew, Andover, MA, USA) 
and Myosure (Hologic, Marlborough, MA USA)), which allow simultaneous tissue 
cutting and extraction have been developed 149,150. 
 
Evidence for uterine polyp treatment in abnormal uterine bleeding 
We have undertaken a systematic review of the effectiveness of uterine 
polypectomy building on a previously published systematic review 33, using updated 
methodological advances in search strategies, quality assessment and statistical 
analysis 151,152.   
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Objectives 
1. To systematically review the literature to evaluate the effectiveness of uterine 
polypectomy for the treatment of AUB.  
2. Our secondary aims were to establish if the type of AUB, setting or technique 
influenced outcome. 
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Methods 
Search strategy 
We performed searches on the general bibliographic databases Medline (1950-
2013), EMBASE (1980-2013) and CINAHL (1981-2013).  Based on published 
advice, our search term combination for electronic databases was MeSH headings 
for polyps combined with word variants for endometrium (endometri* OR uter*) and 
surgical polypectomy (surgery OR curettage OR hysteroscopy OR polypectomy).  
Furthermore, all the bibliographies of relevant studies were hand searched to 
identify articles not captured by the electronic searches (Appendix 11). 
 
Study selection 
Two reviewers (PPS and NAMC) independently selected articles in a two-stage 
process.  Firstly, abstracts obtained by either the electronic database searches or 
bibliography inspections were reviewed and articles that could possibly fulfill the 
following criteria were selected for full text review:  
 
Inclusion criteria 
• Population – Women with intrauterine polyps and AUB 
• Intervention – Uterine polypectomy  
• Outcome – Relief of AUB symptoms*  
*measured in general terms -  e.g. objective, semi-objective or subjective 
measures of change in AUB; normalisation of bleeding patterns; satisfaction 
with AUB outcome; change in quality of life scores from baseline. 
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Once articles were selected, both reviewers used specially designed data extraction 
forms to collect data on the main outcome measure that was relief of AUB 
symptoms.  Secondary outcomes included technical feasibility, complications and 
polyp histology.  Differences in article and information selection were solved by 
deliberation.  Where a consensus could not be found a third reviewer (TJC) made 
the final judgment.  No language restrictions were applied and translation available 
where necessary. 
 
The strength of agreement between reviewers taking into account the play of 
chance was computed using kappa statistic (agreement is considered good if > 0.6 
and very good if > 0.8) 
 
Type of study included 
All relevant randomised controlled studies (RCTs) were included.  Due to the small 
number of RCTs, non-randomised studies including both prospective and 
retrospective observational studies were also included. 
 
Study quality assessment  
The 2007 STROBE checklist was used to assess the quality of the observational 
studies 153, while the Cochrane risk of bias tool checklist was used to assess the 
quality of the randomised controlled studies 151.  Two reviewers independently 
scrutinised the articles against each element of the relevant checklist. 
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Synthesis of results 
Originally, in the absence of heterogeneity, data pooling and meta-analysis was 
planned.  However, due to a lack of controlled studies this could not be performed. 
All extracted data were tabulated to allow qualitative analysis. 
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Results 
 
Figure 4.   Study selection process. 
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Results of search 
From the electronic search we obtained 1122 citations and a further two from 
searching reference lists of relevant articles.  At this stage 1075 citations were 
excluded based on a review of the abstracts and titles.  An attempt was made to 
retrieve the remaining 49 articles for further scrutiny.  One article could not be 
retrieved either online or via the British Library. Review of these articles showed that 
32 did not meet the selection criteria. The characteristics of the excluded articles 
are described in Figure 4.  There was a high level of agreement between reviewers 
for which articles should be retrieved for further scrutiny (Kappa agreement = 0.92; 
P = < 0.001). 
 
Included studies 
The 17 studies that met our inclusion criteria 21,122,142,147,154–165 enrolled a total of 
1829 patients between 1989 and 2009. The population size ranged from 8 to 311 
with only 5 studies having a population size of over 100 122,142,154,157,161. 
 
Study quality and design 
There were two RCTs: one comparing inpatient versus outpatient treatment 165, 
while the second compared polyp removal with observation for six months 122.  The 
RCTs were assessed for quality using the validated Cochrane risk of bias tool 151 
(Figure 5).  Of the remaining 15 observational studies, only two had a comparative 
group: one compared inpatient versus office treatment 147 and the second compared 
hysteroscopic morcellation to electrical resection 154.  The remaining 15 articles 
were non-comparative observational studies. Only six of the studies were 
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prospective although the majority of the studies collected the data consecutively 
21,122,147,163–165.  All observational studies meeting the selection criteria were 
assessed for quality using the validated tool STROBE153 (Figure 6). 
 
Figure 5.  Study quality of the randomised controlled trials using the Cochrane risk 
of bias tool. 
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Figure 6.  Quality of observational studies using the STROBE guidelines. 
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Participant characteristics 
One study looked exclusively at women suffering from PMB21, seven studies looked 
at only women who were premenopausal122,155,156,158,161,162,164 and the remaining 9 
studies examined mixed populations of women with AUB (Table 12).   
 
Interventions 
When the operative technique was described, polypectomy was performed under 
direct vision (hysteroscopically) with the exception of two studies that had inpatient 
arms in which blind avulsion was used 147,165 (Table 13). There were a variety of 
techniques and instruments described for polyp removal under direct vision 
including: scissors, polyp forceps, morcellator devices and a variety of bipolar 
instruments. 
 
Outcomes 
There were large differences in the time of follow-up, ranging from two months 160 to 
over nine years 142 (Table 14).  Only two studies used a validated tool for measuring 
efficacy of polypectomy: both studies used a visual analogue scale (VAS) 147,164.  
The majority of studies defined the primary outcome as an improvement in 
symptoms of AUB as perceived by the patient.  All the studies reported an 
improvement in symptoms from 60-100% 21,122,142,147,154–166.  The study looking 
exclusively at postmenopausal patients presented a survival analysis curve21.  The 
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seven studies looking at premenopausal patients reported improvements in 60-
100% of participants 122,155,156,158,161,162,164. The remaining nine studies looking at 
mixed populations reported 65-100% symptomatic improvements 
142,147,154,157,159,160,163,165,166.  Two of these studies further explored recurrent AUB 
symptoms for those that were pre and postmenopausal at treatment 154,159.  One of 
the studies found no significant difference in AUB at 1 year, although the numbers 
were small (27 of 34 premenopausal patients versus 12 of 12 postmenopausal 
patients; P = 0.2)159.  While a larger study found that premenopausal women were 
more likely to have recurrence of symptoms (Hazard Ratio [HR] 2.42 [95% CI 1.42-
4.11])154.  Another study examined symptom outcome by types of AUB in 
premenopausal women; no differences in outcome were observed for those women 
complaining of HMB or IMB, although the study population was small (HR 1.29 
[0.61 to 2.73]; P = 0.50 and HR 0.42 [0.09 to 1.76] P = 0.24) 158. 
 
The two studies comparing inpatient to office treatment reported no difference in 
symptom improvement, although the study sizes were small: 11 of 12 (92%) after 
office treatment compared with 13 of 14 (93%) after inpatient treatment 147; and 
18/22 (82%) after outpatient treatment compared with 17/26 (65%) after inpatient 
uterine polypectomy RR 1.25 (95% CI 0.88 – 1.83) 165.  In both studies the office 
polypectomies were performed under direct vision, while inpatient polypectomy was 
performed ‘blindly’.   
 
There was one other controlled observational study and that compared mechanical 
polyp resection (using a morcellator) versus electrical resection. Overall, 36 of 172 
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patients (20.9%) undergoing electrical resection and 21 of 139 patients (15.1%) 
undergoing intrauterine morcellation reported recurrence of AUB 154. 
 
The randomised controlled study comparing resection of polyps with observation for 
six months reported no difference in periodic blood loss using the pictorial blood 
assessment chart (PBAC), but did report a significant decrease in recurrence of 
gynaecological symptoms (e.g. IMB and vaginal discharge) in those women having 
polypectomy (7/75 patients [9.3%] versus 28/75 control patients [37.3%]; P < 0.001) 
122. 
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Table 12.  Methodology of the included studies 
Study Methodology   Patient 
Selection 
Population - polyps and AUB   
Author Study design Data collection Number Type (%) Follow-up (%) 
Clark et al165 
Randomised 
controlled trial Prospective Consecutive 60 Unspecified menstrual; PMB  80 
Lieng et al122 
Randomised 
controlled trial Prospective Consecutive 150 
Intermenstrual (47); Menorrhagia (13); 
Irregular (8); Discharge (7); asymptomatic 
(25) 95 
              
AlHilli et al154 
Controlled 
Observational Retrospective Consecutive 
311(IUM 
139, HSR) 
Menorrhagia (19%), menometrohagia 
(10%), postmenopausal bleeding (44%)  100 
Barisic et al155 Observational  Unreported Unreported 8 Unspecified menstrual 100 
Brooks et al156 Observational  Unreported Unreported 9 Excessive menstrual 89 
Clark et al147 
Controlled 
Observational Prospective Consecutive 58 
Unspecified menstrual (10); PMB +/- HRT 
(90) 58 
Cravello et al157 Observational Retrospective Consecutive 195 
Unspecified menstrual (60); PMB + HRT 
(12); tamoxifen (2); PMB (26) 89 
Henriquez et al158 Observational Retrospective Consecutive 56 Unspecified 100 
Nagele et al159 Observational Unreported Unreported 33 
Excessive menstrual (47); intermenstrual 
bleeding (13); PMB 40 100 
Pace et al160 Observational Unreported Consecutive 87 
Unspecified menstrual/PMB (86); subfertility 
(14) 87;49 
Polena et al161 Observational Retrospective Consecutive 367 Menorrhagia, metrorrhagia, intermenstrual 83 
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bleeding 
Preutthipan et al142 Observational Retrospective Unreported 155 
Metrorrhagia(31), hypermenorrhea(29), 
IMB(19), menorrhagia (11) and 
menometrorrhagia(10) 100 
Stamatellos et al162 Observational Retrospective  Unreported 83 Unspecified 100 
Timmermans et al21 Observational Prospective Consecutive 49 PMB 100 
Towbin et al163 Observational Prospective Consecutive 14 
Menorrhagia, metrorrhagia. 
Postmenopausal 100 
Tjarks et al166 Observational Retrospective Unreported 34 Unspecified menstrual (64); PMB (36) 100 
van Dongen et al164 Observational  Prospective Consecutive 21 
Menorrhagia, metrorrhagia, intermenstrual 
bleeding 90 
AUB = abnormal uterine bleeding; ECA = endometrial cancer; EH = endometrial hyperplasia; EH+A = endometrial hyperplasia + cytological atypia; HRT = 
hormone replacement therapy; HSR = hysteroscopic resection; IUM = intrauterine morcellation; NR = not recorded; PBAC = pictoral blood assessment chart; 
PMB = post menopausal bleeding; SD = standard deviation; VAS = visual analogue scale 
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Table 13.  Operative details of included studies. 
Study Author Technique (%) 
Anesthesia 
(%) 
Mean operation 
time Polyp number (%) Mean polyp size (range) 
Polyp 
histology (%) 
Clark et al165 
Outpatient = 
hysteroscopic; inpatient 
= blind 
Outpatient = 
local (93), 
none (7); 
Inpatient = 
General (100)  
Outpatient 
(consultation 
time) 29min; 
Inpatient 24min NR NR NR 
Lieng et al122 
Hysteroscopic resection 
or observation General  NR NR 16.5 mm (5.3SD) 
EH (1.5) Benign 
(98.5) 
              
AlHilli et al154 Hysteroscopic resection General NR 
Single (65); multiple 
(35) 2.1cm EH + ECA(7) 
Barisic et al155 Hysteroscopic resection General NR Single (100) (1.8-3cm) 
EH (13); benign 
(87) 
Brooks et al156 Hysteroscopic resection General NR NR NR NR 
Clark et al147 
Hysteroscopic 
(Versapoint) (50); or 
hysteroscopy + blind 
avulsion (50) 
Local (50); 
general (50) NR NR 0.9cm NR 
Cravello et 
al157 Hysteroscopic resection General 19 min 
Single (90); multiple 
(10) 1.4cm(0.5-4cm) 
EH+A (1); 
benign (99) 
Henriquez et 
al158 Hysteroscopic 
General or 
spinal NR 
single (62); multiple 
(39) 17.5 mm(SD 8.3) NR 
Nagele et al159 
Hysteroscopic resection 
or mechanical excision 
(scissors) 
Local (20); 
general (80%) NR 
Single; "some" 
multiple (1-5cm) 
EH+A(2); ECA 
(2); benign(96) 
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Pace et al160 Hysteroscopic resection General 22 min 
Single (86); multiple 
(14) (<1.5cm[45%]; >1.5cm[55%]) 
EH(1); 
benign(99) 
Polena et al161 Hysteroscopic resection General NR 
Single (81); multiple 
(19) NR 
ECA(0.05); 
benign(99.5) 
Preutthipan et 
al142 Hysteroscopic resection General 
23.1+/-4.7 
microscissors; 
20.9 +/-3.9 
grasping forceps; 
25.2+/-4.9electric 
probe; 31.9+/-8.3 single (74);  
3.4+/-0.9cm premenopausal; 
2.5+/-0.8cm postmenopausal 
EH (3); benign 
(97) 
Stamatellos et 
al162 Hysteroscopic resection 
General or 
none NR 
single (41); multiple 
(59) same as polyp 
size data <1cm[41]; >1cm[59] NR 
Timmermans 
et al21 NR NR NR NR NR NR 
Towbin et al163 NR NR NR NR NR NR 
Tjarks et al166 NR General NR 
Single (88); multiple 
(12) (<1cm[13%]; >1cm[87%]) NR 
van Dongen et 
al164 Hysteroscopic resection 
General or 
spinal NR 
single (38.1); 
multiple (61.9) 13.2 mm (4.7SD) NR 
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Table 14.  Treatment outcomes of included studies 
Study Author 
Failure rate/ 
complication 
rate Outcome assessment (time) Outcome measure Treatment success (%) 
Clark et al165 
Outpatient 
2/1; Inpatient 
0/0 
Postal questionnaire (6 
months) Improvement in VAS Outpatient 18/22(82); 17/26(65) inpatient 
Lieng et al122 0/1 
Postal questionnaire (6 
months) No gynecological symptom 68/75(91) resection; 47/75(63) observation 
      
AlHilli et al154 NR Clinical interview Recurrence of AUB 
118/139(85) IUM; 136/172(79) HSR; 
254/311(81) both 
Barisic et al155 NR/NR NR (first 3 menstrual cycles) Normalisation of AUB 8/8 (100) 
Brooks et al156 NR/0 NR (>3 months) Improved vs not improved 7/8 (88) 
Clark et al147 0/0 
Postal questionnaire at 6 
months 
Better vs not better; satisfied 
vs not satisfied 
Outpatient 11/12 (92); inpatient: 13/14(93); 
Outpatient: 14/18 (78); inpatient: 14/16 (88) 
156/175 (89) 
Cravello et al157 0/2 
Telephone interview with 
patients or referring clinicians 
(NR) Normalisation of AUB 156/175 (89) 
Henriquez et 
al158 NR Review of clinical notes 
Persistence of AUB 
requiring medical therpay or 
surgical intervention 33/56 (60) 1yr 
Nagele et al159 0/0 
Clinical interview (3 months); 
postal questionnaire (5-52 
months) 
Short-term "cure" of AUB; 
maintenace of "cure" (no 
recurrence of AUB) 44/49 (90); 38/49 (78) 
Pace et al160 0/1 
Clinical interview (2 months); 
clinical interview (12 months) 
Normalisation of AUB (no 
"relapse" of symptoms) 85/87 (98);100 
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Polena et al161 
1/4 (out of 
total 
population of 
367) 
Telephone interview and 
postal questionnaire Normalisation of AUB 91/97(94) 
Preutthipan et 
al142 NR/21 
Clinical interview 9 years 2 
months Normalisation of AUB 144/155 (93) 
Stamatellos et 
al162 NR/2  
Telephone interview or 
examination when indicated 
(3-18 months) Normalisation of AUB 76/83(91) 
Timmermans et 
al21 NR/NR 
Patients self reported 
symptoms Recurrence of PMB Survival curve 
Towbin et al163 NR Clinical interview Recurrence of AUB 14/14(100) 
Tjarks et al166 NR/NR 
Telephone interview (5-24 
months) 
Menorrhagia score (scale 0-
3); number of days 
bleeding/month; satisfied vs 
not satisfied 
Significant reduction P<0.05; significant 
reduction P<0.05; 23/26(88) 
van Dongen et 
al164 NR/NR Questionnaire 
Improvement of symptoms; 
menstrual chart score; VAS 
quality of life 
18/21(86); improvement P = <0.001; 
improvement P = <0.001 
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Discussion 
 
Key findings 
The evidence collated in this review supports the notion that removing uterine 
polyps is effective at improving symptoms of AUB. However, most of the evidence 
was derived from observational studies that reported high success rates, but in 
general the quality of the research was poor. The highest quality studies, the two 
randomised controlled trials, reported more modest improvements in symptoms 
122,165.  However, it was unclear whether menopausal status or the exact nature of 
the presenting AUB complaint influences treatment outcome.   
 
Strengths and limitations 
The strengths of this review included the rigorous, systematic approach to literature 
searching; independent selection of studies and data extraction in duplicate; and 
use of recommended study quality assessment tools 151,153.  The included studies 
were however, small and many contained heterogeneous populations of women 
who were both pre and postmenopausal. In addition, follow up was often incomplete 
and short-term, such that the strength of any clinical inference drawn is limited. 
Meta-analysis was precluded because of the observed heterogeneity within and 
between the study populations, as well as variation in follow-up and outcome 
assessment.   
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Comparison with other studies 
The majority of studies reported hysteroscopic polyp resection under direct vision.  
However, although hysteroscopic polypectomy is increasing in popularity, a large 
number of clinicians continue to use blind techniques such as dilation and curettage 
(D&C) affecting the generalisability of the results presented in this review 108,129,130. 
To better ascertain the effect of polyp removal on AUB we decided not to include 
data in which patients had concomitant or subsequent medical or surgical 
treatments e.g. insertion of the LNG-IUS which may also affect generalisability.   
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Conclusions 
Larger randomised controlled studies are necessary to elucidate if certain groups of 
patients benefit more from uterine polypectomy.  However, recruitment may be 
hampered by the unwillingness of both gynaecologists and patients to participate in 
placebo controlled trials 125. A further consideration is the increasing move to office 
polypectomy observed in many units, driven by technological advances in 
instrumentation, patient expectation and scarcity of health care resources 3. Only 
two randomised studies were identified in this review. Large RCTs comparing 
conventional inpatient with novel outpatient approaches to polyp treatment are 
needed to identify best practice before opinion is solidified.   It is also important to 
note that alleviation of AUB is not the only reason why uterine polypectomy is 
performed.  Other reasons include the optimisation of fertility and concerns about 
the potential for polyps to turn malignant.  Further work is needed in these areas to 
inform decisions on how and when to treat uterine polyps.  
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CHAPTER 7:  A RANDOMISED CONTROLLED TRIAL OF 
HYSTEROSCOPIC MORCELLATION OF INTRAUTERINE 
POLYPS 
 
 
 
Publication 
This work has been peer reviewed and published in the Green Journal; Smith P, 
Middleton L, Connor M, Clark J. Hysteroscopic Morcellation Compared With 
Electrical Resection of Endometrial Polyps: A Randomized Controlled Trial.  
Obstetrics and Gynecology 2014 April, Vol 123, No 4 pg 745 – 751 
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Abstract 
Objective  
To evaluate whether hysteroscopic morcellation or bipolar electrosurgical resection 
is more favourable for removing endometrial polyps in an office setting in terms of 
feasibility, speed, pain, and acceptability.  
 
Methods  
A multicenter, single-blind, randomised controlled trial of office hysteroscopic 
morcellation compared with electrosurgical resection was conducted. A total of 121 
women were randomly allocated to polyp removal by one of the two methods in an 
office setting. The outcomes assessed were time taken to complete the endometrial 
polypectomy, defined as the time from insertion to removal of vaginal 
instrumentation, completeness of polyp removal, acceptability, and pain measured 
on a 100mm visual analogue scale.   
 
Results  
The median time taken to complete the procedure was 5 minutes, 28 seconds for 
morcellation compared to 10 minutes, 12 seconds for electrosurgical resection (P < 
0.001).  The polyp(s) were completely removed in 61/62 (98%) of women assigned 
to morcellation compared to 49/59 (83%) of women treated with electrosurgical 
resection (OR 12.5; 95%CI: 1.5 to 100.6, P = 0.02). The mean pain scores during 
the procedure favoured morcellation by 16.1 points on average (35.9 vs. 52.0; 
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95%CI for difference: -24.7 to -7.6, P < 0.001). Overall, 99% of women found office 
polypectomy to be acceptable with only one woman in the electrosurgical resection 
group considering the procedure unacceptable.  
 
Conclusions  
In comparison to electrosurgical resection during hysteroscopic polypectomy, 
morcellation was significantly quicker, less painful, more acceptable to women and 
more likely to completely remove endometrial polyps compared with electrosurgical 
resection. 
 
Clinical Trial Registration:  ClinicalTrials.gov, www.clinicaltrials.gov, 
NCT01509313. 
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Introduction 
Background 
The miniaturisation of hysteroscopes and ancillary instrumentation coupled with 
enhanced visualisation has enabled hysteroscopic surgery to be performed in an 
office setting without the need for general anaesthesia or hospital admission 3.  The 
most common operative hysteroscopic procedure is endometrial polypectomy 121 
i.e. surgical removal of an endometrial polyp.  The feasibility of office hysteroscopic 
polypectomy has been demonstrated 147.  Traditionally these procedures were 
performed using miniature mechanical instruments, but the small size and fragility 
of these ancillary instruments limited office treatment to smaller, isolated focal 
lesions 137.  In recent years those mechanical approaches have been superseded 
by the introduction of a disposable miniature bipolar electrosurgical system that has 
been developed to be used down standard operating hysteroscopes to cut away 
polyps.  The safety, acceptability and feasibility of this approach has been reported 
146–148.  However, as with mechanical technologies retrieval of the detached polyp 
tissue from within the uterine cavity requires additional instrumentation, which may 
prolong the procedure and affect patient tolerability.   
 
Recently, a new technology has been developed to overcome their limitations of 
currently available hysteroscopic instrumentation.  This technology, called the 
hysteroscopic morcellator, incorporates a disposable mechanical cutting device that 
simultaneously cuts and aspirates polyp tissue. The ability to both cut and retrieve 
polyps avoids the need for additional instrumentation of the uterine cavity and may 
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also improve visualisation during surgery by avoidance of bubble formation or the 
production of tissue fragments (‘chips’) associated with the electrosurgical 
approach.  Avoidance of thermal injury may also confer safety and tolerability 
benefits compared with electrosurgical resection. 
 
In view of the development of hysteroscopic morcellation and potential advantages 
associated with this innovation, we designed a randomised controlled trial (RCT).   
 
Endometrial polyps 
Endometrial polyps are localised overgrowths of endometrial tissue that can occur 
anywhere in the uterine cavity.  They contain variable amounts of glands, stroma 
and blood vessels that are covered by a layer of epithelium 110.    Most commonly 
they are attached to the uterus by an elongated pedicle (pedunculated), but they 
may also have a large flat base (sessile).  They range in size from a few millimeters 
to several centimeters. There is some evidence to suggest that some smaller 
polyps (<10mm) may regress naturally without treatment, but most polyps will 
persist 119,124.  Normally polyps are benign, with the prevalence of cancer reported 
in the range of 0.5-3% 109–116. 
 
Review of hysteroscopic morcellation 
After searching four electronic databases (Medline, EMBASE and CINAHL), four 
citations were identified for polyp morcellation.  Of these, two articles were 
retrospective descriptive studies149,167; one was a randomised-controlled pilot study 
amongst residents in training 150 and the last was an abstract describing histo-
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pathological outcomes 168.  Emanuel et al 149 compared traditional electrosurgical 
resection with hysteroscopic morcellation for the removal of focal lesions within the 
uterus, namely endometrial polyps and submucous fibroids (benign smooth muscle 
tumours arising from the underlying myometrium and protruding into the uterine 
cavity).  Electrosurgical resection is a technique where large diameter 
hysteroscopes incorporate a monopolar electrosurgical cutting loop, a set up known 
as a ‘resectoscope’ which removes uterine pathology in a piecemeal fashion, in 
contrast to hysteroscopic morcellation which simultaneously cuts and aspirates 
tissue.  All procedures were carried out under a spinal or general anaesthetic. 
Twenty-seven women had their lesions removed by morcellation with a significantly 
shorter average operating time of 8.7 minutes (95% CI: 7.3 to 10.1) compared with 
30.9 minutes (95% CI: 27 to 34.8) for the 44 women who had their lesions removed 
by traditional resection. A single RCT pilot study has also compared hysteroscopic 
morcellation with resection of fibroids and polyps under either spinal or general 
anaesthetic.  Again, morcellation was found to be significantly quicker compared 
with resection (10.6 minutes vs 17.0 minutes) 150. Unfortunately, it did not 
breakdown the operating times for fibroids and polyps separately. In an uncontrolled 
series of 278 hysteroscopic polyp morcellations under general anaesthesia, the 
reported total installation and operating times were 7.3 minutes and 6.6 minutes 
respectively 167.  One conference abstract was identified assessing the use of 
hysteroscopic morcellation. The study examined the quality of histological 
specimens and found no difference between morcellated or resected tissue 
specimens 168.  
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The need for a randomised trial comparing hysteroscopic 
morcellation with bipolar electrosurgical resection in an outpatient 
setting 
 
The current literature shows that the hysteroscopic morcellation using a large 
diameter (9mm) apparatus is feasible and safe procedure for removal of 
endometrial polyps and is quicker to perform than monopolar electrosurgical 
techniques under general anaesthesia. However, contemporary practice is moving 
to performing hysteroscopic surgery, especially polypectomy, with miniature 
instruments in the office setting without the need for general anaesthesia.  It should 
be noted that this morcellator system is designed for use under a general or 
regional anaesthesia because of its large diameter requiring significant cervical 
dilatation.   
 
The technology most commonly used to perform outpatient polypectomy is the 
Versapoint® bipolar electrosurgical system (GynecareTM; Ethicon Inc., New Jersey, 
USA) a 1.8mm (5F) electrode which can be passed down standard <5.5mm 
continuous flow operating hysteroscope. A 5mm miniature TRUCLEARTM 
hysteroscopic morcellator (Smith&Nephew, Andover MASS, USA) has recently 
become available for use in the office setting without anaesthesia and offers 
potential advantages over traditional electrosurgical resection of polyps.  The ability 
to both cut and retrieve polyps avoids the need for additional instrumentation of the 
uterine cavity in order to retrieve the detached polyp specimen i.e. a single insertion 
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of the hysteroscope is required only. This may enhance the efficacy, tolerability and 
feasibility of office hysteroscopic polypectomy.  The use of mechanical morcellation 
may also improve visualisation during surgery by avoidance of bubble formation or 
the production of tissue fragments (‘chips’) associated with the electrosurgical 
approach.  
 
Thus, this new technology has potential advantages for the patient (acceptability, 
pain, infection, safety), the surgeon (speed, feasibility, completeness of the 
procedure) and health service (avoidance of second stage procedures under 
general anaesthetic). However, the established single use bipolar electrode is 
smaller than the disposable morcellator cutting device (1.6mm vs. 2.9mm). 
Moreover, the bipolar electrode can be used down the operating channel of a 
variety of continuous flow hysteroscopes which are longer and smaller in diameter 
and in day-to-day use in gynaecological practice in outpatient settings (outer 
diameter 4.1mm (Gynecare; Ethicon Inc., New Jersey, USA), 5mm Storz Bettocci 
hysteroscope (Karl Storz Endoscopy-America inc., California, USA) or Olympus 
5.5mm (Olympus Corporation, Shinjuku-ku, Tokyo, Japan).  In contrast, the 
hysteroscopic morcellator system is larger (5.6mm outer diameter) and requires 
acquisition of specific hysterscopes with an offset proximal eyepiece to allow the 
rigid mechanical cutting device to be inserted in direct alignment with the barrel of 
the hysteroscope. Thus in an office setting, the bipolar electrode may have 
advantages over the larger hysteroscopic morcellator in terms of ease of uterine 
instrumentation. 
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Endometrial polypectomy is one of the commonest procedures in modern 
gynaecological practice.  In light of this and to answer uncertainties about potential 
benefits in terms of feasibility and effectiveness of office hysteroscopic morcellation 
compared with current office bipolar electrosurgical resection, we believed that 
there was an urgent need to undertake a robust health technology assessment.  We 
therefore designed an adequately powered RCT to assess the speed, effectiveness 
(in terms of completed procedures) and acceptability of endometrial polyp removal 
between treatment modalities.  Long-term outcomes such as the effect of polyp 
removal on abnormal uterine bleeding (AUB) were not evaluated because a large 
randomised controlled trial comparing inpatient to office polypectomy on alleviation 
of AUB symptoms had recently been completed169.  However, this trial did identify 
increased failure of polypectomy in the office setting with one in five procedures 
being incomplete169 and a lower patient acceptability compared with inpatient 
procedures under general anaesthesia.  Thus, this finding added further support to 
an RCT evaluating a potentially more effective hysteroscopic surgical method. 
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Objectives 
1. To determine if hysteroscopic morcellation is faster than bipolar 
electrosurgical resection. 
2. To assess if hysteroscopic morcellation is more likely to completely remove 
endometrial polyps in the office setting. 
3. To determine if hysteroscopic morcellation is less painful than bipolar 
electrosurgical resection. 
4. To compare hysteroscopic morcellation to bipolar electrosurgical resection in 
terms of patient acceptability. 
5. To compare hysteroscopic morcellation to bipolar electrosurgical resection in 
terms of complications. 
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Methods 
Study design 
A multicenter, single-blinded, parallel-group RCT comparing hysteroscopic 
morcellation versus electrosurgical resection was conducted.  
 
Study setting 
Women were recruited from office hysteroscopy clinics within two large urban 
teaching hospitals; Birmingham Women’s Hospital Foundation Trust and the Royal 
Hallamshire, Sheffield Teaching Hospital.  
 
Patient eligibility 
Inclusion criteria 
All women attending for an office hysteroscopy or who had a hysteroscopically 
diagnosed endometrial polyp and in whom polypectomy was indicated 3 were 
approached to participate in the trial.  All participating women gave written informed 
consent after reading the patient information leaflet (Appendix 12 – 13). 
 
Exclusion criteria 
Women were excluded from participation if they preferred the procedure under 
general anaesthesia or were considered by the surgeon to be unable to tolerate an 
office hysteroscopic polypectomy based upon their response to the office diagnostic 
hysteroscopy. Women with polyps suspected at hysteroscopy to be malignant were 
also excluded. The number and size of polyps were not exclusion criteria.  
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Centre eligibility 
To take part in the trial the centres needed to meet the following eligibility criteria: 1) 
be willing to attend collaborative meetings 2) have staff proficient in both electrical 
resection and morcellation of endometrial polyps in the office setting 3) have the 
equipment to perform both electrical resection and morcellation.   
 
Originally recruitment was planned in three centres: Birmingham Women’s Hospital 
Community Trust, Sheffield University Hospital and Bradford University Hospital.  
However, the clinicians in Bradford University Hospital were not willing to randomise 
all suitable patients so they were not included to maintain the integrity of the trial.  
 
Trial registration 
This trial was registered on clinicaltrials.gov (identifier: NCT01509313).  The 
National Research Ethics Service, UK, granted ethical approval (identifier: 
12/WM/0058).  Research and Development approval was sought and granted at 
Birmingham Women’s Hospital and Sheffield Teaching Hospital. The trial was 
conducted according to the principles of Good Clinical Practice (GCP). 
 
Randomisation 
Women were allocated in a 1:1 ratio to either of the interventions through a 
telephone-based system managed by the Birmingham Clinical Trials Unit.  The 
randomisation blocks were kept centrally in the Birmingham Clinical Trials Unit and 
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the sizes varied so that the allocation could not be deduced pre-randomisation. 
Blocks were stratified by the location of polyp (fundal versus non-fundal) to ensure 
we achieved balance between groups for this variable. Location was chosen 
because access to the base of fundal polyps can be problematic with standard 
mechanical or electrosurgical hysteroscopic instruments3. Women were not told 
which intervention they had been allocated to until after they had completed the 
post-operation questionnaire.   
 
Interventions  
All surgical procedures were performed in the office setting without general 
anaesthesia or conscious sedation. Three surgeons experienced in outpatient 
endometrial polypectomy performed all surgical procedures (TJC, MEC, PS). 
Participating surgeons were proficient in both methods of polypectomy, although all 
three had greater experience with the more established technique of electrical 
resection. Office polypectomy was performed (i) immediately following diagnosis 
(‘see & treat’) or (ii) scheduled within 8 weeks of diagnosis, depending upon local 
circumstances and patient preference.  Vaginoscopy (i.e. passage of the 
hysteroscope into the uterine cavity without the use of a vaginal speculum or 
instrumentation of the ectocervix) was the standard approach, with recourse to 
instrumentation of the lower genital tract where vaginoscopy failed. No cervical 
preparation was used prior to the procedure. Normal Saline (0.9% w/v NaCl) was 
instilled from a three litre bag within a pressure cuff set at 180mmHg which was 
hung from a 180cm stand to provide distension and irrigation of the uterine cavity. 
In line with departmental protocols, fluid deficit was not calculated for office 
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polypectomy because procedures were short, limited to the endometrium, relatively 
avascular and performed through small diameter operating hysteroscopes 3. The 
use of local anaesthesia (direct cervical block using 6.6ml of 3% mepivacaine) was 
restricted to procedures where dilatation of the cervix was required to pass the 
hysteroscope through the endocervical canal and / or to facilitate retrieval of the 
polyp specimen from the uterine cavity 3.   
 
Hysteroscopic morcellation 
Morcellation was carried out under direct hysteroscopic vision using the 
TRUCLEAR™ 5.0 (Smith & Nephew, Andover MA, USA) hysteroscopy system 
incorporating a 2.9mm rotary style hysteroscopic morcellator. The hysteroscopic 
morcellator technology has been previously described; in short it incorporates a 
disposable cutting device that consists of 2 hollow metal tubes that fit inside each 
other.  There is a window or aperture and tissue is sucked into the opening by 
means of vacuum and is shaved as the inner tube is rotated within the outer tube 
149. 
 
Bipolar electrosurgical resection 
Bipolar electrosurgical resection was carried out under direct vision using the 
VersaPoint™ (Gynecare; Ethicon Inc., New Jersey, USA) disposable bipolar 
electrosurgical system. The electrode was placed down a 5Fr operating channel 
within either the 3.5mm ALPHASCOPETM (Gynecare; Ethicon Inc., New Jersey, 
USA) or the 5mm Bettocchi (KARL STORZTM, Tuttlingen, Germany) operating 
hysteroscope.  After electrosurgical resection ancillary mechanical instruments are 
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used the specimen(s) from the uterine cavity. These can be either hysteroscopic 
instruments (miniature grasping forceps, snares) or standard blind polyp forceps 3.  
 
 
Outcomes 
Time taken to complete the endometrial polypectomy   
This was defined as the time from insertion to removal of vaginal instrumentation 
post-randomisation. In addition, the total time the hysteroscopic morcellator 
generator was activated according to the TRUCLEAR™ operating system was 
collected at the Birmingham Women’s Hospital site.  
 
Completeness of polyp removal 
A complete endometrial polypectomy was defined as the detachment and retrieval 
of all visible polyp tissue (single or multiple polyps), such that no polyp remnants 
remained within the uterine cavity. An incomplete procedure included any of the 
following: (a) failure to detach any polyp tissue from the uterine wall; (b) partial 
detachment of polyp(s) from the uterine wall and (c) failure to retrieve the detached 
specimen from the uterine cavity.  
 
Procedural pain & patient acceptability   
These data were collected using previously piloted self-completed questionnaires.  
A pre-operative questionnaire was completed by all women before the procedure to 
collect baseline pain scores and a second questionnaire was given to patients 
immediately after the procedure (Appendix 15 – 16).  Women were asked to 
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complete the questionnaire prior to discharge from hospital in order to limit recall 
bias and increase response rates. To assess acceptability, a four point ordinal scale 
was used with the following response categories: ‘Would you describe the 
procedure as “Totally acceptable”; “Generally acceptable”; “Fairly acceptable”; 
“Unacceptable”.  Pain was assessed using a 100mm visual analogue scale (0 for no 
pain and 100 for worst imaginable pain). Women were asked to assess their pain 
during the procedure and also their short-term post-operative pain just prior to 
discharge from hospital or after 15 minutes of completing the procedure, whichever 
came first.   
 
Surgical technique and complications 
Surgeons completed a standard form following the procedure to record technical 
aspects of the procedure including time taken and peri- or post-operative 
complications (Appendix 14). 
 
Data collected by the operator at the time of polypectomy included: parity, indication 
for polypectomy, menopausal status (pre or postmenopausal), the make and size of 
hysteroscope, the size and number of endometrial polyps, the location of the 
polyp(s), the type of polyp(s) (sessile or pedunculated), the consistency (fibrous or 
glandulo-cystic), the use of local anaesthesia (none, direct cervical, paracervical, 
topical), the need for cervical dilatation, the use of a speculum (as compared with 
pure vaginoscopy), completeness of polyp removal (defined as complete 
detachment and retrieval of all polyp tissue from the uterine cavity for histological 
assessment), details of any adverse events (Genital tract trauma, haemorrhage, 
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vaso-vagal reactions, severe pain etc.). Vaso-vagal reactions were defined clinically 
as the patient being unable to leave the operating couch within five minutes of 
cessation of procedure due to feeling faint or dizzy or nauseous. 
 
 
Serious and unexpected adverse events 
There may be complications associated with either electrical resection or 
morcellation of endometrial polyps (Appendix 17).   In this trial, “serious” adverse 
events (SAE) were defined as those that were life threatening, fatal, disabling or 
caused prolonged hospitalisation as a result of the hysteroscopy or endometrial 
polypectomy.  Any SAE were to be reported immediately to the trial office, followed 
within 2 working days by a completed SAE form (Appendix 18).   
 
Data management 
Anonymised data from Sheffield University Hospital was sent to Birmingham 
Women’s Hospital Community Trust via post.  All data were inputted into the 
electronic Morcellation versus Electrical Resection Trial (MERT) database by PS.  
At the end of the trial, a random 10% sample of all of the trial data were re-entered 
by the Chief Investigator JC to verify correct data input.  Any discrepancies between 
originally entered data and re-entered data were reviewed and checked against the 
original paper copy.  An initial data entry error rate of >5% would have triggered a 
requirement to re-enter the entire data set from that questionnaire.  This was not 
found to be necessary. 
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Trial steering committee 
The trial was originally expected to take 18 months to complete and the first 
meeting was planned at 12 months.  The trial was complete at 10 months so the 
trial steering committee did not convene. 
 
Sample size 
The sample size for this trial was chosen to give high statistical power to detect a 
significant difference in the primary measure of time taken to complete the 
endometrial polypectomy. This size of difference was based upon evidence 
reported from a randomised pilot study among resident in training evaluating the 
hysteroscopic morcellator with formal transcervical resection under traditional 
general anaesthesia150. The results here showed the mean operating time for 
morcellation to be 10.6 minutes compared with 17.0 minutes for resectoscopy with 
a standard deviation of 9.5 minutes over both groups. This size of difference 
reflected an overall operating time reduction of approximately one third which we 
considered to be clinically meaningful difference in the office setting. To detect a 
difference of this size (6.4 minutes) with 90% power (P = 0.05) would require 48 
participants per group, 96 in total. To account for attrition we aimed for 120 
participants in total.   
 
Statistical methods 
Analysis was performed by intention-to-treat. Mean differences and corresponding 
95% confidence intervals were calculated for treatment times and pain scores. A t-
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test was used to assess statistical significance, although in the presence of some 
skewness of distribution for treatment times, a non-parametric Mann-Whitney U test 
was also performed. Logistic regression was employed for dichotomous outcomes 
such as completeness of polyp removal. Odds ratios and 95% confidence intervals 
were derived with a chi-squared test used to assess statistical significance. Fisher’s 
exact test was used to compare treatment failure because sample sizes were small.  
Regression analysis was used to compare trends across the different responses to 
acceptability. All analyses were carried out using SPSS software version 21 (IBM, 
Armonk, NY, USA).   
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Results 
 
Participants 
In total, 121 patients requiring removal of an endometrial polyp(s) as part of their 
standard care were randomised from 2 hospitals over 11 months between July 
2012 and May 2013. There were 98 women recruited from Birmingham Women’s 
Hospital and 23 women from Sheffield Teaching Hospital.  Figure 7 shows total 
recruitment along with the contribution from each site.  Figure 8 summarises the 
flow of participants through the trial in line with the recommendations of the 
consolidation standards of reporting trials (CONSORT) statement 52. 
 
 
 
Figure 7. Trial recruitment over time. 
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Suitable for randomization 
(n=125) 
Excluded (n=4) 
Declined to participate (n=4) 
x Did not want morcellator (n=2) 
x Did not want electrical resection 
(n=1) 
x Did not want to fill in extra 
paperwork (n=1) 
Randomized (n=121) 
Allocated to electrical resection (n=59) 
x Received allocated intervention 
(n=59) 
x Did not receive allocated 
intervention (n=0) 
Allocated to hysteroscopic morcellation 
(n=62) 
x Received allocated intervention 
(n=62) 
x Did not receive allocated 
intervention (n=0) 
Enrollment 
Allocation 
Withdrawal from trial (n=0) 
Follow-up 
Withdrawal from trial (n=0) 
Analysis 
Analyzed (n=59) Analyzed (n=62) 
 
Figure 8. Flow diagram of women in the hysteroscopic morcellation versus 
electrical resection trial. 
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Baseline characteristics 
The majority of baseline variables were balanced between groups post-
randomisation (Table 15). However, women randomised to hysteroscopic 
morcellator had more polyps on average than those randomised to electrical 
resection and proportionately more women were allocated hysteroscopic 
morcellator in Sheffield Teaching Hospital compared with Birmingham Women’s 
Hospital.  
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Table 15.  Baseline Characteristics of Trial Participants 
  
  
Hysteroscopic 
Morcellation 
(n=62) 
Electrical 
Resection 
(n=59) 
Age (years)  Mean (SD) 54.3 (12.7)* 54.9 (14.2)† 
BMI (km/m2) Mean (SD) 31.7 (6.6)‡ 31.5 (8.4)§ 
Parity  Mean (SD) 1.9 (1.6) 2.2 (1.8) 
Previous cesarean Yes 5 (8%) 4 (7%) No 57 (92%) 55 (93%) 
Menopausal status 
Premenopausal  26 (42%) 28 (47%) 
Postmenopausal  35 (56%) 31 (53%) 
Missing 1 (2%) 0 (-) 
Indication  
Bleeding  51 (82%) 52 (88%) 
Fertility  1 (2%) 4 (7%) 
Dysmenorrhoea  0 (-) 2 (3%) 
Incidental 
radiological   3 (5%) 1 (2%) 
Vaginal 
discharge  1 (2%) 0 (-) 
Missing 6 (10%) 0 (-) 
Number of polyps Mean (SD) 1.8 (0.9) 1.2 (0.5) (min, max) (1,4) (1,3) 
 
 
BMI = body mass index; SD = standard deviation; BWHCT = Birmingham Women’s Hospital 
Foundation Trust; STH = Sheffield Teaching Hospital. 
* Four values missing 
† Three values missing 
‡ Eleven values missing 
§ Twelve values missing 
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Outcome data 
Time taken to complete the procedure 
The median time taken to complete the polypectomy procedure was 5 minutes and 
28 seconds for hysteroscopic morcellator compared with 10 minutes and 12 
seconds for electrical resection (P < 0.001).  
 
Completeness of polyp removal 
Complete polyp removal was achieved in 61/62 (98%) women for hysteroscopic 
morcellation compared with 49/59 (83%) in electrosurgical resection (OR 12.5; 95% 
CI: 1.5 to 100.6, P = 0.02) (Table 16).  There was no singular reason why there 
were more failures in the electrosurgical resection group; reasons given were 
equally distributed between inability to locate polyps using blind instruments (i.e. 
where removal under hysteroscopic vision had failed), inadequate visualisation and 
patient discomfort. 
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Table 16.  Surgical Technique and Complications 
  
Hysteroscopic 
Morcellation 
(n=62) 
Electrical 
Resection 
(n=59) 
Odds Ratio       
(95% CI) P 
Surgical technique     
Speculum used  28 (45%) 37 (63%) 0.5 (0.2 to 1.0) 0.05 
Cervical dilatation  30 (48%) 31 (53%) 0.8 (0.4 to 1.7) 0.8 
Cervical anaesthesia 31 (50%) 34 (58%) 0.7 (0.4 to 1.5) 0.4 
Removal success     
Total removal  61 (98%) 49 (83%) 12.4 (1.5 to 100.6) 0.02 
Partial removal  0 (-) 7 (12%)*   
Failed removal  1 (2%)† 3 (5%)*     
Complications     
Vasovagal reactions  1 (2%) 6 (10%) 0.1 (0.0 to 1.2) 0.08 
Others 0 (-) 0 (-)     
 
 
CI, confidence interval. 
*Partial/failed removal reasons: unable to locate blindly (n=4); patient discomfort (n=3); inadequate 
visualisation (n=3) 
†Partial/failed removal reasons: inadequate visualisation (n=1) 
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Pain scores and acceptability 
The mean pain scores for morcellation compared with electrosurgical resection 
were significantly lower both during the procedure and at 15 minutes following the 
procedure (Table 17).  
 
 
Table 17.  Pain Scores (Measured on a 100-Point Visual Analogue Scale) 
 
 
Hysteroscopic 
Morcellation, 
mean (SD, n) 
Electrical 
Resection, 
mean (SD, n) 
Mean Difference 
(95% CI) 
P 
Baseline 8.1 (9.4, 60) 5.1 (9.7, 58) -3.0 (-6.4 to 0.5) 0.1 
During procedure 35.9 (23.5, 60) 52.0 (23.5, 58) 16.1 (7.6 to 24.7) <0.001 
Postprocedure 23.9 (21.2, 60) 31.0 (23.9, 59) 7.1 (-1.1 to 15.3) 0.09 
 
SD, standard deviation; CI, confidence interval. 
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Overall, over 99% of women found office polypectomy to be at least ‘fairly 
acceptable’ (Table 18) with only one woman in the electrosurgical resection group 
reporting the procedure as unacceptable. There was a significant trend towards 
increased acceptability in women receiving morcellation rather than electrosurgical 
resection (P = 0.009).  There was also a significant difference between techniques 
when we dichotomised the acceptability response to totally acceptable/generally 
acceptable versus fairly acceptable/unacceptable.  
 
 
Table 18.  Patient Acceptability  
 
 
Hysteroscopic 
Morcellation 
(n=61) 
Electrical 
Resection 
(n=58) 
P* 
 
Totally acceptable  44 (72) 33 (57) 
0.009 
 
Generally acceptable  15 (25) 12 (21)  
Fairly acceptable  2 (3) 12 (21)  
Unacceptable  0  1 (2)  
 
* Using a logistic regression test for trend. 
Data are n(%). 
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Complications 
The only surgical complications observed in either treatment group were vasovagal 
reactions occurring in 1/62 (2%) and 6/59 (10%) of hysteroscopic morcellation and 
electrosurgical resection procedures respectively (P = 0.08) (Table 16).  One 
serious adverse event occurred. This was in a woman treated in the morcellation 
group who was admitted two weeks after treatment because of vaginal bleeding 
and pain.  She was diagnosed as having an endometritis and treated with broad-
spectrum antibiotics.   
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Discussion 
Key findings 
This RCT provides strong evidence to suggest that hysteroscopic morcellation is 
quicker to perform, more successful at completing polyp removal, less painful, and 
more acceptable to women than traditional electrosurgical resection for the removal 
of endometrial polyps.   
 
Interpretation 
The improved performance of morcellation relative to electrosurgical resection may 
reflect its ability to simultaneously cut and extract polyp tissue under vision.  In 
addition, acquiring proficiency with the hysteroscopic morcellator is rapid150 and this 
relative ease of use may also have contributed to obtaining favourable outcomes.   
 
We used a rigorous definition of what constituted a successfully completed 
procedure.  Data from this trial suggests that the increased success of morcellation 
compared with electrosurgical resection arises from a combination of factors.  
Firstly, failures due to inadequate visualisation were reduced. Although this trial did 
not evaluate reasons behind enhanced visualisation, it may have arisen because 
steam bubble formation from electrically heating saline was avoided.  Alternatively it 
may have reflected better continuous irrigation because the morcellator system 
used a larger diameter hysteroscope with greater inflow of saline and the 
disposable morcellator provided suction when activated. Secondly, failures because 
of inability to blindly locate specimens within the uterine cavity were avoided 
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because simultaneous tissue cutting and extraction under direct hysteroscopic 
vision from the uterine cavity was integral to the morcellation system.  Thirdly, 
failures due to patient discomfort were circumvented. Conventional mechanical or 
electrical instruments necessitate additional hysteroscopic or blind mechanical 
instrumentation of the uterus to retrieve resected polyp tissue via the narrow endo-
cervical canal.  It is likely that the need for these further manoeuvres contributed to 
prolongation of the electrosurgical resection procedure and increased peri-operative 
pain compared with morcellation.  Although the clinical significance of the 
differences in procedural pain are uncertain without further qualitative research, the 
findings appear consistent with the observed increase in acceptability with 
morcellation.  The integration of cutting and aspiration with morcellation may also 
explain why the need for cervical dilatation and local anaesthesia was comparable 
between interventions, despite the larger diameter of the hysteroscopic morcellator. 
The size and number of polyps did not seem to affect the success of morcellation 
although the study was not powered to provide adequate analysis of these 
subgroups. 
 
The need for cervical dilatation and local anaesthesia was similar in both arms of 
the trial.  This may seem counterintuitive due to the smaller diameter of the 
electrosurgical resection tools in comparison to the hysteroscopic morcellator.  
Reasons are likely to reflect the practice of using local anaesthetic if it is anticipated 
that there will be difficulties retrieving the polyp tissue after detachment.  Secondly, 
our practice is to remove the specimen en bloc, because this generates quicker 
procedures that are less likely to result in deteriorating vision.  We believe this 
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technique it more successful than alternative techniques (slicing)170, which requires 
a longer procedure and multiple passes of the hysteroscope.  Therefore, these units 
that routinely adopt slicing techniques may have a decreased rate of dilatation, but 
may have a decreased success rate. 
 
Comparison with other studies 
In a recently completed multi-centre RCT in the UK169, bipolar electrosurgical 
resection was the most commonly adopted modality, but recruitment to this trial 
predated widespread commercial availability of the hysteroscopic morcellator.  
Treatment times and failure rates for electrosurgical resection were comparable to 
those noted in the current study169.  Moreover, the results presented here are 
consistent with data from two trials comparing the morcellator to electrosurgical 
resection using a resectoscope under general anesthetic149,150, both of which found 
the morcellator to be quicker.  In keeping with these data, our trial supported the 
apparent safety of office polypectomy, with adverse events limited to self-limiting 
vaso-vagal episodes affecting a minority of women.  One post-operative 
complication was observed in a woman who developed endometritis after 
morcellation, which resolved with oral antibiotics. All retrieved specimens underwent 
histopathological examination and a diagnosis was provided in all cases consistent 
with another study171.  Thus, concerns over the ability to histologically analyse 
morcellated tissue specimens seem unfounded  
 
The economic advantages of the office compared with the traditional inpatient 
setting for polypectomy is primarily driven by the avoidance of expensive inpatient 
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bed and theatre facilities172,173.  We did not conduct a cost-effectiveness evaluation 
alongside this RCT because symptom outcome data were not collected (these 
shortly to be published data have been collected in the larger Office Polypectomy 
Trial169).  In addition, the known wide variation in costs between different healthcare 
systems, would limit the transferability of findings from such an economic 
evaluation.  Despite these caveats, it is likely that the use of hysteroscopic 
morcellation will be more cost effective compared to electrical resection in terms of 
successfully removing polyps given the magnitude of the observed odds ratio in 
favour of morcellation. 
 
Strengths and limitations 
The strengths of our trial include strict randomisation, the multicentre design and full 
completeness of data collection both pre and post-treatment.  While we did not 
collect longer term clinical follow up data, a retrospective cohort study comparing 
morcellation with electrosurgical resection found that morcellation may be 
associated with lower recurrence of endometrial polyps, although the incidence of 
recurrent abnormal uterine bleeding was unaffected by the technique used 154.  The 
shortly to be published Office Polypectomy Trial169 should also provide data 
pertaining to longer-term outcomes following endometrial polypectomy for abnormal 
uterine bleeding. Our trial does have some limitations. Randomisation did not 
equally distribute the potential confounders of polyp number and surgical site.  
However, the distribution of these confounders would be expected to bias against 
hysteroscopic morcellation by prolonging treatment time as women randomised to 
morcellation had slightly more polyps and were more likely to have been performed 
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at Sheffield Teaching Hospital where there was an overall longer procedure time 
than at Birmingham Women’s Hospital (5 mins 7 secs). Another potential source of 
bias was inability to blind the surgeon from the intervention and indeed whilst every 
effort was made to blind the patient from the allocated intervention, it is probable 
that some women would have been aware of the treatment they received given that 
they were awake and had received thorough pre-trial patient information which 
included a description of morcellation and electrosurgical resection.   
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Conclusion 
The new technology of hysteroscopic morecellation has been shown to have 
advantages for the patient (acceptability, pain, safety), the surgeon (speed, 
feasibility, completeness of the procedure) and health service (avoidance of second 
stage procedures under general anaesthetic).  While advances in technology are 
increasingly allowing more gynaecologic procedures to be performed in the office 
setting, it is important to critically appraise new technologies such as hysteroscopic 
morcellation before they become more widely embedded into clinical practice.  
Assessments of larger patient cohorts are required to more reliably assess the 
relative safety of hysteroscopic morcellation in the wider population.  
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CHAPTER 8:  DISCUSSION 
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Diagnostic office hysteroscopy 
Hysteroscopy has become an essential tool in gynaecological practice.  The 
conventional approach to hysteroscopy involved a scheduled admission to hospital 
so that theatre facilities could be used to conduct the operation under general 
anaesthesia. Advances in technology, including the development of miniature 
endoscopic equipment and in particular enhanced optics and imaging, has 
facilitated the procedure being performed in the office (outpatient) setting without 
the need for general anaesthesia.   Studies have shown that women who undergo 
hysteroscopy in the office setting, compared with those in a day case setting, have 
a more rapid return to normal activities and less need for post-operative 
analgesia49.  There are also substantial economic benefits to patients, employers 
and health care systems in performing hysteroscopy in the office setting174.  
Avoiding a general anaesthetic can be safer for the patient, not only because of the 
risks of anaesthesia, but also because the patient can give feedback to reduce the 
chances of serious complications such as uterine perforation and fluid overload.   
 
The economic and patient benefits have resulted in an increasing number of 
hospitals providing such services and this was reflected in a survey of the British 
Society of Gynaecological Endoscopy (BSGE) members, which found that 90% of 
respondents were performing office hysteroscopy (Chapter 3).   
 
The most common indication for investigation with office hysteroscopy is abnormal 
uterine bleeding, a term that encompasses heavy menstrual bleeding, non-
menstrual bleeding and post-menopausal bleeding (PMB).  The work in Chapter 2 
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showed that women with recurrent PMB who had previously had normal 
investigations could benefit from hysteroscopy to identify and treat endometrial 
polyps.  Although endometrial polyps are invariably benign and so not as serious to 
health as a diagnosis of premalignant endometrial hyperplasia or endometrial 
cancer the morbidity associated with the bleeding caused by endometrial polyps 
should not be ignored.  This morbidity includes anxiety and ongoing symptoms 
impacting adversely on health related quality of life and may result in unnecessary 
further testing because of failure to diagnose the underlying, albeit benign, 
causative uterine pathology.  Current PMB diagnostic pathways14,15 prioritise the 
diagnosis of endometrial cancer, but over 90% of women13 with PMB have benign 
disease, most prevalent of which are endometrial polyps.  Thus, current testing 
algorithms may be ignoring the morbidity and health resource utilisation of 
undiagnosed and thus untreated benign uterine pathologies such as endometrial 
polyps.  Furthermore, previous work exploring women’s preferences in the 
evaluation of PMB has shown women are willing to undergo more invasive 
hysteroscopy to evaluate additional pathology, rather than adopt the currently 
recommended expectant management after ultrasound35.  Patient preferences 
along with the decreasing cost of office hysteroscopy, could lead to office 
hysteroscopy being incorporated as a first line investigation for women who present 
with PMB.   
 
The biggest obstacle to successful, universal implementation of office hysteroscopy 
remains patient discomfort, which can have an adverse impact on acceptability and 
success rates.  A variety of techniques have been used to try to decrease the pain 
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of the procedure39,175–178.  These have mainly focused on traversing the tight and 
often acutely angled or tortuous endocervical canal.  Research work continues in 
this area and recent RCTs that have looked at pre-procedural cervical 
preparation179–181, and intra-operative cervical anaesthesia182 and bladder 
distension178 to ease negotiating of the cervical canal thereby decreasing the pain 
associated with office hysteroscopy.  As hysteroscopes become smaller it has 
become easier to pass the hysteroscope through the cervical canal avoiding the 
precipitation of noxious stimuli arising from resistance to passage of the endoscope.  
Thus the discomfort associated with the aforementioned interventions may obviate 
any potential benefit.  However, vaginoscopy is a technique that avoids the use of a 
speculum and tenaculum to access the uterine cavity in an attempt to minimise 
pain.  Vaginoscopy would still benefit women even with the use of smaller diameter 
hysteroscopes and indeed should become even more feasible as resistance to a 
correctly aligned hysteroscope from the approximated endocervical canal should be 
substantially reduced.  In Chapter 3 vaginoscopy was shown to be more successful 
than standard hysteroscopy using a speculum with or without cervical 
instrumentation for diagnostic procedures.  A large multicentre RCT is needed to 
confirm these preliminary findings and facilitate adequately powered a-priori 
subgroup analyses to ascertain groups of women (e.g. nulliparous, post-
menopausal, previous caesarean section) who may particularly benefit from 
adoption of vaginoscopy.   Further research is also needed to establish whether 
vaginoscopy is beneficial for operative hysteroscopy in which larger diameter 
instruments are used and greater manipulation of the cervix is necessary.   
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Therapeutic office hysteroscopy 
Currently, many hospitals restrict office hysteroscopy to diagnostic procedures.  
However, office hysteroscopy has a bigger role than just diagnosis with a number of 
common therapeutic procedures now being done in the office setting.  Such 
therapeutic procedures are often done in conjunction with diagnostic hysteroscopy 
in so called ‘see and treat’ clinics.  Providing seamless diagnostic hysteroscopy 
followed by immediate therapeutic services in ‘see and treat’ clinics, not only has 
economic benefits to the health service by efficient use of resources, but can also 
reduce inconvenience and social costs such as transport, childcare, absenteeism 
and business costs. Operative procedures include sterilisation, Levonorgestrel 
intrauterine system (LNG-IUS) fitting, retrieval of ‘lost’ intrauterine contraceptive 
devices, endometrial ablation and the removal of polyps, fibroids and adhesions.   
 
Endometrial ablation 
Traditionally, hysterectomy was the preferred surgical treatment for heavy 
menstrual bleeding.  There are a wide variety of medical treatments for heavy 
menstrual bleeding, but only the LNG-IUS has been proven to be as effective as 
hysterectomy183.  Endometrial ablation represents a surgical alternative to 
hysterectomy and has been shown to be cheaper, have lower morbidity and shorter 
hospital stay times57,58.  Research has also shown that endometrial ablation is 
tolerated and effective in the office setting6,65.   
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Our group’s publication of an RCT comparing bipolar radiofrequency ablation to 
thermal balloon ablation in an office setting had shown no significant difference 
between pain scores and acceptability during thermal balloon and bipolar 
radiofrequency ablation procedures6.  However, bipolar radiofrequency ablation was 
more effective in alleviating heavy menstrual bleeding at 12 months follow-up.  In 
contrast, our five year follow-up data presented in this thesis has shown no 
difference in the effectiveness of bipolar radiofrequency ablation and thermal 
balloon ablation performed in an office setting, but importantly the majority of 
treated women were effectively treated with amenorrhoea rates increasing over 
time and only a minority of women ultimately requiring further intervention usually in 
the form of hysterectomy (Chapter 5).  This finding of blunting of relative treatment 
effects is consistent with other longer-term follow-up data from RCTs of different 
endometrial ablation techniques performed in a conventional inpatient general 
anaesthetic setting60,82.  Therefore, there is no evidence to suggest that bipolar 
radiofrequency ablation should be used in preference to thermal balloon ablation in 
the office setting on the basis of improved symptomatic results.  
 
Office endometrial ablation may be convenient, but it is important that women are 
fully counselled about the relative advantages and disadvantages of office as 
compared to inpatient treatment.  Whilst such doctor-patient discussions will focus 
around procedural factors and patient experience between settings, clinical 
outcomes may not be so readily addressed in the absence of longer-term efficacy 
data.  Our five year follow-up data should reassure patient and clinicians that 
clinical outcomes appear equivalent to data from inpatient procedures performed 
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under general anaesthesia and that approximately 10% of women will require 
subsequent hysterectomy within five years (Chapter 5). In particular, women with 
pre-existing dysmenorrhoea or enlarged uteri should be counselled about their 
increased chance of requiring additional uterine surgery after endometrial ablation 
(Chapter 4).  This information should be used following clinical assessment (history 
and patient examination) to inform shared clinical decision making.   
 
Endometrial Polypectomy 
The majority of gynaecologists advocate the removal of endometrial polyps.  The 
rationale behind this is: 1) to exclude sinister pathology; 2) the perception that they 
are unlikely to spontaneously resolve and 3) that removal will alleviate AUB 
symptoms or increase fertility.  However, some of these beliefs maybe misplaced 
because endometrial polyps are found in up to 10% of asymptomatic women117, 
some polyps may spontaneously regress119 and sinister pathology such as 
endometrial cancer and hyperplasia is rare in premenopausal women109–116.    
 
We tried to address whether removal of polyps alleviates AUB symptoms by 
performing a systematic review of the literature (Chapter 6).  However, the 
systematic review showed there is a paucity of quality literature assessing the 
efficacy of uterine polypectomy.  All studies showed an improvement in symptoms, 
but the percentage of women that improved ranged from 60 to 
100%122,155,156,158,161,162,164.   Large and thoroughly designed RCTs are needed to 
establish whether all polyps need to be removed particularly in premenopausal 
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women.  Such trials should assess clinically relevant outcomes such as alleviation 
of bleeding symptoms and fertility outcomes.   
 
A survey of UK gynaecologists in 2001, found that the default technique for 
removing endometrial polyps was by blind avulsion or curettage after hysteroscopic 
location of the lesion under general anaesthesia108.  Hysteroscopic removal of 
polyps under direct vision was generally restricted to those gynaecologists with an 
interest in endoscopic surgery108.   Although it is possible to the remove endometrial 
polyps using blind curettage and avulsion techniques, such approaches usually 
require general anaesthesia and are associated with increased uterine trauma and 
discomfort3,28,131–136.  However, most polyps removed in the office setting are done 
under direct hysteroscopic vision, because avoiding potentially traumatic abrasive 
techniques, with the necessity to dilate the cervix, is especially important in the 
conscious patient.  For this reason it will be increasingly important for 
gynaecologists to acquire the skills necessary for hysteroscopic polyp removal 
under direct vision as more hospitals adopt office hysteroscopy.  
 
A recently completed large RCT found office polypectomy was non-inferior to 
inpatient polypectomy and more cost-effective for treating women with abnormal 
bleeding (‘OPT’ http://www.opt.bham.ac.uk, ISRCTN65868569)169.  However, 
failure to remove a uterine polyp was more likely and procedure acceptability was 
slightly lower.  The OPT study recommended further work to identify and develop 
strategies to decrease the pain and failure rate while increasing acceptability of 
hysteroscopic polyp removal in the office setting.  
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The main technique used for office polypectomy in the OPT trial was Versapoint® 
bipolar electrosurgical system (GynecareTM; Ethicon Inc., New Jersey, USA).  The 
development of a new group of instruments called hysteroscopic morcellators may 
help overcome some of the difficulties of bipolar electrical resection, namely 
extraction of the intrauterine tissue specimen.  We therefore designed and 
performed a randomised controlled trial comparing polypectomy using the new 
TRUCLEARTM hysteroscopic morcellator (Smith&Nephew, Andover MASS, USA) to 
Versapoint® bipolar electrosurgical system (GynecareTM; Ethicon Inc., New Jersey, 
USA) (Chapter 7).  This trial provided strong evidence that morcellation is faster, 
less painful, more acceptable and more likely to completely remove the polyp than 
the current standard of electrical resection in the office setting (Chapter 7)8.  A 
previous randomised controlled trial comparing morcellation to conventional 
resectoscopy under general anaesthetic for the removal of intrauterine polyps and 
myomas found that hysteroscopic morcellation was quicker and easier to learn 
when used by residents in training150.  In view of the mounting evidence supporting 
the superiority of morcellation, when compared to electrosurgical treatment, it is 
likely that endometrial polyp removal in the office setting will increasingly be 
performed using hysteroscopic morcellators. 
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Research and Future Developments in Office 
Hysteroscopy 
Cervical preparation 
The role of cervical preparation on the patient experience in the office setting has 
been, and continues to be, the subject of much research.  A systematic review and 
meta-analysis of six studies showed there maybe a benefit of using prostaglandins 
for postmenopausal women and there is some evidence that prostaglandins reduce 
the force and requirement for dilatation of the cervix beyond 5 mm175.  They 
concluded that cervical priming with vaginal prostaglandins may be considered in 
postmenopausal women if using hysteroscopic systems >5 mm in diameter. 
 
Since the completion of the systematic review further trials with conflicting results 
have been completed179–181. The conflicting results may reflect heterogeneity in the 
patient cohort, operative technique and equipment.  If Misoprostal is to be used, 
current opinion is  that it should be given 3-4 hours prior to the procedure, although 
it may work quicker than this.  In fact, both pharmaceutical and mechanical dilation 
of the cervix require time. To be compatible with modern office hysteroscopy, which 
aims to avoid the need for hospital admission, future developments and research 
will have to focus on a faster mechanism of action.  With no obvious method 
currently meeting the criteria of speed, cervical preparation will probably only be 
suitable for selected cases in the office setting.   
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Analgesia 
A systematic review and meta-analysis looked at local anaesthesia for pain control 
during office hysteroscopy176.  They were able to meta-analyse 15 trials, showing 
intracervical and paracervical injections of local anaesthetic significantly reduced 
pain (Standard Mean Difference (SMD) -0.36; 95% CI -0.61 to -0.10 and SMD -
1.28; 95% CI -2.22 to -0.35 respectively) in women undergoing office hysteroscopy, 
whereas transcervical and topical application did not.  Since the review, a small 
RCT with a sample size of 58 women has been completed with similar results182. 
However, as the techniques for introducing hysteroscopes into the uterine cavity 
improve in conjunction with ever decreasing hysteroscope diameters, inevitably 
trauma and stretching of the cervix will reduce.  This may then make it counter 
productive to use local anaesthetic, because the process of injecting local 
anaesthetic in itself can be painful.  
 
Cervical anaesthesia does not address pain generated by the upper third of uterus 
which is innervated from the thoracic nerves, largely derived from the sympathetic 
fibres of the superior hypogastric plexus T8-T10 and L1 roots 184.  Using a 
cyctoscopy needle through the operating channel of a hysteroscope, local 
anaesthetic can be injected to target these nerves to create an intrauterine cornual 
block185.  This has the potential to make operative procedures, such as endometrial 
ablation, more acceptable to women and future research should look to perform a 
placebo controlled RCT to evaluate the efficacy of this technique. 
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Hysterocopic technique 
There have been many alternative methods to minimise patient discomfort.  
Recently an RCT has been completed which assessed the role of bladder 
distension on patient comfort and ease of cervical entry178.  Women in the 
intervention group were asked to drink 500mL of water prior to the procedure and 
asked not to empty their bladder.  In contrast, the control group of women were 
asked to ensure an empty bladder prior to the procedure.  The status of the bladder 
(full or empty) was checked by ultrasound prior to the procedure.  They found 
bladder distension prior to office hysteroscopy was associated with significantly less 
pain (P = 0.01), quicker procedure times (P = 0.03) and easier cervical entry (P = 
0.01).  However, the practicalities of introducing bladder distension into a busy clinic 
where there can be delays in appointments is yet to be proven, although it is routine 
for women to attend gynae/early pregnancy scans with a full bladder. 
 
The pilot RCT in chapter 3 provided evidence to suggest that vaginoscopy is 
quicker to perform and more successful than standard hysteroscopy.  A larger, 
multicentre RCT is now needed to confirm these preliminary findings and to allow 
subgroup analysis to estimate types of women that may particularly benefit from 
vaginoscopy. 
 
Biopsy 
The idea of the vaginoscopic approach has also extended to global biopsy tools.  
The H Pipelle can be used after a hysteroscope has been introduced into the 
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uterine by withdrawing the optic from the diagnostic sheath, then passing the H 
Pipelle into the uterus through the sheath, before removing sheath allowing a 
biopsy to be taken in the usual way.  An RCT comparing the H Pipelle to the 
standard Pipelle found that endometrial sampling with the H Pipelle was 
significantly quicker (median times: 39 seconds for H Pipelle versus 102 seconds 
for Pipelle; P <0.001) and less painful (median visual analogue scale: 1 for H Pipelle 
and 5 for the Pipelle; P = 0.01) 186 
 
Hysteroscopes and instruments 
New developments in hysteroscopes and sheaths have traditionally been 
dominated by miniaturisation and it is likely that future developments will also be 
focused on miniaturisation.  Fundamental to the decrease in diameter of 
hysteroscopes are improvements in optics, and more can be expected from the 
introduction of optical chip technology in hysteroscopes, such as the Invisio Digital 
Hysteroscope (GyrusACMI/Olympus, Tokyo, Japan) 
 
In chapter 7 we showed that morcellation appears to be better than electrosurgical 
resection for the removal of endometrial polyps.  Future work with morcellators is 
likely to lead to the development of products with smaller outer diameters.  
Furthermore, there is a need to establish the efficacy and safety of morcellators for 
the treatment of fibroids and other intrauterine pathology, such as retained products 
of conception.   
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The hysteroscopic resectoscopes were developed from the cystoscopic 
resectoscopes used in urology and consist of a movable cauterisation loop.  These 
versatile tools can be used to resect fibroids, polyps and endometrium for heavy 
menstrual bleeding.  Initially these devices used monopolar cutting energy and 
required a non-conducting distension media.  Non-conducting distension media are 
not isotonic so are more likely to cause electrolyte imbalances than normal saline.  
Recently, bipolar electrosurgical devices have been made which allow normal 
saline irrigation, which reduces the effects of fluid intravasation.   Future 
developments in resectoscopy will involve devices with smaller outer diameters.  
However, the skills needed to perform resectoscopy, along with serious 
electrosurgical complications that occur, may mean that surgeons increasingly look 
to safer alternatives such as the morcellators.   
 
Hysteroscopic sterilisation 
Since the introduction of hysteroscopic sterilisation in 2001, it has increasingly 
gained popularity over laparoscopic sterilisation.  Hysteroscopic sterilisation has 
several advantages over laparoscopic sterilisation, that includes avoiding an 
abdominal entry and avoiding a general anaesthetic (by performing the procedure in 
the office setting).  The most commonly applied technique is ESSURETM, which 
involves the placement of microcoils into the fallopian tubes.  It has recently been 
improved by the introduction of new catheters with better microcoil release 
mechanisms.  The main competitor for ESSURETM was the AdianaTM. The AdianaTM 
involved inserting a catheter into the fallopian tube that emitted radiowaves causing 
injury to the tubal lining.  Subsequent scarring was promoted by the insertion of a 
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silicon stent. However, it was removed from market in 2012 to resolve patent 
infringement claims.  
 
The main disadvantage of hysteroscopic sterilisation compared to laparoscopic 
sterilisation is that it is not immediately effective; at least 3 months is required 
before tubal fibrosis and occlusion to occur for the procedure to be effective.  After 3 
months a post-procedure hysterosalpingogram or pelvic ultrasound is required to 
check for placement and occlusion.  Patients need to use an alternative 
contraception and occlusion does not occur in 1-12% of cases7,187,188.  Future 
advancements in hysteroscopic sterilisation will include methods that do not require 
the gradual fibrosis and occlusion of tubes, but instead will have an immediate 
effect. 
 
Ablation devices 
There have been few surgical techniques that have been evaluated as rigorously as 
endometrial ablation.  The first generation techniques have been superseded by the 
second-generation techniques, which are easier to learn and associated with fewer 
complications.    
 
The NovosureTM device uses bipolar radiofrequency ablation and a recent 
development includes a reduction in diameter, which promises to reduce the degree 
of cervical dilation needed.  ThermachoiceTM is a thermal balloon ablation device, 
which has the advantage of requiring less cervical dilation, but it has an 8 minute 
treatment time.  The Thermachoice IIITM model circulates hot water within the 
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balloon more evenly than previous models, which seems to make them more 
effective at ablation64,92. The ThermablateTM thermal balloon system was introduced 
in 2005 and has a treatment time of 2min 8seconds189.  Future developments in 
thermal balloon procedure may look at further reducing the treatment time.  
 
There are a number of other devices using different techniques that have entered or 
are coming to market.  These include developments in technology that have 
previously gone out of favour, such as cryotherapy and microwave ablation. 
  
Antibiotics 
A recently completed double-blind, randomised, placebo controlled trial assessed 
the role of antibiotic administration during hysteroscopic procedures in the office 
setting190.  A total of 1046 women who had operative hysteroscopy were given 
either 1g Cefazolin intramuscularly or 10mL of isotonic sodium chloride solution.  
There was no significant difference in the rates of postsurgical infection between the 
two groups.  These results give credence to the current practice of not using 
antibiotics as standard for hysteroscopic procedures in the office setting.   
 
Distension media and fluid management 
The correct choice of distension media has been the subject of the many 
randomised controlled trials. The evidence from these trials has been synthesised 
in a recent systematic review and meta-analysis comparing carbon dioxide to 
normal saline191.  The review combined 10 randomised controlled trials involving a 
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total of 1,839 women.  There were problems with clinical heterogeneity and study 
quality, but the results showed normal saline to be superior to carbon dioxide in 
terms of procedural pain, side effects (mainly shoulder pain), speed of procedure, 
quality of view and patient satisfaction. 
 
A double blind RCT looking at the effect of filling pressures on visibility and pain 
scores has recently been completed192.  They found visibility was lower with 40 
mmHg compared with 70 and 100 mmHg (P < 0.05). While there was no difference 
in mean pain scores between 40, 70 and 100 mmHg.  
 
As operation times become shorter there should be less chance of fluid overload 
and the increased use of isotonic distension media should decrease the chances of 
electrolyte imbalances.   Nevertheless, it is necessary for patient safety to keep a 
careful fluid balance in longer procedures and new developments should include 
more reliable and precise fluid management systems.   
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Summary 
 
Chapter 1 provides an introduction and describes the scope of the subsequent 
studies in this thesis.  Historically, dilation and curettage was used to investigate the 
uterine cavity.  When it was realised that hysteroscopy was more accurate, 
diagnostic hysteroscopy with or without biopsy became the investigation of 
choice193.  Advances in technology have minituarised hysteroscopes and provided 
novel energy systems and endoscopic therapeutic tools these innovations have 
increasingly allowed diagnostic and operative hysteroscopic procedures to be 
moved to the office setting, where they are performed without general anaesthesia.   
 
Office investigation of post-menopausal bleeding 
In Chapter 2, the role of hysteroscopy in recurrent postmenopausal bleeding is 
described.  106/1938 (5%) of consecutive women that presented to Birmingham 
Women’s Hospital with postmenopausal bleeding had a recurrent episode after 
previously having normal investigations. The fact that most women with PMB do not 
have serious endometrial disease and that failure to address the underlying 
pathology once malignancy has been excluded results in high rates of 
representation21 has largely been ignored.  Our work presented in this thesis on 
recurrent PMB is reassuring because it appears to show that after previous normal 
investigation the likelihood of pre-malignant and malignant endometrial disease is 
decreased, although one in four women have benign endometrial polyps as the 
most likely cause of their PMB.  First line investigation for women with recurrent 
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PMB should be with tests that have a high accuracy for diagnosing focal 
pathologies such as office hysteroscopy or saline infusion sonography.  
 
Vaginoscopy for diagnostic office hysteroscopy 
Vaginoscopy is a technique used to access the uterine cavity without the use of a 
vaginal speculum or cervical instrumentation.  By avoiding instrumentation of the 
lower genital tract we hypothesised that vaginoscopy could lead to a better patient 
experience.  Chapter 3 compared vaginoscopy against standard hysteroscopy in 
the office setting.  A total of 200 women were randomly allocated to a diagnostic 
hysteroscopy with either vaginoscopy or standard technique using a speculum.  
Vaginoscopy was found to be more successful than standard hysteroscopy where 
success was defined using a composite outcome of: a complete procedure, no 
complications, a level of pain acceptable to the patient and no sign of infection two 
weeks after the procedure.  The choice of this aggregated outcome was based 
upon clinical outcomes deemed important to practitioners and likely to influence 
their current practice.  Thus, based on the preliminary findings from this pilot RCT, 
vaginoscopy may be the preferred technique replacing standard approaches 
utilising vaginal speculum.  However, large RCT’s allowing analysis of important 
subgroups of where genital tract examination can be more challenging are needed 
to confirm and further elucidate these findings. 
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Office endometrial ablation for heavy menstrual bleeding 
Endometrial ablation has become an established treatment for heavy menstrual 
bleeding.  Nevertheless, many women go on to require further surgical treatment, 
usually in the form of hysterectomy.  Chapter 4 explores whether clinical factors 
can predict women that require further surgical intervention after endometrial 
ablation such that treatment choices can be better informal and the need for 
repeated surgical intervention minimised. 51/391 (13%) of consecutive women who 
had endometrial ablation in the office setting required further surgical intervention. 
Dysmenorrhoea before treatment (aOR 4.01; 95% CI 1.63 to 9.91) or a uterine 
cavity length >9cm (aOR 2.65; 95% CI 1.33 to 5.27) were associated with the need 
for further surgical interventions after office endometrial ablation.  These findings 
should help inform more rational clinician and patient decision making when 
considering treatment options for heavy menstrual bleeding. 
 
In Chapter 5, the five year follow-up data for a randomised controlled trial 
comparing bipolar radiofrequency to thermal balloon ablation in the office setting 
was presented.  At five years follow-up, 59 (73%) of women responded to 
questionnaires, of which seven (11.9%) had undergone a further surgical 
intervention in the form of a hysterectomy.   There was no significant difference in 
amenorrhoea rates, satisfaction rates, further intervention rates, condition specific 
or generic health related quality of life measures.   Thus both approaches can be 
equally recommended from a clinical symptomatic outcome perspective. 
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Office uterine polypectomy for abnormal uterine bleeding 
Chapter 6 presents a systematic review to assess the efficacy of uterine 
polypectomy in the treatment on abnormal uterine bleeding. 17 studies met our 
inclusion criteria enrolling a total of 1829 patients between 1989 and 2009.  
However, most of the evidence was derived from observational studies that 
reported high success rates, but in general the quality of the research was poor. 
The heterogeneity of available study designs, population, interventions and 
outcome assessments precluded meta-analysis.  All the studies reported an 
improvement in symptoms from 60-100%. The evidence we aggregated supports 
the notion that removing uterine polyps is effective at improving symptoms of AUB. 
 
Office endometrial polypectomy 
A new technology known as hysteroscopic morcellation has recently become 
available in clinical practice.  In Chapter 7 we compared the hysteroscopic 
morcellator to bipolar resection for the treatment of endometrial polyps in the office 
setting. A total of 121 women were randomly allocated to polyp removal by one of 
the two methods. In comparison to electrosurgical resection during hysteroscopic 
polypectomy, morcellation was significantly quicker, less painful, more acceptable 
to women and more likely to completely remove endometrial polyps compared with 
electrosurgical resection.  Thus hysteroscopic morcellation should be advocated 
above conventional electrosurgical resection in the office setting from a feasibility 
and patient experience perspective. 
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Conclusion 
In Chapter 8 the results of the studies described within this thesis are discussed 
and put into a broader context.  In conclusion, an increasing number of hospitals 
are adopting office diagnostic and surgical procedures.  However, further work is 
needed to optimise patient selection and techniques to achieve the best results and 
experience to women. 
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Recommendations for clinical practice 
Based on the results of this thesis the following is recommended: 
 
Diagnostic Hysteroscopy 
• Women with recurrent PMB should be investigated with a treatment modality 
that can identify discrete pathology like hysteroscopy or saline infusion 
sonography. 
 
• Vaginoscopy should probably be used in preference to other techniques to 
introduce the hysteroscope into the uterine cavity, because overall it is 
associated with better patient experience and outcomes. 
 
Therapeutic office hysteroscopy 
Endometrial ablation 
 
• Women who have a uterine cavity >9cm or dysmenorrhoea should be 
warned they are more likely to require further intervention after endometrial 
ablation. 
 
• Women should be informed that symptomatic alleviation of heavy menstrual 
bleeding with office endometrial ablation is high but 1:10 treated women will 
require further intervention, usually in the form of hysterectomy.  They should 
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be aware that there appears to be no difference between the effectiveness of 
bipolar radiofrequency ablation and thermal balloon ablation at five years of 
follow up and choice of health technologies should be based on procedural 
factors, and patient experience and satisfaction.   
 
Hysteroscopic endometrial polypectomy 
 
• Women who present with abnormal uterine bleeding and an endometrial 
polyp should have it removed. 
 
• The hysteroscopic morcellator should be used in preference to bipolar 
resection for endometrial polyp removal, because it is associated with 
quicker, less painful, more acceptable and more successful polyp treatment. 
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Appendix 1: Consent form for VAST 
VAST consent form version 1.2 01/01/14 
A randomised controlled trial of 
Vaginoscopy Against Standard 
Hysteroscopy !!
 
 
 
 
 
 
 
 
 
 
I confirm that I have read and understand the information sheet for the above study 
(PIS v1.2 01.01.2014).  I have had the opportunity to consider the information, ask 
questions and these have been answered satisfactorily.         
 
 
I understand that my participation is voluntary and that if I take part, I am free to 
withdraw at any time, without giving a reason, and without my medical care or legal 
rights being affected.  
 
 
I accept that the study researchers will telephone or email me to check how I’ve been 
since the procedure.   
   
I understand that the personal information and details about my treatment will be 
used for medical research only.  I will not be identified in any way in the analysis and 
reporting of the results.  I understand that relevant sections of my medical notes and 
data collected during the study may be looked at by individuals from Birmingham 
Women’s Hospital or regulatory authorities, where it is relevant to my taking part in 
this research.  I give permission for these individuals to have access to my record. 
 
I agree to my GP being informed of my participation in the VAST Trial.  I understand 
my GP may be contacted to obtain information about any complications or further 
gynaecology consultations. 
 
I understand what is involved in the trial, agree to participate and be randomised 
between trial treatments.      
 
 
…………………………………. ……………  ………………………….. 
Name of Patient   Date   Signature 
 
…………………………………. ……………  ………………………….. 
Name of Person taking consent Date   Signature 
 
Trial Number !!! 
Participant Consent Form 
Please initial each 
box to confirm 
consent !
!
!
!
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!
Page 236 
Appendix 2: Patient information leaflet for VAST 
 
 
 
 
 
 
Birmingham Women’s Hospital 
Metchley Park Road 
Edgbaston 
Birmingham 
B15 2TG 
 
Switchboard: 0121 472 1377 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participant Information Sheet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VAST information leaflet version 1.2 01/01/14 
 
 
 
 
Part 1 This tells you the purpose of the study and 
what will happen to you if you take part. 
 
Invitation to participate a new technique study 
You are invited to take part in a research study to find out 
which is the best technique to enter the womb.  The 
study is entirely voluntary – you do not have to take part, 
nor give a reason why, if you decide not to.  Before you 
decide whether or not to take part, it is important for you 
to understand why the research is being done and what it 
would involve if you do choose to take part.  Please take 
your time to read this information carefully.  Talk to others 
such as family, friends or your GP about the study if you 
wish.  If there is anything that is not clear, or you would 
like more information you should ask your gynaecologist 
or clinic nurse for further advice. 
 
What is hysteroscopy? 
Hysteroscopy is an investigation in which a special 
telescope is inserted into the womb.   
 
What is the purpose of the study? 
The established technique for hysteroscopy involves 
using a speculum inserted into the vagina to visualise the 
opening of the womb.  Pain during hysteroscopy can lead 
to poor patient experience and even failure. There is 
uncertainty whether an alternative technique, known as 
vaginoscopy, will minimise the pain experienced by the 
patient. Vaginoscopy is where the telescope is inserted 
directly into the vagina, and guided into womb avoiding 
the need for potentially painful introduction of other 
instruments. However, this technique may be more prone 
to failure due to an inability to cross the entrance to the 
womb and infection rates may be higher due to vaginal 
contamination. 
 
Do I have to take part? 
No.  Taking part is entirely voluntary and it is up to you to 
decide.  If you do not wish to take part your decision will 
not affect the standard of care you will receive. 
 
If I take part will the hysteroscope be inserted using 
the standard technique or using vaginoscopy?  
Women are allocated at random to either vaginoscopy or 
standard technique by the central study office.  There is 
an equal chance of being allocated to the vaginoscopy or 
standard technique group. Neither you nor your 
gynaecologist will know which of the groups you will be in 
until after you have been entered into the study.  This 
means that doctors can not choose which women will 
receive which treatment and this makes the results much 
more reliable.  This is called a ‘randomised clinical trial’ 
and it is the standard medical research method for 
comparing treatment. 
 
What will happen to me if I take part? 
If you agree to take part you will be randomised to either 
standard technique or vaginoscopy.  The process of 
randomisation will prolong the procedure by up to 2 
minutes.  You will then have the hysteroscopy, which 
takes 2-5 minutes. .  After the procedure you will be able 
to rest and have a cup of tea in comfortable 
surroundings.  While you are resting you will be asked to 
fill in a short, confidential, questionnaire on your 
experience.  About 2 weeks after the procedure you will 
be contacted by email or phone to ask how you have 
been since the procedure. 
 
How will I feel during and after outpatient 
hysteroscopy? 
During the procedure you may get some crampy period 
type pains in your lower abdomen, which usually settle 
once treatment is completed.  If it does not the nurse will 
give you some simple painkillers. A minority of women 
may feel a little faint following the procedure requiring 
them to lie down for a few minutes until the sensation 
passes.  Light spotting or fresh blood loss is not 
uncommon but again should settle within a few hours of 
the procedure, although some women may experience 
light vaginal blood loss for a few days.  After the 
procedure you will be able to rest and have a cup of tea 
in comfortable surroundings.  It is advisable to have 
someone with you when you get home.  You will need to 
rest for the remainder of the day.  If you do require further 
pain relief, we suggest simple painkillers such as 
paracetamol every 6 hours. 
 
What are the alternatives for diagnosis and 
treatment? 
Pelvic ultrasound is the usual first line investigation to 
look at the womb.  However, this has limited accuracy in 
A randomised controlled trial 
of Vagi osc py Against 
Standard Technique for 
outpatient hysteroscopy !
VAST 
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detecting problems.  Another alternative is to be put to 
sleep to have the procedure.  
 
What are the risks and disadvantages of taking part? 
Outpatient hysteroscopy is widespread in the NHS and all 
doctors involved will have the relevant experience.  Both 
vaginoscopy and the standard technique for 
hysteroscopy have been shown to be safe.  
 
What happens when the research study stops? 
When the results of the study are known they will be 
published in medical journals and the results circulated to 
medical staff and participants.  The results will influence 
the way hysteroscopy is performed in the future.   
 
What are the side effects of treatment received when 
taking part? 
Minor side-effects of hysteroscopy include prolonged 
blood stained vaginal discharge, and infection of the 
womb lining or bladder (cystitis requiring a short course 
of antibiotics).  Some women can experience severe, 
cramping period-like pain and some may feel faint for a 
few minutes immediately following the procedure.  The 
only serious and rare complication specific to the 
procedure of hysteroscopy is making a hole in the wall of 
the womb (‘perforation’), which normally heals naturally, 
but occasionally can cause bleeding or damage to other 
organs in the abdomen that requires immediate 
abdominal surgery to repair. 
 
Are there any benefits for me from taking part in the 
study? 
Participants may not gain any individual benefit.  
However, if one technique is shown to better, in the 
future women could benefit in terms of safety and 
acceptability. 
 
What if there is a problem? 
Any compliant about the way you have been dealt with 
during the study or any possible harm you might suffer 
will be addressed.  The detailed information is given in 
Part 2. 
 
Will my taking part in the study be kept confidential? 
Yes.  The study will follow ethical and legal practice and 
all information about you will be handled in confidence.  
The details are included in Part 2 
 
Part 2  If the information in part 1 has interested you 
and you are considering participation, please read 
part 2 before making a decision 
 
What if there is a problem? 
You have the same legal rights whether or not you take 
part in this study.  If you are not satisfied with any aspect 
of the way you have been approached or treated during 
the course of this study, you should speak to the 
researchers who will do their best to answer your 
questions. If you remain unhappy and wish to complain 
formally, the normal NHS complaints mechanisms are 
available and you should ask for the complaints manager 
at the hospital. Taking part in the trial should not affect 
any private medical insurance you may have, but you are 
advised to contact your medical insurance provider to 
confirm this. 
 
Will information about me be kept confidential? 
Yes, all information will be kept strictly confidential like 
your other medical records.  If you agree to take part, 
your doctor will send basic information about you and 
your condition to Birmingham Women’s Hospital.  This 
information will be put into a computer and analysed by 
the study staff only.  The questionnaires will not contain 
your name and will be identified using code number and 
not be seen by your GP or gynaecologist.  No named 
information about you will be published in the study 
report.  Occasionally, inspectors of clinical study data are 
undertaken to ensure that, for example, all participants 
have given consent to take part.  But, apart from this, 
only the study organisers will have access to the data. 
 
Involvement of the General Practitioner 
With your consent we will inform your GP of your 
participation in the trial. 
 
What will happen to the results of the research 
study? 
It is expected that the results will be reported in a medical 
journal around 12months after recruitment is completed.  
Everyone who takes part will then be told the results in a 
newsletter that will be posted directly to them. 
 
Who is funding and organising the research? 
The doctors and researchers involved are not being paid 
for recruiting women into the study.  Patients are not paid 
to take part either, but their help in finding out more about 
how best to treat polyps is much appreciated. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent 
group of people, called a Research Ethics Committee to 
protect your safety, rights, wellbeing and dignity. 
 
Do you have any further questions? 
If you have any questions about the study now or later 
feel free to ask your gynaecologist or clinic nurse.  Their 
names and telephone numbers are given below.  Please 
take the time before your appointment to decide whether 
you wish to take part in the trial.  You may like to discuss 
your decision with friends or relatives. 
 
The UK Clinical Research Collaboration has produced a 
guide entitled, ‘Understanding Clinical Trials’.  This can 
be down loaded from their website: www.ukcrn.org.uk 
and maybe useful if you require general information 
about research.  If you require specific information about 
the research project please contact any of the trial staff 
listed below. 
 
Contact details 
Study Organisers: 
Mr Justin Clark, Chief investigator, Consultant 
Gynaecologist, Birmingham Women’s Hospital, Metchley 
Park Road, Edgbaston, Birmingham B15 2TG Tel: 
  
Patient Advice & Information Centre: 
If your would like to speak to someone else, you can 
contact the Patient Advice and Liason Service 
dhft.contactpals@nhs.net or freephone 0800 783 7691 
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Appendix 3: Screen shots for VAST ipadTM application. 
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Appendix 4: Surgical treatment form for VAST. 
!
 
VAST Treatment form version 1.0  07/11/13 !
A Randomised Controlled Trial of Vaginoscopy against 
Standard Technique !
Patient details 
Trial Number: !!!  Patient initials: !!  Weight (kg): !!! 
 
Date of birth (dd/mm/yyyy): ……../……./………  Height (cm): !!! 
 
Parity: !!  (Vaginal: !! C/S: !!) 
 
Indication for hysteroscopy:  Bleeding !    Fertility !  Dysmenorrhoea ! 
Lost intrauterine device !    Thickened endometrium/polyp ! 
 
Menopausal status: Premenopausal !    Postmenopausal ! 
 
 
Vaginoscopy !      Standard  ! Date of procedure: ……../……./…… 
 
Surgical technique: 
Local anaesthetic: None !   Direct cervical ! Paracervical ! 
 
Tenaculum used:   Yes ! No ! 
 
Cervical dilatation:   Yes ! No ! 
 
Speculum !  No speculum (i.e. ‘vaginoscopic’ polyp removal) ! 
 
Endometrial biopsy performed:   Yes ! No ! 
 
Any other surgical procedure performed: …………………………………………. 
 
If procedure failed please state why: 
 Patient discomfort !     Equipment failure ! 
 Other ! (if Other, please state) ………………………………………….. 
 
 
Operative complications (attach separate sheet if necessary) 
None !   Vaso-vagal episode !   Cervical trauma !                 Uterine 
perforation !    Haemorrhage !    Other ! (if other please 
state)………………………………. 
 
Time taken 
From insertion to removal of vaginal instrumentation post randomisation 
!! (mins) 
 
Name and grade of surgeon ……………………………………………………… 
Grade: Consultant !    Associate specialist !    Staff Grade !    
Specialist registrar !    Other ! if other, please specify: ………………………. 
Signed: ……………………………………… Date: ……/……/…… (dd/mm/yy) 
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Appendix 5: Serious adverse event form for VAST. 
 
 
VAST Serious Adverse Event Form Version 1 07/06/13 
A randomised controlled trial of 
Vaginoscopy Against Standard 
Technique 
 
 
 
 
 
Please report any serious and unexpected adverse events that are suspected to be due to 
treatments1 given as part of the trial by sending or faxing the following details to the trial office 
(Fax: 0121 415 9135) within 2 days of the event. 
 
Patient Identification: 
Patient’s full name: ……………………………………………………………………… 
Trial No: …………………………….. 
Date of birth: day/month/year    …../…../….. 
Centre Name: ……………………………………………..  
Responsible doctor: …………………………………………………………………….. 
 
Associated Treatment: 
Vaginoscopy  !    Standard Technique  ! 
Date of treatment: day/month/year     …../…../….. 
 
SAE description: 
Category of event:  Death  !  Life threatening  !  
Hospitalisation (or prolongation of)  !  Persistent or significant disability/incapacity ! 
Date SAE started: day/month/year  …./…. /….  
Date SAE ceased: day/month/year  …./…. /…. 
 
Outcome: 
 Fatal  !   Recovered Continuing  ! 
Details of adverse event (please attach copies of relevant reports): 
………………………………………………………………………………………………………
………………………………………………………………………………………………………
………………………………………………………………………………………………………
……………………………………………………………………………………………………… 
……………………………………………………………………………………………………… 
 
Did the event require or prolong hospitalisation? No ! Yes !  No. of days 
Please give reasons why you consider the event to be treatment related: 
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………………………………………………………………………………………………… 
…………………………………………………………………………………………………………… 
 
 
Name of person reporting (please print):…………………………………………………… 
Signed: ………………………………………………………………………………………………… 
Tel No: ………………………………………………………. Date: day/month/year …../….. /….. 
 
 
1For the purposes of this study, “serious” adverse events are those that are fatal, life-threatening, 
disabling or require hospitalisation. “Unexpected” adverse experiences are defined as those that 
would not be expected among patients given these treatments. It is not required to report in this 
way side-effects or adverse events that might reasonably be expected. 
 
VAST 
SERIOUS ADVERSE EVENT FORM 
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Appendix 6: Patient information leaflet for COAT. 
 
 
 
 
 
 
Invitation to take part in the COAT research study 
You will have decided to have an outpatient endometrial ablation for the treatment of your heavy menstrual periods 
(menorrhagia). Your consultant will have explained to you what this involves and you will have consented for treatment.  
We would like to invite you to take part in a study comparing two of the most commonly used techniques for 
endometrial ablation, ‘Thermachoice’ and ‘NovaSure’. We have called this study the COAT trial that stands for the 
Comparison of the effectiveness of Outpatient endometrial Ablation Techniques (NovasureTM versus ThermachoiceTM) 
in the treatment of menorrhagia.  80 women, who like you have had problematic heavy menstrual periods, will take part 
in the study. Half will be randomly allocated to have the NovaSureTM technique for endometrial ablation and the other 
half will have the ThermachoiceTM endometrial ablation technique. Women in the study will not be told which group 
they are in because we don’t want this to influence how they feel after the operation. This is called ‘blinding’ and allows 
us to trust the results we obtain from the study.  
 
What is the purpose of the COAT study? 
Endometrial ablation is an established surgical treatment for heavy menstrual bleeding and has shown to be very 
effective. Advances in technology have resulted in the production of several ablative devices that can be used in an 
outpatient setting without the need for general anaesthesia. However, we do not know which, if any, of the available 
devices are more acceptable to women and effective in terms of reducing the amount of bleeding a woman has during 
her period and improving her quality of life. Two of the most established devices used for outpatient endometrial 
ablation are called ThermachoiceTM and NovasureTM . The COAT study aims to find out which outpatient ablation 
treatment: 
! controls menstrual bleeding symptoms the best 
! has the best overall effect on women’s quality of life 
! is easier to use 
! is the more acceptable to women 
! can avoid the future need for hysterectomy 
! is the most cost-effective treatment 
What is Outpatient Endometrial Ablation? 
Endometrial ablation is a surgical technique to reduce the amount of bleeding that a woman experiences during her period. 
The technique involves removal of the lining of the uterus called the ‘endometrium’ by the use of controlled heat known as 
‘ablation’. Endometrial ablation can be done in a variety of ways, all of which do not require surgical incisions and are 
associated with minimal side effects and rapid recovery, usually within 48 hours. Two techniques, NovasureTM and 
ThermachoiceTM can be performed with or without the need for general anaesthetic (i.e women can be awake or asleep for 
the procedure). If women choose to have the procedure without general anaesthetic then the procedure is termed an 
‘outpatient’ endometrial ablation as admission to hospital is not usually required and the operation is performed in an 
outpatient treatment room rather than a formal operating theatre.  
COAT 
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Women undergoing outpatient endometrial ablation do not need to fast prior to the procedure and are 
usually discharged from hospital within 2 to 6 hours of the procedure. 
 
What are ‘NovaSure’ and ‘Thermachoice’? 
NovaSureTM and ThermachoiceTM are both techniques of endometrial ablation. They use specially 
designed, miniaturized equipment, which allow the procedures to be carried out safely without the need 
for general anaesthetic and require less than 10 minutes to complete. Both techniques involve the use of 
small devices that are placed inside the uterus (womb). These devices impart heat to the lining of the 
uterus (the ‘endometrium’) so that it is removed and subsequent menstrual periods either disappear or 
become much lighter. One technique involves the use of a hot water balloon device called 
‘Thermachoice’ and the other a fan-shaped electrical device called ‘NovaSure’. 
 
Will ‘NovaSure’ or ‘Thermachoice’ Help Me? 
Previous clinical studies have shown that most women with heavy menstrual bleeding undergoing 
endometrial ablation with ThermachoiceTM or NovasureTM  are satisfied with their results because they 
get substantial improvement in their bleeding symptoms. This improvement can mean complete relief of 
bleeding (periods stop altogether or just monthly ‘spotting’ occurs) or partial relief of bleeding (reduction 
in amount of bleeding during a menstrual period) depending on the individual woman. By taking part in 
this trial, you will help us find out whether outpatient treatment by ThermachoiceTM or NovasureTM  
relieves bleeding more effectively.  In addition we will be able to assess which outpatient treatment is the 
better tolerated and more acceptable to women so that women in the future obtain the best treatment for 
their condition.  
 
What happens during Outpatient Endometrial Ablation?  
Outpatient endometrial ablation is a simple technique that does not require you to be put to sleep under 
general anaesthetic in an operating theatre. For this reason you can eat and drink before arriving at the 
designated hospital ward for the procedure where you will be given simple pain killers and an anti-sickness 
tablet. You will asked to remove you’re undergarments and wear a hospital gown. You will then be taken to 
a private outpatient treatment room where you will be required to lie flat on a special couch where your legs 
will be placed apart in leg rests. A speculum will be placed in the vagina (like when you have a cervical 
smear test), which enables a tiny telescope (called a hysteroscope) to be passed through the cervix 
(entrance to the womb) into the uterus (womb). The gynaecologist will examine your uterus to see if you 
have any obvious reason for your heavy bleeding and to confirm that you are suitable for outpatient 
endometrial ablative treatment. A local anaesthetic will then be injected into the cervix to ‘freeze it’ which 
enabled the ThermachoiceTM or NovaSureTM  device to be placed inside the uterus and the treatment cycle 
commenced according to which technique you have been randomly allocated to. It is not possible to 
anaesthetise or ‘freeze’ the entire uterus so you will experience some abdominal discomfort during the 
procedure which most women describe as cramping period-like pain (it should be noted that the uterus 
does not sense heat). The discomfort experienced varies from woman to woman but is usually described 
as mild to moderate although some women may experience more severe cramping pain. The time taken to 
complete either ablation procedure is under 10 minutes and you can request the treatment to be stopped at 
anytime if the discomfort is not tolerable, although this situation is unusual. 
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Following the procedure you will return to the hospital ward where you will be encouraged to drink and 
be given pain killers if required. Over the next 1-4 hours most women will continue to experience 
cramping period-like pain, which gradually settles, and the majority of women are discharged within 2-6  
 
hours following the procedure but occasionally some patients may be required to stay in overnight. Any 
abdominal discomfort, should settle over the next 24 hours and you will be given simple pain killers to 
control this. It should be noted that the procedures do not require any cuts or stitches. 
 
What else will I be asked to do? 
Before you have the surgery, you will be asked to complete a questionnaire to assess you’re menstrual 
bleeding (heavy periods) and how this bleeding affects you. After the procedure, but before discharge 
from hospital, you will be asked to rate the amount of discomfort associated with the procedure and 
comment upon your experience. The same questionnaire will be sent to you at home 3, 6,12 and 24 
months after the surgery and then once more at 5 years after surgery. You will not need to make any 
special trips back to the hospital. There are four parts to the questionnaire - your assessment of your 
menstrual bleeding and related symptoms, what additional treatment you have taken for your bleeding, 
questions on how it affects your sexual relationships and some questions to determine your overall state 
of health and quality of life. The results of the trial will be reported once everyone in it has reached the 
six-month time point after surgery. We would, however, like you to complete the same questionnaires 
yearly until 5 years after the surgery to see if the effects of the treatment are long lasting. 
 
What are my rights? 
You have the right to be given all-important information about your condition, your treatment, the COAT 
study and what you will be asked to do if you decide to take part. You should only agree to take part if 
you feel happy that you know enough about all these things. You do not have to take part in the study if 
you do not want to. If you decide not to take part in this research, your doctor will respect your 
decision and advise you of the current standard treatment options that are available. If you do 
agree to take part, you are entitled to withdraw from the study at any time without having to give a 
reason. This will not affect your medical care in any way either.  
Whether or not you take part in the study, you have the right to confidentiality of your medical records 
(although we will inform your GP that you are taking part in the COAT study, unless you object). If you 
agree to take part, your doctor will send basic information about you and your condition to the study’s 
central organisers at the University of Birmingham Clinical Trials Unit to allow the results to be analysed. 
The information will be kept securely and in strict confidence. The questionnaires will be identified only 
by a code number and will not be seen by your doctor. No named information about you will be 
published in the trial report. If there are any further questions, you can ask your doctor or contact: 
 
 
 
 
 
 
 
 
 
Both are based at Birmingham Women’s Hospital, Birmingham. B15 2TG
 
Mr T.J. Clark    Jan Godwin 
Consultant Gynaecologist  Charge Nurse 
0121 607 4712   0121 472 1377 ext 8705 
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Appendix 7: Patient consent form for COAT 
 
 
A RANDOMISED CONTROLLED TRIAL TO COMPARE THE 
EFFECTIVENESS OF OUTPATIENT ENDOMETRIAL ABLATION 
TECHNIQUES (NOVASURE VERSUS THERMACHOICE) IN THE 
TREATMENT OF MENORRHAGIA 
 
 
I         agreed to take part in the COAT study, which 
has been explained to me by Dr.  
The explanation included  
• a patient information sheet which I have read, understood and accepted 
• the purpose and length of the study 
• What the study involves, if I take part 
 
I understand that I am free to withdraw from this study at any time and that, if I do, this will not adversely 
affect my future treatment. I am aware and agree that information obtained during the study will be sent to the 
central study organisers for analysis, where it will be treated as strictly confidential and nothing identifying me 
personally will be made publicly available. 
Signature of patient       Date 
 
Signature of investigator      Date
 
COAT 
PATIENT CONSENT FORM 
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Appendix 8: Letter to patient’s general practitioner for COAT. 
 
Doctors name 
Ambulatory Gynaecology Department 
Birmingham Women’s Hospital 
Edgbaston 
Birmingham 
B15 2TG 
 
NAME  
DATE OF BIRTH  
HOSPITAL NUMBER  
DATE RANDOMISED  
TRIAL NUMBER  
 
Dear Dr gp, 
You will be aware that your patient named above has had heavy menstrual bleeding which 
has not responded to medical therapy and has been seen by Dr consultant at hospital. With 
her written consent, she is participating in a clinical trial named COAT to compare the 
effectiveness of two outpatient endometrial ablation techniques (ThermachoiceTM and 
NovaSureTM) for the treatment of heavy menstrual bleeding refractory to medical therapy. 
If she fulfils all the surgical eligibility criteria she will have her operation on date. Treatment 
allocation will be ThermachoiceTM or NovaSureTM ablation of the endometrium. The result of 
the randomisation cannot be disclosed until the end of the trial, which is anticipated to be 
December 2005. The patient will receive postal questionnaires, including questions on 
menstrual bleeding and related symptoms, quality of life, sexual function and demands on 
health care resources, at 3, 6, 12, 24 and 60 months post-operatively. 
The patient should not need any additional treatment for her menstrual bleeding, but the trial 
does not preclude GP intervention. The investigators do not anticipate that there will any 
complications that would necessitate the unblinding of the treatment, but in exceptional 
circumstances the consultant has a record of the treatment, which is kept separate from her 
notes. 
The local co-ordinator for the trial is Mr Clark, Consultant Gynaecologist, Birmingham 
Women’s Hospital, Birmingham, B15 2TG. Ethical approval from the Local Research Ethics 
Board has been granted.  
Please file this letter in the patient’s notes. I would appreciate being notified if there are any 
errors or if she is no longer one of your patients. 
Yours sincerely, 
 
Justin Clark. 
Trial Co-ordinator
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Appendix 9: Randomisation form for COAT 
   
COAT REGISTRATION AND RANDOMISATION FORM 
Patient Surname: Forenames: 
Address:  
Postcode:  
Date of Birth:   ____/____/____ Hospital Number: 
 Hospital:  
Referring Surgeon: Patient GP  
Patient GP Address: 
PRE-ABLATION ELIGIBILITY CHECKLIST : Complete in clinic  
! Women with heavy menstrual bleeding without organic pathology (DUB) 
! Duration of symptoms over 6 months 
! Age over 25 
! No desire to preserve fertility 
! Negative effect of symptoms on life quality 
! Non-response to recommended medical treatment 
! No previous open myomectomy or endometrial ablation / resection 
! Uterine cavity length less then or equal to 11cm 
! Premenopausal follicular follicle stimulating hormone (FSH) level less than 40 IU/L. 
! Prepared to undergo endometrial ablation without general anaesthesia 
! Written informed consent given.  
 
Patient is eligible if all clinical questions are ticked ‘yes’. 
 
 
 
 
 
 
 
 
 
 
 
TREATMENT ALLOCATION ThermachoiceTM   
   NovaSureTM   
 
   Trial number   
 
" 
Pre-Ablation Registration: 
Fax:  0121 414 7602 
Randomisation line: 0800 371969 Or 0800 731 7625 
Ask for ‘COAT’ trial 
 
 
 
Signed: ………………………………… Date of Randomisation:  ____/____/____ 
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Appendix 10: Surgical treatment form for COAT 
   
1 
 
 
Patient Surname: Forenames: 
Address:  
Date of Birth:  Hospital Number:   
Hospital:   Referring Surgeon: 
 
GENERAL INFORMATION 
! Age:    
! Parity:      (    vaginal   C/S) 
! Occupation:  part-time  full-time) 
! Partners occupation: 
! Sexually active:  Yes   No  
  
 CLINICAL INFORMATION 
! Duration of symptoms:     years    months 
! Flood or pass large clots: Yes    No 
! Cycle regularity:  Regular / Irregular (please circle) 
! Past or present treatment for periods (you may tick more than one category): 
   
 None      Mefanamic acid    Tranexamic acid 
 
Combined oral contraceptive  Oral progestin     Depot / implant progestin
  
Mirena      Hysteroscopic myomectomy 
  
Other       (please state) 
  
! Period pain:   Yes   No 
! Pain killers:   Yes   No 
! Pre-menstrual symptoms: Yes    No 
! Significant medical conditions: (please state) 
 
 ADDITIONAL INFORMATION (Your doctor will complete this section) 
! Antiplatelet / coagulants: Yes   No 
! Pre-treatment GnRH-a: Yes   No 
! LMP:  ____/____/____  
! Phase of cycle:  prolif / sec / mens / other (circle &confirm at hysteroscopy) 
! BMI: 
! Uterine axis:   anteflexed / retroflexed / axial (please circle) 
! Uterine length:      cm 
! Operating surgeon:       Grade: 
! Pre-treatment GnRH-a: Yes   No 
Signed: ……………………… Date of completion:  ____/____/____ 
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Appendix 11: Search History for polypectomy systematic review 
1. MEDLINE; exp POLYPS/; 26612 results.  
2. MEDLINE; (endometri* OR uter*).ti,ab; 205911 results.  
3. MEDLINE; (surgery OR currettage OR hysteroscopy OR polypectomy).ti,ab; 
809885 results.  
4. MEDLINE; 1 AND 2 AND 3; 408 results.  
5. EMBASE; exp POLYP/; 50684 results.  
6. EMBASE; (endometri* OR uter*).ti,ab; 229380 results.  
7. EMBASE; (surgery OR currettage OR hysteroscopy OR polypectomy).ti,ab; 
1012684 results.  
8. EMBASE; 5 AND 6 AND 7; 1114 results.  
9. CINAHL; exp POLYPS/; 1771 results.  
10. CINAHL; (endometri* OR uter*).ti,ab; 8907 results.  
11. CINAHL; (surgery OR currettage OR hysteroscopy OR polypectomy).ti,ab; 
69959 results.  
12. CINAHL; 9 AND 10 AND 11; 12 results.  
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Appendix 12. Patient information leaflet for MERT 
 
 
 
 
 
 
Birmingham Women’s Hospital 
Metchley Park Road 
Edgbaston 
Birmingham 
B15 2TG 
 
Switchboard: 0121 472 1377 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participant Information Sheet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MERT information leaflet version 1.0 11/11/11 
 
Part 1 This tells you the purpose of the study and 
what will happen to you if you take part. 
 
Invitation to participate a new technology study 
You are invited to take part in a research study to find 
out which is the best treatment to remove polyps in the 
outpatient setting.  The study is entirely voluntary – you 
do not have to take part, nor give a reason why, if you 
decide not to.  Before you decide whether or not to take 
part, it is important for you to understand why the 
research is being done and what it would involve if you 
do choose to take part.  Please take your time to read 
this information carefully.  Talk to others such as family, 
friends or your GP about the study if you wish.  If there 
is anything that is not clear, or you would like more 
information you should ask your gynaecologist or clinic 
nurse for further advice. 
 
What is the procedure that is being tested? 
Outpatient polyp treatment with electrical operating 
instruments compared to mechanical operating 
instruments.  
 
What is a polyp? 
A polyp is an overgrowth of tissue that may be the 
cause of your bleeding or infertility. Polyps can be found 
at the cervix (neck of the womb) or inside the uterus 
(womb).  Polyps require removal for examination under 
the microscope. 
 
What is the purpose of the study? 
Outpatient polyp treatment can be performed in a few 
different ways but generally involves passing a special 
type of hysteroscope (3-6 millimetre in diameter) into 
the womb through which specifically designed miniature 
operating instruments are passed to remove the 
polyp(s).  At present the most commonly used 
instruments use an electrical cutting edge.  However, a 
new instrument using a mechanical cutting edge has 
come to market.  In patients having a general 
anaesthesia the mechanical cutting instrument has 
been shown to be easier to learn, more effective at 
completely removing polyps and quicker.  However, the 
instrument is slightly larger, which could potentially 
cause more discomfort and prolong the procedure in the 
outpatient setting.  Therefore, we want to compare the 
electrical and mechanical instruments for speed, 
completeness of polyp removal and patient 
acceptability. 
 
 
 
Do I have to take part? 
No.  Taking part is entirely voluntary and it is up to you 
to decide.  If you do not wish to take part your decision 
will not affect the standard of care you will receive. 
 
If I take part will I be treated with the electrical or 
mechanical operating instruments? 
Women are allocated at random to either electrical or 
mechanical operating instruments by the central study 
office.  There is an equal chance of being allocated to 
the mechanical instrument or electrical instrument 
group. Neither you nor your gynaecologist will know 
which of the groups you will be in until after you have 
been entered into the study.  This means that doctors 
can not choose which women will receive which 
treatment and this makes the results much more 
reliable.  This is called a ‘randomised clinical trial’ and it 
is the standard medical research method for comparing 
treatment. 
 
What will happen to me if I take part? 
If a polyp is seen on diagnostic hysteroscopy you will be 
eligible to enter the trial.  The diagnostic hysteroscopy 
usually takes 2-5 minutes and the process of 
randomisation will prolong the procedure by up to 2 
minutes.  Depending on the local circumstances you will 
then either have the polyp removed immediately or you 
will be listed on an outpatient operative list at a later 
date.  The operative procedure usually takes 5-20 
minutes on average. In some cases the procedure 
requires local anaesthetic to be applied to the neck of 
the womb to help make the procedure easier and more 
comfortable.  After the procedure you will be given a 
short, confidential, questionnaire about your experience. 
 
How will I feel during and after outpatient polyp 
treatment? 
During the procedure you may get some crampy period 
type pains in your lower abdomen, which usually settle 
once treatment is completed.  If it does not the nurse 
will give you some simple painkillers. A minority of 
women may feel a little faint following the procedure 
requiring them to lie down for a few minutes until the 
sensation passes.  Light spotting or fresh blood loss is 
not uncommon but again should settle within a few 
hours of the procedure, although some women may 
experience light vaginal blood loss for a few days.  After 
the procedure you will be able to rest and have a cup of 
tea in comfortable surroundings.  It is advisable to have 
someone with you when you get home.  You will need 
to rest for the remainder of the day.  If you do require 
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further pain relief, we suggest simple painkillers such as 
paracetamol every 6 hours. 
 
What are the alternatives for diagnosis and 
treatment? 
The vast majority of doctors recommend removing 
polyps with the aim of improving symptoms and 
examining the removed specimen to make sure that 
they are not precancerous, which would require 
additional treatment.  However, most polyps are not 
worrying and some may even disappear on their own 
naturally, but this is uncommon and generally applies to 
very small polyps only.  Another alternative is to remove 
the polyp at a later date as a day-case procedure under 
a general anaesthetic 
 
What are the risks and disadvantages of taking 
part? 
Outpatient treatment of polyps is widespread in the 
NHS and all doctors involved will have the relevant 
experience.  Both the electrical and mechanical 
instruments for polyp removal have been shown to be 
safe. 
 
What happens when the research study stops? 
When the results of the study are known they will be 
published in medical journals and the results circulated 
to medical staff and participants.  The results will 
influence the way women with polyps are treated in the 
future. 
 
What are the side effects of treatment received 
when taking part? 
Minor side-effects of hysteroscopy include prolonged 
blood stained vaginal discharge, and infection of the 
womb lining or bladder (cystitis requiring a short course 
of antibiotics).  Some women can experience severe, 
cramping period-like pain and some may feel faint for a 
few minutes immediately following the procedure.  The 
only serious and rare complication specific to the 
procedure of polyp removal is making a hole in the wall 
of the womb (‘perforation’), which normally heals 
naturally, but occasionally can cause bleeding or 
damage to other organs in the abdomen that requires 
immediate abdominal surgery to repair. 
 
Are there any benefits for me from taking part in the 
study? 
Participants may not gain any individual benefit.  
However, if the mechanical polyp removal instruments 
are better, in the future women could benefit in terms of 
speed, safety and acceptability. 
 
 
What if there is a problem? 
Any compliant about the way you have been dealt with 
during the study or any possible harm you might suffer 
will be addressed.  The detailed information is given in 
Part 2. 
 
Will my taking part in the study be kept 
confidential? 
Yes.  The study will follow ethical and legal practice and 
all information about you will be handled in confidence.  
The details are included in Part 2 
 
Part 2  If the information in part 1 has interested you 
and you are considering participation, please read 
part 2 before making a decision 
 
What if there is a problem? 
You have the same legal rights whether or not you take 
part in this study.  If you are not satisfied with any 
aspect of the way you have been approached or treated 
during the course of this study, you should speak to the 
researchers who will do their best to answer your 
questions (Mr Justin Clark, Chief investigator, Tel:0121 
607 4712).  If you remain unhappy and wish to complain 
formally, the normal NHS complaints mechanisms are 
available and you should ask for the complaints 
manager at the hospital.  Taking part in the trial should 
not affect any private medical insurance you may have, 
but you are advised to contact your medical insurance 
provider to confirm this. 
 
Will information about me be kept confidential? 
Yes, all information will be kept strictly confidential like 
your other medical records.  If you agree to take part, 
your doctor will send basic information about you and 
your condition to Birmingham Womens Hospital.  This 
information will be put into a computer and analysed by 
the study staff only.  The questionnaires will not contain 
your name and will be identified using code number and 
not be seen by your GP or gynaecologist.  No named 
information about you will be published in the study 
report.  Occasionally, inspectors of clinical study data 
are undertaken to ensure that, for example, all 
participants have given consent to take part.  But, apart 
from this, only the study organisers will have access to 
the data. 
 
Involvement of the General Practitioner 
With your consent we will inform your GP of your 
participation in the trial. 
 
What will happen to the results of the research 
study? 
It is expected that the results will be reported in a 
medical journal around 12months after recruitment is 
completed.  Everyone who takes part will then be told 
the results in a newsletter that will be posted directly to 
them. 
 
Who is funding and organising the research? 
The study researchers have received support from the 
instrument manufacturers. 
 
The doctors and researchers involved are not being 
paid for recruiting women into the study.  Patients are 
not paid to take part either, but their help in finding out 
more about how best to treat polyps is much 
appreciated. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent 
group of people, called a Research Ethics Committee to 
protect your safety, rights, wellbeing and dignity. 
 
Do you have any further questions? 
Having read this leaflet, it is hoped that you will choose 
to take part in the trial.  If you have any questions about 
the study now or later feel free to ask your 
gynaecologist or clinic nurse.  Their names and 
telephone numbers are given below.  Please take the 
time before your appointment to decide whether you 
wish to take part in the trial.  You may like to discuss 
your decision with friends or relatives. 
 
The UK Clinical Research Collaboration has produced a 
guide entitled, ‘Understanding Clinical Trials’.  This can 
be down loaded from their website: www.ukcrn.org.uk 
and maybe useful if you require general information 
about research.  If you require specific information 
about the research project please contact any of the 
trial staff listed below. 
 
Contact details 
Local Study Organisers: 
Doctor:……………………………………………………….. 
Nurse:………………………………………………………... 
Central Study Organisers: 
Mr Justin Clark, Chief investigator, Consultant 
Gynaecologist, Birmingham Women’s Hospital, 
Metchley Park Road, Edgbaston, Birmingham B15 2TG 
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Appendix 13: Patient consent form for MERT. 
MERT consent form version 2 22/11/11 
A Randomised Controlled Trial of 
Morcellation versus Bipolar 
Resectoscopy 
 
 
 
 
 
 
 
 
 
 
 
I confirm that I have read and understand the information sheet for the above study.  
I have had the opportunity to consider the information, ask questions and these have 
been answered satisfactorily.         
 
 
I understand that my participation is voluntary and that if I take part, I am free to 
withdraw at any time, without giving a reason, and without my medical care or legal 
rights being affected.       
 
 
I accept that the study researchers may telephone or email me, if necessary, to 
remind me to complete questionnaires, or to ask the questions over the phone.  
 
 
I understand that the personal information and details about my treatment will be 
used for medical research only.  I will not be identified in any way in the analysis and 
reporting of the results.  I understand that relevant sections of my medical notes and 
data collected during the study may be looked at by individuals from Birmingham 
Women’s Hospital or regulatory authorities, where it is relevant to my taking part in 
this research.  I give permission for these individuals to have access to my record. 
 
I agree to my GP being informed of my participation in the MERT Trial.  I understand 
my GP may be contacted to obtain information about any complications or further 
gynaecology consultations. 
 
I understand what is involved in the trial, agree to participate and be randomised 
between trial treatments.      
 
 
 
…………………………………. ……………  ………………………….. 
Name of Patient   Date   Signature 
 
…………………………………. ……………  ………………………….. 
Name of Person taking consent Date   Signature 
 
Trial Number !!! 
MERT 
Participant Consent Form 
Please initial each 
box to confirm 
consent 
!
!
!
!
!
!
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Appendix 14: Surgical treatment form for MERT.  
MERT Treatment Form Version 1 
MERT: Morcellation and Electrical Resection 
Trial 
 
 
!
 
 
Patient details 
 
Trial Number: ………..    Patient initials: …………  Weight (kg): ………. 
 
Date of birth (dd/mm/yyyy): ……../……./………     Height (cm): ……… 
 
Parity: ………  (Vaginal: ……. C/S: ……..) 
 
Indication for surgery:  Bleeding !    Fertility !    Incidental ! 
 
Menopausal status: Premenopausal !    Postmenopausal ! 
 
Morcellator ! Versapoint ! Date of procedure: ……../……./…… 
 
If Versapoint, please state make, size and angle of hysteroscope………………………............. 
 
……………………………………………………………………………………………………………. 
 
Polyp(s): 
Number: ……. Size (cm, to 1 decimal place): ……… (largest if multiple) 
 
Location(s): anterior !    posterior !    left lateral !    right lateral ! 
          fundal !    isthmic !    left cornual !    right cornual ! 
 
Type: sessile ! pedunculated ! both ! 
 
Consistency: Glandulo-cystic !  Fibrous ! 
 
Surgical technique: 
Local anaesthetic: None !   Direct cervical !  Paracervical !   Topical !   
 
Cervical dilatation:   Yes ! No ! 
 
Speculum !  No speculum (i.e. ‘vaginoscopic’ polyp removal) ! 
 
Complete polyp removal ! Partial removal !      Failed removal ! 
If failed or partial removal please state why: 
 Patient discomfort !    Inadequate visualisation ! 
 Unable to locate ‘blindly’ !    Equipment failure ! 
 Other ! (if Other, please state) ………………………………………….. 
 
Complications: (attach separate sheet if necessary) 
None !   Vaso-vagal episode* !   Cervical trauma !   Uterine perforation !    
Haemorrhage !    Other ! (if other please state)………………………………. 
 
Prolonged post-operative stay (>1 hour stay due to a CLINICAL reason) Yes ! No ! 
 
 
 
 
 
TREATMENT FORM 
 MERT 
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MERT Treatment Form Version 1 
Page 2 of 2 
MERT: Morcellation and Electrical Resection 
Trial 
 
 
!
 
 
 
 
 
Time taken 
From insertion to removal of vaginal instrumentation post randomisation…………… (mins) 
 
From insertion of instrument for polypectomy (i.e. versapoint or Truclear) to removal of  
 
vaginal instrumentation …………... (mins) 
 
Analgesia 
Pre-operative (ask patient) Yes !  No !  (If Yes please specify) ……………………………….. 
 
Post-operative    Yes !  No !  (If Yes please specify) …………………………………………… 
 
Name and grade of surgeon ……………………………………………………… 
 
Grade: Consultant !    Other ! if other, please specify: ………………………. 
 
Signed: ……………………………………… Date: ……/……/…… (dd/mm/yy) 
 
 
* Definition of vaso-vagal episode: unable to get off examination couch within 5 minutes due to 
dizziness, feeling faint or nausea. 
TREATMENT FORM 
 MERT 
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Appendix 15: Pre-procedure patient questionnaire for MERT.  
V1.2 
 
A Randomised Controlled Trial of 
Morcellation versus Bipolar 
Resectoscopy 
 
 
 
Thank you very much for taking part in the MERT study 
 
Before you have your treatment we would be grateful if you would complete this 
short questionnaire. The completed questionnaire should be handed into one of 
the nurses or ward staff. If you take it home with you could you return it as soon 
as possible to the FREEPOST address given below: 
 
MERT Study Office, FREEPOST Minimal Access Research Team, Birmingham 
Womens Hospital, Birmingham B15 2TG 
 
 
Thank you again for your participation in the MERT study, your time and 
interest are very much appreciated 
The MERT study is organised by the 
University of Birmingham Clinical Trails 
Unit.  
 
The MERT study staff will return this completed 
questionnaire in the pre-paid envelopes to: 
MERT Study Office  
FREEPOST  
 Minimal Access Research Team  
Birmingham Womens Hospital  
Birmingham  
B15 2TG 
 
MERT study staff, please complete at 
hysteroscopy clinic: 
MERT Study No.   
   
Patient Initials 
 
Date form completed:    
Date of procedure:        
 
Centre name: ………………..………………………… 
 
MERT 
Pre Procedure 
Questionnaire 
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Please check that you have answered each question on this page. 
MERT Acceptability Questionnaire (Version 2, 22nd November 2011)        Page 2 of 2 
Randomised Controlled Trial of 
Morcellation versus Bipolar Resectoscopy 
 
 
 
 
 
Assessment of baseline pain level 
We would like to assess how much lower abdominal pain you experienced before your treatment. Please place a 
mark (x) on the lines shown below to indicate how much pain you had. One extreme of the line represents “no 
pain at all” while the other represents “as much pain as you can possibly imagine”. 
 
 
 
 
1. Pain before the procedure 
 
No pain at all     Worst imaginable pain 
 
 
 
 
 
2. We are also interested in knowing how much pain you have currently with your periods.  Please tick 
the most appropriate box: 
 
I do not have periods 
I get little or no period pain 
I get a moderate amout of period pain 
I get some severe period pain 
I get very severe period pain 
 
 
 
Thank you for taking the time to complete this questionnaire 
MERT 
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Appendix 16: Post-procedure patient questionnaire for MERT.  
V1.2 
 
A Randomised Controlled Trial of 
Morcellation versus Bipolar 
resectoscopy 
 
 
 
Thank you very much for taking part in the MERT study 
 
You have now had your treatment and we would be grateful if you would 
complete this short questionnaire about your experience before you go home. 
The completed questionnaire should be handed into one of the nurses or ward 
staff. If you take it home with you could you return it as soon as possible to the 
FREEPOST address given below: 
 
MERT Study Office, FREEPOST Minimal Access Research Team, Birmingham 
Womens Hospital, Birmingham B15 2TG 
 
 
Thank you again for your participation in the MERT study, your time and 
interest are very much appreciated 
The MERT study is organised by the 
University of Birmingham Clinical Trails 
Unit.  
 
The MERT study staff will return this completed 
questionnaire in the pre-paid envelopes to: 
MERT Study Office  
FREEPOST  
 Minimal Access Research Team  
Birmingham Womens Hospital  
Birmingham  
B15 2TG 
 
MERT study staff, please complete at 
hysteroscopy clinic: 
MERT Study No.   
   
Patient Initials 
 
Date form completed:    
Date of procedure:        
 
Centre name: ………………..………………………… 
 
MERT 
Post Procedure 
Questionnaire 
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Please check that you have answered each question on this page. 
MERT Acceptability Questionnaire (Version 2, 22nd November 2011)        Page 2 of 2 
Randomised Controlled Trial of 
Morcellation versus Bipolar Resectoscopy 
 
 
 
Assessment of polypectomy experience 
We would like to assess how much abdominal pain you experienced during and after your treatment. Please 
place a mark (x) on the lines shown below to indicate how much pain you had. One extreme of the line 
represents “no pain at all” while the other represents “as much pain as you can possibly imagine”. 
 
 
 
1. Pain during the procedure 
 
No pain at all     Worst imaginable pain 
 
 
 
2. Pain at 15 minutes post-procedure/or at discharge if earlier 
 
No pain at all     Worst imaginable pain 
 
 
 
3. Would you describe the procedure as: 
Totally acceptable              Generally acceptable 
Fairly acceptable Unacceptable  
 
 
4. Please give any comments about your treatment experience: ………………………………………………….. 
…………………………………………………………………………………………………………………………………... 
 
 
 
 
Thank you for taking the time to complete this questionnaire 
MERT 
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Appendix 17: Toxicity and known side effects form for MERT.  
Complications of uterine instrumentation (diagnostic hysteroscopy, ‘blind’ 
mechanicalpolypectomy, mechanical or electrosurgical polypectomy under direct 
hysteroscopic vision) are as follows: 
• Genital tract infection 
• Uterine trauma 
• Haemorrhage 
• Uterine perforation leading to exploratory laparoscopy / laparotomy to 
exclude or repair damage to internal abdominal structures (e.g. bowel, 
urinary tract) or stop internal bleeding 
 
 
Side-effects specific to outpatient polypectomy: 
• Intravascular injection of local anaesthetic resulting in depression of the 
central nervous system (dizziness, light-headedness, feeling of inebriation, 
nausea and vomiting, circumoral anaesthesia and feeling of numbness, 
auditory disturbance (tinnitus), visual disturbance (difficulty focusing, blurred 
vision), tingling (‘pins and needles’), disorientation and nervousness, 
drowsiness and loss of consciousness, shivering and twitching, fitting) and 
cardiac toxicity (arrhythmias, bradycardia, hypotension, asystole (cardiac 
arrest)) 
• Vaso-vagal reaction (episode of hypotension, bradycardia, pallor and fainting 
associated with feelingcold, sweaty, shivery and vomiting. Usually self-
limiting but may require medical intervention (e.g. intravenous line, blood 
pressure support, atropine reversal) 
 
 
 
 
 
 
 
The information within this form was copied from the ‘toxicity and known side effects form’ developed 
for the outpatient polypectomy trial (OPT) 194. 
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Appendix 18: Serious adverse event form for MERT.   
MERT Serious Adverse Event Form Version 1 22/11/11 
A Randomised Controlled Trial of 
Morcellation versus Bipolar 
Resectoscopy 
 
 
 
 
 
Please report any serious and unexpected adverse events that are suspected to be due to 
treatments1 given as part of the trial by sending or faxing the following details to the trial office 
(Fax: 0121 415 9135) within 2 days of the event. 
 
Patient Identification: 
Patient’s full name: ……………………………………………………………………… 
Trial No: …………………………….. 
Date of birth: day/month/year    …../…../….. 
Centre Name: ……………………………………………..  
Responsible doctor: …………………………………………………………………….. 
 
Associated Treatment: 
Morcellation  !    Bipolar resectoscopy  ! 
Date of treatment: day/month/year     …../…../….. 
 
SAE description: 
Category of event:  Death  !  Life threatening  !  
Hospitalisation (or prolongation of)  !  Persistent or significant disability/incapacity ! 
Date SAE started: day/month/year  …./…. /….  
Date SAE ceased: day/month/year  …./…. /…. 
 
Outcome: 
 Fatal  !   Recovered Continuing  ! 
Details of adverse event (please attach copies of relevant reports): 
………………………………………………………………………………………………………
………………………………………………………………………………………………………
………………………………………………………………………………………………………
……………………………………………………………………………………………………… 
……………………………………………………………………………………………………… 
 
Did the event require or prolong hospitalisation? No ! Yes !  No. of days 
Please give reasons why you consider the event to be treatment related: 
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
……………………………………………………………………………………………………………
…………………………………………………………………………………………………………… 
…………………………………………………………………………………………………………… 
 
 
Name of person reporting (please print):…………………………………………………… 
Signed: ………………………………………………………………………………………………… 
Tel No: ………………………………………………………. Date: day/month/year …../….. /….. 
 
 
1For the purposes of this study, “serious” adverse events are those that are fatal, life-threatening, 
disabling or require hospitalisation. “Unexpected” adverse experiences are defined as those that 
would not be expected among patients given these treatments. It is not required to report in this 
way side-effects or adverse events that might reasonably be expected. 
 
MERT 
SERIOUS ADVERSE EVENT FORM 
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Appendix 19: Letter to patient’s general practitioner for MERT. 
MERT GP letter version 1.0 23/11/11 
A Randomised Controlled Trial of 
Morcellation versus Bipolar 
Resectoscopy 
 
 
 
 
 
 
 
 
Dear Doctor Name of Doctor 
 
 
Your patient ………………………………………………………………………… 
 
 
Date of Birth: date/month/year ………/…….../………  MERT trial No: ………… 
 
 
Date randomised: date/month/year ………/…….../………  
 
was referred to the outpatient hysteroscopy clinic. With her written consent, 
she has agreed to participate in the Morcellation versus Electrical Resection  
Trial (MERT). 
 
On finding a benign intrauterine polyp during diagnostic hysteroscopy, 
randomisation was carried out to decide whether the polyp should be 
removed using instruments with a mechanical cutting edge or those using 
electrical cutting point.  There is no long term follow-up of the patient other 
than the routine care they would expect for the condition they were referred 
for. 
 
 
The Chief Investigator for MERT is Dr Justin Clark, Consultant Obstetrician 
and Gynaecologist, Birmingham Women's Hospital, United Kingdom B15 
2TG, .  Please file this letter in the patient’s notes. Please 
contact the MERT Trial Office Tel: 0121 627 4712 if there are any errors in the 
details above or if she is no longer one of your patients. 
 
 
 
Yours sincerely 
 
 
 
Name of Local Study Doctor 
MERT 
GP INFORMATION SHEET 
 
 
